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Résumé 
 
L’implication des protéines tyrosines phosphatases (PTPs) dans la régulation de la 
signalisation et la médiation des fonctions cellulaires a été bien établie dans les 
dernières années. Cependant, les mécanismes moléculaires par lesquels les PTPs 
régulent les processus fondamentaux tels que l’angiogenèse demeurent méconnus. Il 
a été rapporté que l’expression de la PTP DEP-1 (Density-enhanced phosphatase 1) 
augmente avec la densité cellulaire et corrèle avec la déphosphorylation du récepteur 
VEGFR2. Cette déphosphorylation contribue à l’inhibition de contact dans les 
cellules endothéliales à confluence et diminue l’activité du VEGFR2 en 
déphosphorylant spécifiquement ses résidus catalytiques Y1054/1059. De plus, la 
plupart des voies de signalisation en aval du VEGFR2 sont diminuées sauf la voie 
Src-Gab1-AKT. DEP-1 déphosphoryle la Y529 de Src et contribue à la promotion de 
la survie dans les cellules endothéliales. 
 L’objectif de cette thèse est de mieux définir le rôle de DEP-1 dans la 
régulation de l’activité de Src et les réponses biologiques dans les cellules 
endothéliales. Nous avons identifié les résidus Y1311 et Y1320 dans la queue C-
terminale de DEP-1 comme sites majeurs de phosphorylation en réponse au VEGF. 
La phosphorylation de ces résidus est requise pour l’activation de Src et médie le 
remodelage des jonctions cellules-cellules dépendantes de Src. Ce remodelage induit 
la perméabilité, l’invasion et la formation de capillaires en réponse au VEGF. Nos 
résultats démontrent que la phosphorylation de DEP-1 sur résidu tyrosine est requise 
pour diriger la spécificité de DEP-1 vers son substrat Src. Les travaux révèlent pour 
la première fois un rôle positif de DEP-1 sur l’induction du programme angiogénique 
des cellules endothéliales.  
 En plus de la phosphorylation sur tyrosine, DEP-1 est constitutivement 
phosphorylé sur la thréonine 1318 situé à proximité de la Y1320 en C-terminal. Cette 
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localisation de la T1318 suggère que ce résidu pourrait être impliqué dans la 
régulation de la Y1320. En effet, nous avons observé que la T1318 de DEP-1 est 
phosphorylée potentiellement par CK2, et que cette phosphorylation régule la 
phosphorylation de DEP-1 sur tyrosine et sa capacité de lier et d’activer Src. En 
accord avec ces résultats, nos travaux révèlent que la surexpression du mutant DEP-1 
T1318A diminue le remodelage des jonctions cellules-cellules et par conséquent la 
perméabilité. Nos résultats suggèrent donc que la T1318 de DEP-1 constitue un 
nouveau mécanisme de contrôle de la phosphorylation sur tyrosine et que ceci résulte 
en l’activation de Src et l’induction des fonctions biologiques des cellules 
endothéliales en réponse au VEGF. 
 Suite à ces travaux dans les cellules endothéliales qui démontrent un rôle 
positif de DEP-1 dans la médiation des réponses angiogéniques, nous avons voulu 
approfondir nos connaissances sur l’implication potentielle de DEP-1 dans les 
cellules cancéreuses où l’activité de Src est requise pour la progression tumorale. 
Malgré le rôle connu de DEP-1 comme suppresseur tumoral dans différents types de 
cancer, nous avons émis l’hypothèse que DEP-1 pourrait promouvoir les fonctions 
biologiques dépendantes de Src telles que la migration et l’invasion dans les cellules 
cancéreuses. Ainsi, nous avons observé que l’expression de DEP-1 est plus élevée 
dans les lignées basales de cancer du sein qui sont plus invasives comparativement 
aux lignées luminales peu invasives. Dans les lignées basales, DEP-1 active Src, 
médie la motilité cellulaire dépendante de Src et régule la localisation des protéines 
impliquées dans l’organisation du cytosquelette. L’analyse d’un micro-étalage de 
tissu a révélé que l’expression de DEP-1 est associée  avec une réduction tendencielle 
de survie des patients. Nos résultats proposent donc, un rôle de promoteur tumoral 
pour DEP-1 dans la progression du cancer du sein.  
Les travaux présentés dans cette thèse démontrent pour la première fois que 
DEP-1 peut agir comme promoteur des réponses angiogéniques et du phénotype pro-
invasif des lignées basales du cancer du sein probablement du à sa capacité d’activer 
Src. Nos résultats suggèrent ainsi que l’expression de DEP-1 pourrait contribuer à la 
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progression tumorale et la formation de métastases. Ces découvertes laissent donc 
entrevoir que DEP-1 représente une nouvelle cible thérapeutique potentielle pour 
contrer l’angiogenèse et le développement du cancer. 
 
Mots-clés : Angiogenèse, cellules endothéliales, DEP-1, VEGFR2, Src, VE-
cadhérine, perméabilité, invasion, cancer du sein 
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Summary 
 
The implication of protein tyrosine phosphatases (PTPs) in the regulation of cell 
signalling events and the mediation of cellular functions in response to growth factors 
such as VEGF has been well-established in the last years. Nonetheless, molecular 
mechanisms by which PTPs regulate fundamental processes such as angiogenesis are 
not well-characterized. Expression of the PTP DEP-1 (Density-enhanced phosphatase 
1) was reported to increase with cell density and was associated with VEGFR2 
dephosphorylation contributing to cell contact inhibition in confluent endothelial 
cells. We previously demonstrated that DEP-1 attenuates VEGFR2 activity by 
dephosphorylation of its Y1054/1059 leading to decreased activation of major 
signalling pathways downstream of VEGFR2 with exception of the Src-Gab1-AKT 
pathway. Increasing Src activity due to DEP-1-mediated dephosphorylation of its 
Y529 promotes endothelial cell survival.  
The objective of this thesis was to gain a better understanding of the role of 
DEP-1 in the regulation of the Src activity and of biological responses in endothelial 
cells.  We identified tyrosine Y1311 and Y1320 in the C-terminal tail of DEP-1 as 
major phosphorylation sites in response to VEGF. These residues are required for Src 
activation and mediate the Src-dependent remodelling of endothelial cell junctions 
inducing permeability, invasion and capillary formation upon VEGF stimulation. We 
showed that VEGF-induced DEP-1 tyrosine phosphorylation directs DEP-1 
specificity towards its substrate Src. Our results thus highlighted for the first time the 
promoting role of DEP-1 on the angiogenic program in endothelial cells.  
In addition to tyrosine phosphorylation, DEP-1 is constitutively 
phosphorylated on a threonine residue (T1318) proximal to Y1320 in its C-terminal 
tail suggesting it might be involved in the regulation of Y1320. Indeed, we found that 
DEP-1 T1318 is phosphorylated, potentially by CK2, and regulates the tyrosine 
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phosphorylation of DEP-1 and its ability to bind to and activate Src. Consistent with 
this, remodelling of endothelial cell junctions and permeability are impaired in 
endothelial cells expressing the DEP-1 T1318 mutant. Thus, DEP-1 phosphorylation 
on T1318 displays a regulatory control over DEP-1 tyrosine phosphorylation and 
subsequently Src activation and endothelial cell functions in response to VEGF. 
 Our results demonstrating that DEP-1 promotes angiogenic cell responses in 
endothelial cells, prompted us to consider a possible involvement of DEP-1 in cancer 
cells, where Src activation has been linked to cancer progression. Thus, although, 
DEP-1 is believed to act as a tumour suppressor in different cancer types, we 
hypothesized that it might also promote Src-dependent functions such as migration 
and invasion in cancer cells. Interestingly, we found that DEP-1 is higher expressed 
in more invasive basal-like breast cancer cells than in luminal-like cell lines. 
Moreover, DEP-1 is implicated in the regulation of Src activity, Src-mediated cell 
motility and appropriate localization of proteins mediating cytoskeletal organization 
in basal-like breast cancer cell lines. To further support these results, analysis of a 
breast cancer tissue microarray revealed that DEP-1 expression is associated with a 
tendency towards reduced overall survival. Thus, our results provide first evidence 
for a tumour-promoting role of DEP-1 in breast cancer.  
Altogether, the work performed in the context of this thesis revealed that 
DEP-1 can similarly behave as a promoter of the angiogenic response and of the pro-
invasive phenotype in basal-like breast cancer cell lines, most likely due to its ability 
to activate Src. This suggests for the first time that DEP-1 expression could contribute 
to tumour progression and the formation of metastases, and as such, represent a 
potential new target for anti-angiogenic and anti-cancer therapy. 
 
Keywords : Angiogenesis, endothelial cells, DEP-1, VEGFR2, Src, VE-cadherin, 
permeability, invasion, breast cancer 
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 CHAPTER I 
Introduction 
 
Angiogenesis is the formation of new blood vessels starting from already existing 
vessels and is essential for life and development. Hence, blood vessels are formed 
early to provide oxygen and nutrients to developing organs. In adults, angiogenesis 
occurs only in particular physiological situations including the ovarian cycle in 
women, wound healing processes, and placenta formation in pregnancy. However, 
angiogenesis can also contribute to the development of pathological conditions when 
it is either over- or under-regulated, for instance, in atherosclerosis, arthritis, cardiac 
ischemia, diabetic retinopathy, and during cancer progression. Understanding the 
complex regulation of vessel formation during physiological but especially in 
pathological situations is therefore of significant interest in medical research. Most 
notably, in cancer, angiogenesis is implicated in the development and the progression 
and the malignancy of the disease. Cancer-related angiogenesis is responsible for 
various steps of cancer progression including rapid tumour growth and metastasis 
formation. To date, several anti-angiogenic therapies targeting the VEGF pathway 
have been developed and have been shown to successfully inhibit local tumour 
growth and metastasis formation. However, anti-angiogenic therapies were less 
beneficial for cancer patients than predicted (1, 2). Even worse, it was suggested that 
potential adverse effects of anti-angiogenic therapies might select for tumour cells 
with higher fitness and higher invasive capacities (3, 4).  In agreement with this 
hypothesis, it was recently demonstrated in a mouse model that cancer cell invasion 
as well as metastasis formation were increased during “short term” anti-angiogenic 
treatment (5-7). Thus, the ongoing challenge in the application of anti-angiogenic 
therapies in cancer is to overcome the tumour evasion of these therapies. Therefore, a 
deeper understanding of the various components of vessel formation and resistance to 
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anti-angiogenic treatment is required to design novel and more efficient anti-
angiogenic therapeutic approaches. 
 
1.1 Capillary formation under normal conditions 
 
Blood vessels are the first functional organ system formed in the embryo. Initial 
evidence of a primitive vascular network occurs at day 8.0 of gestation in the mouse 
embryo (8). The formation of new vessels during development involves two 
processes. The early simple circulatory loop of the vascular system is formed by 
vasculogenesis and implicates the differentiation of progenitors of endothelial cells, 
called angioblasts, followed by their assembly into a simple labyrinth of small 
capillaries. Although tubes adopt a branched pattern, they appear diffuse and not well 
organized. During the angiogenic phase, the simple vascular plexus expands due to 
endothelial cell proliferation and remodels into a more highly organized vascular 
network (figure 1). This matured vascular system is characterized by blood vessels 
that are ramified into smaller capillaries, increasing the network complexity. The 
maturation process involves the recruitment of pericytes and vascular smooth muscle 
cells (VSMCs) that promote vessel stabilization and quiescence (9). 
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Figure 1 : Development of the vascular system. 
During development a primitive vascular network is formed by angioblasts, the 
endothelial cell progenitors. This first vascular network is formed through 
vasculogenesis. The tubular network develops and becomes more complex during 
angiogenesis. Pericytes (PC) and smooth muscle cells (SMC) are recruited to the 
tubular network to stabilize the major and highly organized vascular system. 
Adapted from (9). 
 
Vascular sprouting is an early step during the angiogenic process that initiates the 
formation of new vessels. This process encompasses the activation of quiescent 
endothelial cells by angiogenic stimuli and results in small sprouts. Subsequently, 
endothelial cells loosen their cell-cell junctions and begin to degrade the local basal 
membrane. Only a fraction of endothelial cells adopt the specialized tip cell 
phenotype, generating an endothelial cell that can sense angiogenic factors (figure 
2A). Tip cells distinguish themselves by a high number of filopodia as well as high 
expression of VEGFR2 and the Notch ligand DII4, which both favour the tip cell 
phenotype. Tip cells direct the migration of the sprout to the stimulus (10-12). Tip 
cells induce a lateral inhibition mechanism on neighbouring endothelial cells, which 
is mediated by the DII4/Notch pathway. As a consequence, VEGF receptors are 
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downregulated and the motile, invasive tip cell phenotype is suppressed in these 
neighbouring cells (13, 14). They stay behind the tip cells and form the stalk of the 
sprout, maintaining vessel integrity and perfusion of the new vessel (figure 2B). Stalk 
cells undergo cell proliferation to elongate the new vessel (15, 16). Upon contact with 
other vessels, the motile tip cell phenotype is suppressed in these cells and they 
convert into stalk cells. The quiescent status of the newly formed vessel is established 
by the tightening of cell-cell junctions and the recruitment of pericytes and VSMCs 
as well as deposition of the extracellular matrix (ECM) (17). The equilibrium and the 
fine-tuning of different angiogenic factors during vessel formation are essential for 
proper angiogenesis.   
 
 
Figure 2: Endothelial cell dynamics during vascular sprouting. 
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A) Following VEGF stimulation, endothelial cells form protrusions and adopt a 
motile phenotype along with the loosening of cell-cell junctions. Tip cells are selected 
by Notch and DII4 signalling at the angiogenic front. VEGF increases the expression 
levels of DII4 in tip cells, resulting in elevated Notch levels in adjacent cells and the 
subsequent inhibition of VEGF receptor expression in these cells. B) Tip cells have 
many filopodia to sense their environment and to direct the sprout towards the 
angiogenic stimuli. Adjacent cells form the stalk of the sprout, and elongate the new 
vessel. Quiescent phalanx cells maintain vessel integrity and perfusion. Adapted from 
(18). 
 
1.2 Regulation of angiogenesis – a balance between pro- and anti-
angiogenic factors 
 
Angiogenesis is regulated by several pro- and anti-angiogenic factors to maintain the 
balance for appropriate formation of new vessels. A main pro-angiogenic factor is 
VEGF. In 1983, Senger and colleagues identified a factor in the conditioned medium 
of a tumour cell line able to induce vascular leakage in the skin, which they called 
VPF (vascular permeability factor). They proposed that this factor can induce high 
permeability in tumour blood vessels (19). In 1989, Ferrara and colleagues isolated a 
diffusible endothelial-cell specific mitogen which they called VEGF (20). In the same 
year, cDNA cloning revealed that both factors are the same molecule (21, 22). Gene 
knockout studies revealed that the knockout of both VEGF gene copies is lethal at 
embryonic day 8-9 and the inactivation of one single allele is sufficient to induce 
severe angiogenic failure and embryonic lethality between day 10 and 12 (23, 24). 
The VEGF family contains different genes, VEGF-A, -B, -C, VEGF-D and PIGF. In 
addition, there are structurally related forms of VEGF, namely, VEGF-E, found in 
parapoxvirus, and VEGF in snake venoms, which are generally known as VEGF-F 
(25, 26). Alternative exon splicing of the VEGF-A gene results in four distinct 
isoforms, which are VEGF-A121, VEGF-A165, VEGF-A 189 and VEGF-A206. (27, 28) 
The most frequent isoform is VEGF-A165. This isoform was the first described and is 
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a potent inducer of endothelial permeability (29, 30). Other VEGF isoforms including 
VEGF-A111, VEGF-A145, VEGF-A162 and VEGF-A183 are less frequent (31, 32). In 
contrast to mouse models only expressing the less frequent VEGF-A121 or VEGF-A 
189 isoform, mice exclusively expressing VEGF-A165 are perfectly viable and healthy. 
Moreover, it was shown that VEGF-A165, in contrast to VEGF-A121 or VEGF-A 189, 
could completely rescue tumour growth in VEGF-/- tumorigenic mice (33-35). These 
studies support the principal role of VEGF-A165 as an effector of VEGF functions. 
The VEGF-A isoforms have different capacities to bind to heparan sulphate 
proteoglycan (HSPG). Proteolytic cleavage of the VEGF-A isoforms abrogates their 
binding to heparin and consequently generates free soluble fragments, regulating the 
local VEGF activity and its bioavailability. While VEGF-A189 and VEGF-A206 are 
completely sequestered in the ECM due to their high affinity to bind to HSPG, 
VEGF-A121 fails to bind to heparin and is freely diffusible (29). Interestingly, the 
HSPG-bound form of VEGF-A165 is in equilibrium with the soluble form that is 
generated by proteolytic cleavage (36, 37). Thus, the VEGF-A165 isoform combines 
optimal bioavailability characteristics due to intermediate extracellular matrix binding 
with high biological potency. VEGF-C and VEGF-D are generated through 
proteolytic processing and are mainly involved in the regulation of lymphatic 
angiogenesis (38-40). Several factors can regulate the expression of angiogenic 
stimulators. For instance, hypoxia-inducible factor (HIF-1) can induce the expression 
of several VEGF forms and the VEGF receptors in physiological and pathological 
conditions. Moreover, a wide range of transcription factors and ROS can modulate 
the expression levels of VEGF (41-43). 
Further specific factors acting on the vascular endothelium are four 
angiopoietin members and members of the ephrin family (44-48). There are also 
multiple other factors including members of the HGF, FGF, PDGF and TGFβ 
families that can directly act on endothelial cells or induce VEGF expression in cells 
(49-51). Even if VEGF is the main angiogenic factor, it has to work in concert with 
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these factors to ensure proper vessel formation, maturation and stabilisation of the 
tube network. 
 Anti-angiogenic factors, also called natural inhibitors of angiogenesis, are 
TSP-1, angiostatin and endostatin. Endostatin was purified from tumour cell-
conditioned medium and is a fragment of collagen type XVIII (52). It inhibits 
endothelial cell proliferation and migration and induces apoptosis (53). Angiostatin, a 
fragment of plasminogen, was purified from serum of tumour-bearing mice and 
inhibits the proliferation of endothelial cells in growing vessels (52, 54). TSP-1, a 
heparin-binding protein, was purified as the first endogenous angiogenic inhibitor. It 
is stored in the ECM and inhibits endothelial cell proliferation (55, 56). Angiogenesis 
in physiological situations has to be tightly regulated. The balance of pro-angiogenic 
factors as well as endogenous anti-angiogenic factors is crucial for appropriate 
angiogenesis. 
 
1.3 Angiogenesis in pathological situations – the loss of the balance of 
angiogenic factors 
 
In pathologies such as cancer, the local balance between pro and anti-angiogenic 
factors is shifted towards pro-angiogenic factors. This imbalance is often found in the 
primary tumour, and in late stage cancer it is also found at sites of distant metastasis 
(57). Angiogenesis is one of the hallmarks of cancer and a key element in cancer 
progression (58). Once the developing tumour reaches a diameter of few mm, blood 
and nutrient flow inside the tumour lesion are diminished, initiating hypoxia and 
nutrient deprivation (59). Hypoxia induces HIF-1α expression, which in turn induces 
the secretion of stimulatory factors from different cell types including endothelial, 
stromal and tumour cells (43, 60). These conditions allow the “angiogenic switch” 
and cancer progression (61). Cancer-associated angiogenesis is significantly altered 
by many processes, giving rise to vessels that never become quiescent. The tumour 
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vessel network is characterized by an irregular formation with tortuous and typically 
fenestrated vessels and without stable cell-cell contacts, thus generating a highly 
permeable phenotype (30).  Tumour cells and a variety of tumour-associated cells 
including fibroblasts create their microenvironment by the secretion of angiogenic 
factors and deposition of ECM to influence the angiogenic response in a tumour (62-
64). Due to an overwhelming secretion of cytokines and growth factors especially by 
tumour cells, signalling becomes dysregulated, leading to a constant activation of 
normal and quiescent EC. The high PDGF concentration secreted by platelets or 
activated EC in normal angiogenesis stimulates perivascular cells to cover newly 
formed vessels. In contrast, vessels remain uncovered and consequently unstable and 
activated in tumour angiogenesis (65, 66). Thus, the overall angiogenic response is 
poor due to constant vessel growth without maturation and stabilization although 
PDGF is secreted. Moreover, inflammatory cells accumulate in the tumour lesion, in 
turn releasing more angiogenic factors (67, 68). These conditions prompted Dvorak 
to describe these lesions as “wounds that do not heal” due to aberrant vasculature, 
inflammatory cell accumulation and sites of necrosis (62, 68, 69).  
 
1.4 Transmission of the angiogenic signal through VEGF receptors 
 
The VEGF receptor family is composed of 3 members that are structurally 
homologous. VEGFR2 (Flk-1, KDR) is essential for the vascular system in 
development and life, as illustrated by VEGFR2-/- knockout studies. Mice lacking 
Flk-1 die at embryonic day 8.5 due to failures in the development of angiogenic 
structures (70). Flk-1 is the main transducer of VEGF-A-induced signals that 
maintain important biological responses of endothelial cells such as permeability, 
migration and proliferation. VEGF-A is the main VEGFR2 ligand, but VEGF-C and -
D can also bind to it, although with a lesser affinity than to their principal receptor 
VEGFR3 (71). VEGFR2 is composed of an extracellular domain consisting of 
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numerous Ig-like domains, followed by a transmembrane domain and an intracellular 
portion exhibiting tyrosine kinase activity (see figure 3) (72-74). Alternative splicing 
can generate a soluble form of VEGFR2, called sVEGFR2 (figure3). This isoform is 
present in various tissues and binds to VEGF-C, but not VEGF-A. Binding of 
sVERGR2 to VEGF-C blocks lymphatic endothelial cell proliferation, suggesting that 
sVEGFR2 acts as a competitor for VEGF-C-binding to VEGFR3 (75). Moreover, 
sVEGFR2 can bind to the full length VEGFR2 molecule, inhibiting tumour 
angiogenesis (76). In adults, VEGFR2 is prominently expressed in endothelial cells, 
but also in a range of non-endothelial cells (77).  
Interestingly, while VEGFR2 has promoting roles, VEGFR1 (Flt-1) 
suppresses angiogenesis in early embryogenesis as demonstrated in FLt-1-/- mice, 
which die at E8.5-9 due to overgrowth and disorganization of blood vessels (78). In 
contrast, the lack of the intracellular domain of Flt-1 did not affect the viability and 
blood vessel formation in mice, suggesting that the extracellular and transmembrane 
domain is sufficient to suppress angiogenesis in early development (79). VEGFR1-
dependent signalling is implicated in certain phenomena of tumour angiogenesis, in 
inflammation-associated angiogenesis and the progression of rheumatoid arthritis and 
arteriosclerosis (80-84). Interestingly, the mRNA of VEGFR1 also codes for a shorter 
protein that gives rise to a soluble form of VEGFR1 (sVEGFR1), consisting only of 
the extracellular domain (figure 3) (85). The soluble form of VEGFR1 is abnormally 
expressed in pre-eclampsia, but high plasma levels are also found in cancer and 
ischemia (86-88). Pre-eclampsia occurs during pregnancy and is characterized by 
hypertension and proteinurea, and it was suggested that these symptoms are caused 
by an abnormal suppression of VEGF-A signalling (88, 89). VEGFR1 can suppress 
VEGF-A-dependent signalling due to a higher binding affinity to VEGF-A than 
VEGFR2. Although VEGFR1 binds VEGF-A with a higher affinity, it induces only 
moderate signalling due to its weak kinase activity compared to that of VEGFR2 in 
endothelial cells (90). Thus, VEGFR1 can act as a natural inhibitor for VEGF-A, able 
to block VEGF-dependent signalling of VEGFR2 (91). The differences in kinase 
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activity between VEGFR1 and VEGFR2 following VEGF-A binding are due to 
sequence differences in both proteins (92-94). Both receptors can form heterodimers 
in response to VEGF-A in vitro, suggesting that this might be a mechanism for 
VEGFR1 to influence VEGFR2 signalling (95-97). Additional ligands of VEGFR1 
are VEGF-B and PIGF. Regulation of inflammatory cell recruitment is mediated by 
PIGF, whereas VEGF-B has minor angiogenic roles in vivo but regulates the fatty-
acid uptake in endothelial cells (98-100). 
VEGFR3 (Flt-4) is expressed in blood vessels in early embryogenesis and it 
was demonstrated that mice lacking VEGFR3 expression die at E10.5 due to 
cardiovascular failure and disorganization of vasculature (101). In contrast, its 
expression is unique to lymphatic vessels in adults, suggesting its implication in the 
regulation of lymphogenesis (102). In endothelial cells, its expression is induced 
during active angiogenesis, for instance, in tumour blood vessels or in tip cells (16, 
103). VEGFR3 only binds specifically to VEGF-C and -D and can form heterodimers 
with VEGFR2 necessary to induce VEGFR3 kinase activity and downstream 
signalling (figure 3) (104-107). 
 
 
Figure 3: Different receptor forms of VEGFR and their specific ligands. 
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Schematic presentation of five VEGF isoforms with their specific binding to 
different VEGFR receptors, inducing homo- and heterodimerization. Soluble 
VEGFR1 and VEGFR2 lack the seventh Ig-like domain. Taken from (108). 
 
1.4.1 VEGFR2 is the main mediator of the pro-angiogenic VEGF 
signalling   
 
Although all three VEGF receptors are expressed during development, in vivo and in 
vitro studies demonstrated that VEGFR2 is the main receptor in adults, transmitting 
VEGF-dependent signalling. Upon VEGF binding to VEGR2, conformational 
changes in the receptor structure induce receptor dimerization (109). This 
dimerization is accompanied by the activation of its kinase activity and 
autophosphorylation on tyrosine residues in the C-terminal tail, creating docking sites 
for signalling molecules. Major phosphorylation sites of VEGFR2 are Y801 at the 
juxtamembrane domain, Y951/Y996, in the kinase insert domain, Y1054/1059, 
located in the autoactivation loop of VEGFR2, Y1175, and Y1214 in the C-terminal 
tail (figure 4). Additional phosphorylation sites are Y1223, Y1305, Y1309 and 
Y1319, but their function is still unclear (110, 111). Tyrosines 1054 and 1059 are 
located in the kinase activation loop of VEGFR2, and their phosphorylation is 
required for the induction of its kinase activity (112). Signal transducing molecules 
such as PLCγ, PI3K, AKT, TSAd, Shc, Grb2, Nck, SHP-2 and Src bind to the 
phosphorylated tyrosines of VEGFR2 via SH2-domains, inducing signalling cascades 
to promote biological functions of endothelial cells (113-117). For example, Src was 
reported to bind to phosphorylated Y1059 of VEGFR2, inducing phosphorylation of 
the VEGFR2 residue Y1175 (figure 4). This residue in turn serves as a binding site 
for PLCγ and induces cell proliferation (111). Src kinase activity is required for 
various ECs function including cell proliferation, survival, migration and vascular 
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permeability (114, 118). Thus, these data suggest a central role of Src in the 
mediation of angiogenic responses downstream of VEGFR2.  
 
1.4.1.1 Migration / Invasion 
 
New vessel formation requires cell migration of endothelial cells (figure 5). 
Interestingly, several signalling pathways can induce VEGF-dependent cell 
 
Figure 4: VEGFR2 and its downstream signalling. 
The receptor VEGFR2 is localized at the cell membrane of EC. The dimerized 
VEGFR2 is active and its tyrosine phosphorylation sites are shown. Tyrosines 
1054/1059 are important residues in the kinase autoactivation loop. Other main 
phosphorylation sites are Y801, Y951, Y1175 and Y1214. Signalling molecules bind 
to specific tyrosine residues and induce signalling cascades resulting in the 
establishment of various biological function of EC upon VEGF stimulation. Taken 
from (108). 
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migration. Numerous studies demonstrated that VEGF-induced cell migration 
involves Src activity. For instance, SHB (SH2-domain-containing adaptor protein B) 
binds to Y1175 of VEGFR2 resulting in the activation of FAK, a central player in cell 
adhesion and migration (119, 120). In association with Src, the FAK-Src complex 
transmits signals from sites of ECM-cell contact into the cell, thereby influencing 
cytoskeleton remodelling and cell motility (figure 4) (121, 122). The binding of 
TSAd (T cell-specific adaptor molecule) to Y951 of VEGFR2 creates a binding site 
for Src, leading to Src activation (110, 123). Activated Src can induce the activation 
of Gab1, which in turn induces the PI3K pathway and the GTPase Rac to promote 
cell migration (110, 124, 125). In addition, Y1214 of VEGFR2 is also implicated in 
the mediation of cell migration via the binding of Nck and subsequent induction of 
Cdc42, p38 MAPK and PAK2 (126-128). 
Invasion is an essential Src-dependent function of EC during new vessel 
formation downstream of VEGFR2 (figure 5) (129). Endothelial sprouting implicates 
the breakdown of the basement membrane by EC as one of the earliest steps. The 
induction of Matrix-metalloproteinases (MMPs) is essential for ECM degradation. 
For instance, it was shown that the JNK- and PI3K-pathways account for MT1-MMP 
induction in response to VEGF in rat EC, leading to ECM degradation (130). 
Moreover, MT1-MMP is involved in the invasion of EC during early events of 
angiogenic sprouting (131). Invasion can also be induced by angiogenic factors as 
well as biodynamic signals including blood flow (132, 133) 
1.4.1.2 Vascular permeability 
 
One of the key functions of VEGF is the induction of vascular permeability in ECs 
(figure 5). Several studies demonstrated that VEGFR2 mediates permeability in vivo 
(134). During angiogenic sprouting the remodelling of endothelial cell-cell junctions 
is one of the first steps, allowing subsequent induction of permeability. The entirety 
of in vitro and in vivo studies suggests a major role for Src in the mediation of 
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permeability (135, 136). Accordingly, vascular permeability is impaired in mice 
lacking Src expression (114). In response to VEGF, VE-cadherin, the major protein 
forming the adherens junctions, and β-catenin are phosphorylated in a Src-dependent 
manner (137-139). As a consequence of VE-cadherin and β-catenin phosphorylation, 
cell-cell contacts are loosened, impairing their integrity. Subsequently, the angiogenic 
sprout starts to invade the ECM to form a new capillary. Vascular permeability can 
also be induced by VEGF-mediated eNOS activation and NO production (140, 141). 
eNOS activity is stimulated by PLCγ-dependent Ca2+-influx following Y801 
phosphorylation or by its direct AKT-dependent phosphorylation on serine 1179 
leading to increased permeability of endothelial cells (142, 143).  
 
1.4.1.3 Proliferation 
 
PLCγ is the major promoter of endothelial cell proliferation (figure 4). Upon VEGF 
stimulation, tyrosine residue 1175 of VEGFR2 is phosphorylated in a Src-dependent 
manner and recruits PLCγ to the receptor (144). The binding of PLCγ results in the 
induction of the Raf-MEK-MAPK-pathway via PKC and consequently in the 
proliferation of endothelial cells (111, 145). Additionally, endothelial cell 
proliferation is driven by the Src-mediated induction of the Ras-pathway and 
implicates the binding of Shc or Grb2 to Y1175 of VEGFR2 (146-148). Moreover, 
adherens junctions play a major role in the regulation of endothelial cell proliferation. 
The engagement of VE-cadherin mediates contact inhibition of endothelial cells via 
the dephosphorylation of VEGFR2 and ERK1/2. This process involves protein 
tyrosine phosphatases that colocalize with VE-cadherin and mediate the inhibition of 
cell proliferation (149, 150). Moreover, increasing amounts of Csk were shown to 
associate with VE-cadherins in cells at high density. Csk is a negative regulator of 
Src activity and mediates inhibition of cell proliferation under these conditions (151). 
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These data demonstrate that proliferation is tightly regulated in EC, implicating 
numerous mechanisms.  
 
1.4.1.4 Survival 
 
Endothelial cell survival is crucial to maintain blood vessel integrity and 
subsequently nutrition and oxygen supply for the organism (figure 5). PI3K/AKT is 
the main pathway promoting cell survival in response to VEGF (152). The adaptor 
protein Gab1 was shown to be involved in the promotion of cell survival in vitro and 
in vivo in response to VEGF (124, 153). Gab1 mediates the activation of PI3K, which 
in turn induces the generation of PIP3, leading to AKT activation and 
phosphorylation of its downstream target FOXO1/4 (154, 155). Moreover, AKT can 
directly phosphorylate BAD (Bcl-2 associated death promoter) and caspase 9 to 
inhibit apoptosis and promote cell survival (156, 157). The Src-FAK complex 
presents another pathway inducing cell survival. Upon VEGF stimulation, Src-
dependent phosphorylation of Y861 of FAK is required for the inhibition of 
apoptosis, which is distinct from the P3K-AKT pathway (158). Interestingly, the 
interaction of VEGFR2 and VE-cadherin is essential to mediate PI3K-AKT-induced 
cell survival (159). Previous work in our laboratory showed that at adherens junctions 
activated Src induces the phosphorylation of Gab1 and the recruitment of PI3K to the 
complex, leading to the activation of AKT and FOXO1/4 and to the induction of cell 
survival in response to VEGF (160). 
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Figure 5: Endothelial cell functions that are implicated in capillary formation in 
response to VEGF. 
Upon VEGF stimulation, endothelial cells loosen their cell-cell contacts to induce 
permeability and the degradation of the basal membrane. Specialized cells that can 
sense the pro-angiogenic gradient have high filopodia formation at the leading edge 
of the cell. These cells are characterized through high cell motility. Cells behind the 
high motile tip cells proliferate to elongate the newly formed sprout. Finally, the new 
sprout is stabilized by the recruitment of pericytes and VSMCs allowing the new 
vessel to mature. Quiescent EC are dense and form stable cell-cell contacts along with 
high cell survival. 
 
1.5 Regulation of angiogenesis by protein tyrosine phosphatases 
(PTPs) 
 
The dynamic equilibrium between activators and inhibitors of cellular signalling is 
essential for appropriate cellular functions. Receptor tyrosine kinases have crucial 
roles in the phosphorylation of tyrosine or serine residues and in the mediation of 
biological cell functions. The most important antagonists of receptor tyrosine kinases 
Survival
Proliferation
Permeability
Migration
Invasion
VEGF
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are protein tyrosine phosphatases (PTPs), which negatively regulate induced cell 
signalling by the dephosphorylation of signal transducer molecules and growth factor 
receptors. They are involved in the regulation of numerous cell functions including 
proliferation, motility, cell-cell interactions, metabolism and immune response (161-
165). Interestingly, many of the 38 classical PTP genes are present in EC, although 
their mRNA levels are low (166). The first protein tyrosine phosphatase was purified 
in 1988 by Tonks and colleagues approximately ten years after the discovery of 
tyrosine kinases (167). To date, the phosphatase family has enlarged to a structurally 
diverse and tightly regulated family. The human phosphatome encodes 107 PTP, 
which can be subdivided into several subfamilies based on structural and sequential 
diversity. The classic PTP family contains the receptor-like PTP (RPTP) and non-
receptor cytoplasmic PTPs. Classic PTPs are specific towards tyrosine residues. The 
structure of RPTP includes a variable extracellular domain, a transmembrane domain 
and an intracellular domain containing in general two PTP domains (D1 and D2) with 
location of the catalytically active site in the D1 domain in most of the members 
(figure 6). The RPTP family can be subdivided into eight families (R1-R8) based on 
sequence similarities among the catalytic domains of these PTPs (168, 169). The 
members of the R1, R2 and the R4-R8 subfamilies contain two catalytic domains. In 
contrast to the R3 family of PTPs including DEP-1, VE-PTP, GLEPP1 and SAP-1 
contains only one catalytic domain. The extracellular domain of RPTPs is often 
composed of Ig-like or fibronectin type III domains similar to cell adhesion 
molecules, suggesting the implication in processes that involve cell-cell or cell-matrix 
contacts (170). 
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Figure 6: The family of classic PTPs.   
Classic PTPs can be divided into receptor-like PTPs (RPTPs) and non-receptor 
PTPs. The R3 family of the RPTPs includes PTPs such as GLEPP1 (PTPRO), SAP1 
and DEP-1 (PTPRJ), which are characterized by a large extracellular domain 
composed of eight fibronectin III motifs and a single catalytic domain with a small 
C-terminal tail. Adapted from (171). 
 
 
The phosphatase activity domain contains a highly conserved cysteine residue 
responsible for the reaction of dephosphorylation by acting as a nucleophile attractant 
for the substrates. The two-step mechanism of dephosphorylation is highly specific 
towards the respective substrates and involves the formation of a cysteinyl-phosphate 
intermediate (figure 7). The reaction finally terminates with the hydrolysis of the 
intermediate resulting in the dephosphorylated protein (172). Even if the substrate 
specificity is mainly defined by phosphotyrosine of the substrate and specific 
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phosphotyrosine flanking sequences, recent studies also demonstrate a contribution of 
substrate-PTP binding domains in the target selection (173-175). 
 
 
 
Figure 7: The catalytic mechanism of PTPs.   
The nucleophilic cysteine residue recognizes the phosphate of the target protein. The 
first step of the catalysis involves the nucleophilic attack on the phosphorylated target 
protein to form a phosphoenzyme intermediate. The second step involves the 
hydrolysis of the intermediate. Finally, the substrate is dephosphorylated and the 
nucleophilic cysteine restored for a new reaction. Adapted from (170).  
 
1.5.1 Regulatory mechanisms of classic PTP activity 
 
PTPs are implicated in the mediation of different cell functions including growth, 
motility and immune response (162-165). In order that PTPs can tightly regulate 
RTK, they have to be precisely regulated by several mechanisms. For instance, 
substrate specificity of PTPs is regulated by the catalytic domain and substrate-
specific sequences. Moreover, other mechanisms including subcellular localisation 
and expression level of PTPs, post-translational modifications such as 
phosphorylation and oxidation are involved in the regulation of PTP activity. 
nucleophilic cysteine 
of the PTP 
nucleophilic cysteine 
of the PTP 
1. step – nucleophilic attack
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Especially for RPTPs, dimerization and ligand binding are important processes to 
regulate their activity.  
 
1.5.1.1 Dimerization as a mean to control PTP activity 
 
Receptor-like PTPs such as PTPα, PTPε, PTPδ, LAR, CD45 can form dimers (176-
178).  PTP can form homo-or heterodimers. Several PTPs such as PTPα, CD45 and 
DEP-1 can generate homodimers in the membrane by the interactions of 
transmembrane domains as has already been shown for receptor dimerization (179-
184). Interestingly, the PTPμ forms homodimers via its extracellular domain and the 
dimer length is similar to the width of adherens junctions connecting two cells, 
suggesting that PTPμ homodimers control the distance between cells (185-187). 
However, homodimers can also be formed by the interaction of catalytic domains of 
PTPs. The interaction mechanism of the catalytic domain is explained with the 
“wedge-wedge” model. This model suggests that the N-terminal helix-turn-helix 
wedge motif binds to the catalytic domain of the other interacting monomer, leading 
to dimerization of the complex and PTP inactivation. This is the case for the 
homodimer formation of PTPα and for the heterodimer CD45-EGFR upon EGF 
stimulation (188-190). Hence, dimerization can inactivate PTPs, but there is also 
evidence that active dimers exist. For instance, DEP-1 was reported to form active 
dimers following binding with a bivalent anti-DEP-1 antibody. In contrast, the same 
study showed that the binding with a monovalent antibody failed to induce DEP-1 
dimerization. Using the bivalent antibody results in the increase of DEP-1 activity 
and subsequently the inhibition of cell growth in vitro and the blocking of 
angiogenesis in vivo (191). Recently, it was proposed that the DEP-1 catalytic 
domain could form dimers in solution similar to the inhibitory wedge-wedge model 
proposed for PTPα, resulting in the inhibition of DEP-1 activity (192). But, notably, it 
was not shown if DEP-1 dimerizes in this manner in living cells. In contrast to PTPα, 
21 
 
 
DEP-1 and other members of the RPTP R3 family such as SAP-1 contain only one 
catalytic domain and SAP-1 was shown to dimerize via its extracellular rather than 
the catalytic domain (174). Another study demonstrated that DEP-1 dimerization can 
be induced by H2O2 or by the cross-linking agent BS3, leading to the formation of 
disulphide bonds in the extracellular domain (184). 
 
1.5.1.2 Ligands as regulators of PTP activity 
 
Due to the large diversity of the extracellular domain structure, the number of 
potential ligands is huge. Most RPTPs have more than one ligand. Certain PTPs can 
be a ligand for themselves, resulting in the dimerization of two PTP monomers. This 
was shown for PTPμ, PTPλ as well as PTPκ (193-195). Moreover, during 
development in Drosophila PTP-LAR-mediated functions are regulated by two high 
affinity ligands (196). A previous study demonstrated that a component in the 
extracellular matrix leads to the activation of DEP-1, indicating the presence of a 
potential ligand for DEP-1 in the ECM (197). Recently, syndecan-2 was identified as 
a ligand that activates DEP-1 and promotes the dephosphorylation of PI3K in 
fibroblasts. This process implicates Src activity to finally transmit the signal for the 
promotion of β1 integrin-dependent adhesion (198). Moreover, another recent study 
described soluble Thrombospondin-1 (TSP-1) as a high specific ligand for DEP-1, 
increasing its catalytic activity. TSP-1 binds to the extracellular domain of DEP-1, 
suggesting that DEP-1 acts as receptor for TSP-1 mediating EC growth inhibition 
(199). 
 
1.5.1.3 Post-translational modification: Phosphorylation on tyrosine and serine 
residues 
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Phosphorylation is considered as a regulatory mechanism of protein activity and was 
proposed to also be a regulatory mechanism for PTP activity. Phosphorylation 
regulates the intramolecular conformation of PTPs as well as their interaction with 
other proteins. 
Tyrosine phosphorylation is commonly reported to activate PTPs and/or to 
direct them selectively to specific substrates. Several PTPs such as CD45, PTPα, 
SHP-1 and SHP-2 were reported to be phosphorylated on tyrosine, leading to higher 
PTP activity in different conditions (200-202). For instance, observations in NIH3T3 
cells demonstrated that 20% of PTPα is phosphorylated on Y789 and bound to Grb2. 
Previous reports demonstrated that in basal conditions Grb2 binding to Y789 
competes with Src binding to this residue, circumventing Src activation. During 
mitosis, the affinity of Y789 for the SH2 domain of Grb2 was reported to decrease, 
leading to its dissociation from PTPα. Y789 is now accessible for Src binding and Src 
is subsequently activated by PTPα. In contrast, Vacaru and colleagues observed 
recently that Grb2 does not dissociate from Y789 during mitosis. Consequently, the 
authors showed that Src binding to PTPα is not dependent on Y789 (203-206). The 
same study demonstrated that serine 204 of PTPα is dephosphorylated during mitosis, 
leading to increased Src binding to PTPα and subsequent Src activation (206). 
Interestingly, CD45 can regulate PTPα activity in T cells through the 
dephosphorylation of PTPα Y789 increasing Fyn activity and Pyk2 phosphorylation 
in T cells (207). This study provided evidence that PTPs can regulate the catalytic 
activity of another PTP, describing an additional regulatory level of PTP activity 
regulation. CD45 was reported to be also phosphorylated on serine residues. 
However, the impact of serine phosphorylation on CD45 activity is poorly defined. 
For instance, Phorbolester treatment induced the phosphorylation of two serine 
residues in lymphocytes, nonetheless no notable changes in the catalytic activity of 
CD45 were observed under these conditions (208). In the other hand, it was reported 
that the loss of serine phosphorylation decreases CD45 catalytic activity (209). 
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Certain PTPs of the R3 family including VE-PTP, GLEPP1 and SAP-1 are 
phosphorylated in a Fyn-dependent manner in their C-terminal tail, allowing the 
association with Grb2 and Fyn. While the functional significance for the binding with 
Grb2 remains unclear, the association of Fyn was proposed to be important for Fyn 
activation. Moreover, co-expression of SAP-1, GLEPP1 and VE-PTP with activated 
Ras leads to induction of cell spreading and lamellipodia formation in CHO cells 
(210). DEP-1, which is also part of the R3 family, was shown to be phosphorylated 
on tyrosine in several breast cancer cell lines following pervanadate treatment (211). 
Further analysis in the same study showed that a serine/threonine kinase is associated 
with DEP-1 and could phosphorylate DEP-1 in the C-terminal tail. Another study 
found that active Src stimulates DEP-1 activity via direct association and 
phosphorylation in a somatostatin-dependent manner (212). In HeLa cells, weak 
EGF-induced tyrosine phosphorylation of the catalytically inactive DEP-1 D/A 
mutant was observed, confirming previous reports that DEP-1 can be phosphorylated 
on tyrosine (213). Nevertheless, these studies did not answer the question whether 
endogenous DEP-1 is phosphorylated in physiological conditions, which residues are 
phosphorylated and if DEP-1 phosphorylation has an impact on DEP-1 activity, cell 
signalling and cell function. 
1.5.1.4 Post-translational modification: Oxidation 
 
Reversible oxidation of the cysteine in the catalytic site negatively regulates PTP 
activity. Due to a low pKα, the conserved cysteine usually exists as a thiolate anion at 
physiological pH in cells and is highly susceptible to oxidation (214, 215). Production 
of reactive oxygen species (ROS) is driven by NADPH oxidase, but also indirectly in 
response to various cellular stimuli by a number of metabolic processes as by 
cyclooxygenases (COX), lipoxygenases (LipOX) and mitochondrial respiration, nitric 
oxide synthases and xanthine synthases. Recently, it was shown that peroxidized 
lipids can act as inducer of PTP oxidation (216). ROS transiently convert the active 
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cysteine site into either sulphenic, sulphinic or sulphonic acid (figure 8) (217-219). 
For the reaction to be reversible, the cysteine should not oxidize further than to 
sulphenic acid, otherwise the oxidation is irreversible and the PTP remains 
inactivated (figure 8). For instance, PTP1B oxidation to sulphenic acid is 
accompanied by a conformational change of the active site and disrupts the 
interaction with its substrate to finally expose the oxidized cysteine to the cell 
environment (220). This conformational change avoids irreversible oxidation and 
complete inhibition of PTP activity, so that the PTP can be reduced to restore the 
active form. In response to PDGF, the formation of an intramolecular disulphide bond 
protects the catalytic cysteine of LW PTP from irreversible oxidation (221). A recent 
study demonstrated that DEP-1 could be oxidized in cultured cells following 
induction of hypoxia. In the same study, results suggested that increased PTP 
oxidation correlated with decreased PTP activity when cells were exposed to hypoxic 
conditions followed by reoxygenation (222). Godfrey and colleagues demonstrated 
that DEP-1 is inactivated by oxidation in FLT3-ITD-induced AML, leading to the 
induction of FLT3-ITD-dependent cell transformation (223).  
Thus, oxidation represents an important mechanism to regulate PTP activity in 
a time-dependent manner via a rapid reversible inhibition of PTP activity to allow 
transmission of cell signalling events. 
 
 
Figure 8: Reversible inactivation of PTPs through oxidation. 
The oxidized catalytic cysteine has impaired nucleophilic function leading to the 
reversible inactivation of the PTP. The rapid conversion of the sulphenic form of the 
oxidized cysteine to a cyclic sulphenamide protects the catalytic cysteine from being 
further oxidized into the irreversible forms sulphinic or sulphonic acid.  
 
PTP    S PTP    S   OH PTP    S   O2H PTP    S   O3H
sulphenic acid sulphinic acid sulphonic acid
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1.5.1.5 Subcellular localisation  
 
Many PTPs display high activity, which is tightly controlled by different 
mechanisms. The subcellular localisation of PTPs defines the access to PTP 
substrates and is a manner to control PTP activity. Different domains including PDZ, 
FERM, SH2, proline-rich domains and Sec14 allow PTPs to localise to the 
appropriate cell compartment. For instance, SH2 domains allow that PTPs such as 
SHP-1 and SHP-2 are localised at the cell membrane, where they interact with RTK 
or regulate tyrosine phosphorylation in the context of cell-cell or cell-matrix adhesion 
(224, 225). PDZ and FERM domains as well as proline-rich domains allow PTPs to 
bind to their substrates. For instance, PTP-BL is recruited via a FERM domain to the 
apical site of epithelial cells, regulating its catalytic and substrate specificity (226). In 
addition, the Sec14-homology domain targets PTP-MEG2 specifically to secretory 
vesicles to regulate vesicle fusion (227). Furthermore, specific target sequences can 
direct PTPs to their compartment. For instance, a hydrophobic sequence, which 
anchors PTP1B and TC-PTP to the ER, contributes to limited substrate recognition 
(228-230). Lastly, nuclear localisation signals in PTPs exist to direct them to the 
nucleus as it was shown for the alternatively spliced form of TC-PTP (231). 
Interestingly, deletion of the DEP-1 extracellular domain prevents its localisation at 
the membrane and induces the formation of disulphide bond-dependent higher order 
complexes in the intracellular compartment that are unable to block cell proliferation. 
These results suggest that the localisation of DEP-1 at the plasma membrane is 
important to mediate cellular functions as the growth arrest (184). Hence, the 
presented examples demonstrate an essential contribution of the localisation factor to 
regulate the availability of substrates and to define PTP specificity.  
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1.5.1.6 Expression 
 
An obvious regulatory mechanism of proteins is their expression level. Thus, it is not 
surprising that PTPs can be regulated by their expression level. Several PTPs are 
ubiquitously expressed such as PTP1B, DEP-1 and SHP-2. However, there are also 
examples of PTPs whose expression is limited to specific tissues or cell types such as 
PTPH1 expression to neuronal tissue and VE-PTP to endothelial cells (232, 233). 
Several mechanisms were described regulating the mRNA expression of specific 
PTPs. A number of PTPs including DEP-1, VE-PTP and PTPμ are upregulated when 
cells reach confluence, proposing a role in the regulation of cell growth (234-236). 
Several studies demonstrated that different expression levels of CD45 have different 
effects on T cell signalling. High expression above physiological levels was 
demonstrated to inhibit T cell signalling, while small amounts of CD45 are sufficient 
to rescue inducible TCR signalling in CD45-/- mice (237). Interestingly, the activation 
of the SFK family member Lck is impaired in T cells expressing high levels of CD45 
due to the dephosphorylation of the inhibitory Y505 and activatory Y394 of Lck. In 
contrast, lower levels of CD45 only promote the dephosphorylation of the inhibitory 
Y505 Lck, leading to Lck activation (238). Thus, different expression levels of CD45 
are required to tightly balance TCR signalling and T cell development via the 
regulation of Lck activity. Additionally, alternative use of PTP gene promoters leads 
to tissue-specific PTP mRNA expression, as described for SHP-1, or the expression 
of different PTP isoforms as described for PTPε (239, 240). The regulation of PTP 
mRNA allows the control of PTP expression at different levels concomitant with the 
access limitation to specific PTP substrates.  
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1.5.1.7 Proteolytic cleavage  
 
Certain PTPs can be regulated by limited proteolysis to control PTP activity and 
function. This mechanism is described for several members of RPTP including PTPμ, 
PTPλ, PTPδ and PTPκ. The extracellular domain is the subject of proteolytic 
cleavage by proteinases/convertases during PTP biosynthesis. This modification leads 
to a non-covalent association of the extracellular to the transmembrane and 
intracellular domains in mature PTPs (241, 242). Additional cleavage enzymes such 
as ADAM10, γ-secretase and calpain contribute to further cleavage of mature PTPs, 
defining the cellular redistribution that can be associated with changes in PTP activity 
(243, 244). For instance, calpain-mediated cleavage of PTP1B leads to its 
relocalisation from the plasma membrane to the cytosol, which is accompanied by an 
increase in PTP1B activity (245). Calpain also promotes PTPα cleavage at the 
intracellular domain, resulting in PTPα translocation away from the membrane and 
limiting the access to its substrate Src (246).  
 
1.6 Regulation of VEGFR2-dependent signalling and biological 
functions by PTPs 
 
Based on the crucial role of VEGFR2 in the mediation of angiogenic responses, it is 
important to define molecular mechanisms implicated in the regulation of VEGFR2. 
Maintenance and integrity of the endothelial cell barrier is crucial to sustain 
functional blood vessels and cell-cell contacts. Adherens junctions were shown to be 
especially important for this. The major protein in adherens junctions is VE-cadherin 
(247). Additionally, various proteins are associated with VE-cadherin in adherens 
junctions including β-catenin, plakoglobin, p120 catenin, Src and Csk (figure 9) (151, 
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248). The VE-cadherin complex was proposed to relate VEGFR2 to junction-
associated PTPs. To date a number of PTPs were identified that are able to 
dephosphorylate VEGFR2 including SHP-2, PTP1B, VE-PTP, PTPµ, TC-PTP and 
DEP-1. PTP-mediated regulation of VEGFR2 was proposed to be important for 
maintaining low tyrosine phosphorylation levels at adherens junctions to ensure cell-
cell contact homeostasis and integrity of the endothelial cell barrier. For instance, the 
site-specific dephosphorylation of VEGFR2 by PTPs mediates the inhibition of cell 
proliferation (149, 249-253). Silencing of PTPμ, TC-PTP and PTP1B leads to 
enhanced vascular permeability, demonstrating their negative role on VEGFR2 
signalling and the phosphorylation of junctional proteins (250, 254, 255). Moreover, 
the dissociation of VE-PTP and SHP-2 from the VE-cadherin complex is necessary to 
increase vascular permeability, suggesting that they inhibit VEGFR2 signalling (224, 
256). Different extracellular matrices can influence the function of PTPs at sites of 
cell contacts. For instance, TC-PTP and VE-PTP mediate different biological 
outcomes in endothelial cells dependent on which extracellular matrix was used to 
culture these cells. VE-PTP expression is upregulated in endothelial cells cultured on 
a three dimensional collagen gel and mediates the formation of tubular structures, 
while endothelial cells cultured on fibronectin do not increase VE-PTP expression but 
induce proliferation (252). Although several PTPs are implicated in the 
dephosphorylation of VEGFR2, the impact on VEGFR2 signalling at cell contacts is 
dependent on PTP localisation to these sites, the response to different type of 
extracellular matrix and the angiogenic stimulus. 
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Figure 9: The adherens junction complex with the associated proteins and the 
associated PTPs DEP-1 (CD148), PTPμ and VE-PTP. 
In confluent endothelial cells, VE-cadherin is clustered to form adherens junctions. 
VE-cadherin molecules can form these intercellular connections through the 
homophilic binding to another VE-cadherin monomer of a neighbouring cell. The 
cytoplasmic tail of VE-cadherin molecules is bound to the cytoskeleton via various 
connecting protein such as p120 catenin, plakoglobin and α-,β-,γ-catenin. 
Commonly, PTPs as VE-PTP and DEP-1 but also RTK as VEGFR2 are localised in 
this complex. Adapted from (257). 
1.6.1 VE-PTP/PTPRB 
 
VE-PTP-/- mice die at embryonic day 10 due to abnormal angiogenesis the failure to 
remodel the primitive vascular network especially in the yolk sac (233, 258). 
Interestingly, VE-PTP expression is limited to endothelial cells and increases with 
cell density, suggesting a function in cell contact inhibition (233, 235, 259). 
Accordingly, VE-PTP can dephosphorylate VEGFR2, leading to the inhibition of 
VEGFR2 signalling in resting cells. Under these conditions, VE-PTP is also 
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associated with VE-cadherin, mediating cell contact adhesion and the maintenance of 
EC contact integrity in cooperation with plakoglobin (252, 260). In contrast, in 
VEGF-stimulated cells VE-PTP association with VEGFR2 and VE-cadherin is lost, 
thus permitting VEGF-dependent signalling as well as phosphorylation of VE-
cadherin and associated junctional proteins. The VEGFR2-VE-PTP complex is 
reconstituted with time and consequently leads to VEGFR2 dephosphorylation and 
deactivation (252). These data demonstrated that VE-PTP exerts its role in EC 
contact maintenance, while its dissociation from cell contacts is essential to induce 
VEGFR2-dependent signalling and endothelial cell functions such as vascular 
permeability during angiogenesis (256, 260). 
 
1.6.2 SHP-2/PTPN11 
 
The implication of SHP-2 in the regulation of VEGFR2 signalling is well known. It 
was shown that the important negative Src regulator Csk associates with Y685 of VE-
cadherin at cell contacts (151). Moreover, SHP-2 was shown to be recruited to VE-
cadherins in response to VEGF and to dephosphorylate the Csk-binding site Y685 of 
VE-cadherin. The dissociation of Csk from VE-cadherins decreases the 
phosphorylation of Src Y529, promoting its activation (261). Thus, SHP-2 can 
control the phosphorylation of the inhibitory tyrosine Y529 of Src in an indirect 
manner through the regulation of Csk availability at endothelial cell contacts in 
response to VEGF. 
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1.6.3 DEP-1/CD148/PTPRJ 
 
DEP-1 is a member of the RPTP family which was first described in 1994 by Östman 
et al. and which is expressed in many cell types including EC, haematopoietic and 
epithelial cells (234, 262-264). It is composed of a large extracellular domain 
containing eight fibronectin III motifs, a transmembrane domain and a single 
intracellular domain containing the unique phosphatase catalytic motif and a small C-
terminal tail. Expression levels were reported to increase when cells reach high 
density, suggesting its implication in the mediation of contact inhibition (234). DEP-1 
expression is also observed in early zebrafish and mouse embryos as well as in 
C.elegans, indicating that DEP-1 already has a role in evolutionary lower organisms 
such as nematodes (265-267). Moreover, in zebrafish embryos DEP-1 expression is 
especially observed in the neuronal tube, in muscles and endothelial cells (268). 
Various lines of evidence suggest a role for DEP-1 in the regulation of 
angiogenesis. In 2003, a DEP-1 knock-in mouse model showed that the replacement 
of the intracellular domain of DEP-1 with GFP abrogates the remodelling of the 
primitive vascular network and interferes with the viability of embryos at embryonic 
day 10.5. During early development, homozygous mouse embryos display higher 
numbers of EC in the yolk sac, indicating increased proliferation. Vessels in the yolk 
sac are enlarged and less branched. In these mice the dorsal aorta is narrowed and the 
mice show severe abnormalities in the heart (265). Thus, DEP-1 function is 
indispensable for angiogenic processes during development and DEP-1 has a positive 
role on remodelling and ramification of newly formed vessels. Interestingly, 
consistent with defects in vasculature seen in the DEP-1 knock-in mouse model 
during development, VE-cadherin knockout mice show a similar phenotype with 
severe vascular defects and embryonic lethality (269, 270). In contrast, a study 
demonstrated that the deletion of exon 3, 4 and 5 of DEP-1 gene results in mice 
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which have a null mutation in this specific locus. The knockout of DEP-1 exerts no 
effect on the vasculature and mice are perfectly viable and fertile (271). Consistent 
with this in vivo study, another mouse model in which the DEP-1 transmembrane 
domain was deleted (DEP-1TM-/TM-), supports the findings that aberrant deletion of 
DEP-1 does not affect the viability of mice (272). However, analysis of the mouse 
immune system of homozygous DEP-1TM-/TM- mice revealed that peripheral B cell 
development is partially blocked similarly to what was observed for the CD45-/- 
mouse model (273). Therefore, these data suggest that CD45 and DEP-1 have 
redundant roles in B cell development since the double mutation CD45 and DEP-1 
severely affects B cell and myeloid development as well as immune receptor 
signalling. In immune cells of the double mutant, SFK are not activated due to 
elevated phosphorylation of Y529 (272). Further evidence that DEP-1 is implicated in 
the regulation of angiogenesis was shown during zebrafish development. In this 
model, DEP-1 is implicated in cell differentiation of arterial and venous EC whereas 
DEP-1 promotes the specification of arterial ECs. Experiments in DEP-1 knockdown 
zebrafish revealed that DEP-1 seems to be important for blood circulation. The study 
showed that blood flow is impaired due to the reduction of arterial differentiation, 
which is accompanied by an expanded expression of venous cell markers (268).  
In cells, DEP-1 localizes in proximity to VEGFR2 and VE-cadherins at cell 
contacts where it binds to p120 catenin, β-catenin and plakoglobin (274, 275). The 
formation of the β-catenin/VE-cadherin/p120 catenin complex was proposed to link 
VEGFR2 to DEP-1 (figure 10). DEP-1 accomplishes its important role in VE-
cadherin-mediated contact inhibition in endothelial cells through the 
dephosphorylation of VEGFR2 concomitant with inactivation of the ERK1/2 
pathway (149, 159, 262). The decreased clustering of VE-cadherin along with 
dissociation of DEP-1 from VE-cadherin in sparse cells leads to higher VEGFR2 
phosphorylation and higher VEGFR2 endocytosis in intracellular compartments. 
Endocytosed VEGFR2 forms particular signalling complexes to promote cell 
proliferation (150). In sparse cells, VEGFR2 promotes proliferation through MAPK 
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signalling, whereas in confluent cells it induces cell survival through the activation of 
the PI3K/AKT pathway (149, 159). The binding of VEGFR2 to VE-cadherin 
increases in confluent cells and concomitantly with DEP-1 expression as shown in a 
VEC positive cell model (149). In agreement with this, DEP-1 was shown to 
colocalise with VE-cadherins in double-labelled EC, indicating its accumulation at 
sites of cell-cell contact and suggesting that VE-cadherin expression defines the 
quantity of DEP-1 protein at these sites (191). These results suggest that DEP-1 
expression and localisation in adherens junctions is marginal in sparse cells in 
contrast to confluent EC. Thus, DEP-1 expression levels are dependent on VE-
cadherin expression levels and in turn partially dictated by cell confluence. 
DEP-1 expression is decreased in vascular smooth muscle cells (VSMCs) 
after vessel injury. The same study showed that, downregulation of DEP-1 expression 
in VSMCs and MEF cells is concomitant with extensive PDGFR phosphorylation, 
proliferation and chemotaxis in the intima (276). In accord with this study, DEP-1 
expression was reported to decrease in migrating and proliferating endothelial cells 
during vessel repair in vivo (262). Thus, these studies suggest that reduced DEP-1 
expression allows growth factor-induced proliferation and migration and support the 
fact that DEP-1 function in endothelial cells is correlated with its expression level.  
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Figure 10 : Structure of adherens junctions and modulation of VEGFR2 
signalling by VE-cadherin and associated proteins. 
The association of VEGFR2 with VE-cadherins is known to influence VEGFR2 
signalling upon VEGF stimulation at sites of cell-cell contact. In confluent cells, the 
VE-cadherins are clustered and associated with VEGFR2 at adherens junctions. 
Based on the model presented by Lampugnani and colleagues the receptor VEGR2 
in collaboration with DEP-1 promotes cell survival under these conditions. In 
contrast to confluent cells, in sparse cells the clustering of VE-cadherins is reduced 
and the receptor VEGFR2 signals preferentially to promote cell proliferation. 
Adapted from (277). 
1.7 Src family kinases (SFK) as major substrates of PTPs 
 
Src and Src family kinases (SFK) are mediators of many cell functions including 
differentiation, cell motility, cell survival and proliferation and they have a central 
role in transmission of cellular signals to downstream effectors. Tight regulation of 
Src activity is accomplished by many PTPs.  
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 1.7.1 Structure and regulation of Src activity 
 
The tyrosine kinase Src contains numerous domains including an N-terminal carbon-
myristoyl group linked to a SH4- and SH3-domain followed by a SH2-domain, the 
tyrosine kinase domain and the C-terminal tail (278). Two tyrosine residues are 
essential for the regulation of Src kinase activity (figure 11). In the inactive state, the 
phosphorylated inhibitory tyrosine 529 is linked intramolecularly to the SH2-domain, 
keeping Src in a closed conformation. When the inhibitory tyrosine 529 is 
dephosphorylated, Src adopts an open conformation, allowing the 
autophosphorylation of the activatory tyrosine 418 in the activation loop, thereby 
keeping Y418 accessible (279). Under basal conditions the major Src pool is 
phosphorylated on Y529 catalyzed by C-terminal Src kinase (Csk) (204). Both 
enzymes are expressed ubiquitously. However, Csk homology kinase (Csh) 
phosphorylates Src on Y529 as Csk does, with the difference that Chk expression is 
restricted to specialized tissues such as breast, testis, hematopoietic cells and neurons 
(278). Triggered by phosphorylation of another tyrosine in the SH2 domain (Y213), 
Src activation is slightly increased following PDGF stimulation. The interaction of 
Y529 with the SH2 domain is limited by phosphorylation of Y213, representing 
another Src regulation level. However, this residue has a marginal impact on the 
regulation of Src activity (280). Based on crystallization studies elucidating Src’s 3-
D-structure, the SH2 and SH3 domain of Src were shown to be implicated in the 
conformational change of Src upon stimulation, allowing dephosphorylation of Y529 
and Y418 phosphorylation.  
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Figure 11 : Structure of Src and major tyrosine residues. 
Src is composed of one SH2, SH3, SH4 and one kinase domain. The activatory 
tyrosine 418 (Y418) is localized in the activation loop and the inhibitory Y529 is 
found in the C-terminal tail of Src. Adapted from (281). 
 
The SH2 and the SH3 domains contribute to intramolecular interactions mediating 
conformational changes accompanying various activation states of Src. To keep Src 
in an inactive state the Y529 in the C-terminal binds to its SH2 domain. Additionally, 
its SH3 domain is attached to a proline-rich motif in the linker domain to lock Src in 
the closed conformation (282, 283). Following activatory stimuli, Y529 dissociates 
from the SH2 domain. Tyrosine phosphorylated proteins or proline-rich-motif bearing 
proteins can compete with Src SH2 and SH3 domain binding, resulting in 
conformational changes and potential activation of Src (284). For instance, 
phosphorylated PDGFR recruits and activates Src via the interaction with Src SH2 
domain (285, 286). However, to reach maximal Src activation, Y418 phosphorylation 
seems to be the most important event since Y418 phosphorylation was shown to 
block Csk mediated Src inactivation (287). Interestingly, recent studies illustrated a 
complementary regulatory mechanism for Src activation. ROS were shown to be 
implicated in the regulation of Src activity. Based on a thiol reaction, oxidation of 
cysteine residues results in the increase of Src kinase activity due to the induction of 
Y418 phosphorylation. In fibroblasts, ROS are required to fully activate Src in 
response to ECM-induced integrin engagement (288). Treatment with the ROS 
scavenger N-acetyl cysteine (NAC) decreases Src phosphorylation on Y418, leading 
to its localisation to endolysosomal compartments in human cancer cell lines (289). 
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Figure 12: Conformational changes of Src are associated with its activation. 
In basal conditions, Src is in a closed conformation. The phosphorylated inhibitory 
tyrosine Y529 is bound intramolecularly to the SH2 domain, while the SH3 domain 
is bound to the linker domain situated between the SH2 and the catalytic domain of 
Src. Following activatory stimuli, the Y529 is detached from the SH2 domain of Src 
allowing an open conformation. The activatory tyrosine Y418 is accessible for 
phosphorylation resulting in an optimal Src activation. Adapted from (290). 
 
1.7.2 The role of PTP in the regulation of SFK  
 
The best described mechanism promoting Src activation is the dephosphorylation of 
the inhibitory tyrosine 529 in the C-terminal tail (291). Its dephosphorylation 
contributes to the release of the Src SH2 domain and allows the opening of its 
conformation. Depending on the cell system and the stimuli, different PTPs may be 
involved in this process. PTPs can act on both Src tyrosine residues; however, most 
PTPs preferentially act on Y529. 
529
Y529
Y 
418
Y 
418
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1.7.2.1 PTPα 
 
PTPα is a member of the RPTP containing a short extracellular and two intracellular 
catalytic domains (292). It is the first PTP shown to regulate Src activity and it was 
first described in fibroblasts from PTPα-/- mice. In these mice Src phosphorylation on 
Y529 is increased (293, 294). Further, overexpression of PTPα in fibroblasts 
increases Src activity and promotes neoplastic transformation. indicating that PTPα 
activity is directed against Src (162). In this context, the study showed that 
phosphorylation on Y789 of PTPα is required to conduct PTPα action. 
Overexpression studies with PTPα mutants provide evidence that Y789 
phosphorylation is required for selective Src Y529 dephosphorylation and subsequent 
FAK activation (204, 295). The Grb2 SH2 domain was reported to bind to Y789 of 
PTPα with higher affinity than the Src SH2 domain. Thus, these results suggest that 
Grb2 binding to PTPα competes with Src binding and activation in cells (203). Zheng 
and colleagues proposed a “phospho-displacement mechanism” describing Src 
activation by PTPα (figure 13). Notably, this model became the most common model 
for Src activation by PTPs, although it still remains controversial and still gives rise 
to a number of debates (296). Based on this model, Grb2 is released from Y789 of 
PTPα during mitosis. The phosphorylated Y789 is now accessible and promotes the 
dissociation of Src Y529 from the intramolecular binding with the Src SH2 domain 
(figure 13). The opening of Src structure facilitates its interaction with the PTPα D1 
catalytic domain and resulting in the dephosphorylation of Y529 (204). In contrast, 
another study recently proposed an alternative Src activation model for PTPα, 
challenging the role of phosphorylated Y789 in Src activation. The authors elucidated 
the role of serine phosphorylation known to increase PTPα activity during mitosis. 
Previous studies showed that PTPα activation is supported by serine phosphorylation 
(297, 298). However, Vacaru and colleagues demonstrated that dephosphorylation of 
Ser204 enhanced PTPα affinity for Src, leading to dephosphorylation of tyrosine 529 
and 418 of Src and a moderate Src activation in mitosis (206). 
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Interestingly, PTPα WT can also dephosphorylate Src tyrosine 418 in vitro and in 
vivo suggesting that PTPα regulation of Src activity is complex and can be activating 
or inactivating dependent on the cell context and external factors. 
 
 
Figure 13: Mechanism of Src activation via the phospho-displacement model. 
This model was described by Zheng and colleagues in 2000. A) In basal conditions 
Src is inactive and in a closed conformation. This conformation keeps Src locked 
through the intramolecular interaction of Y529 with the SH2 domain. B) Some 
particular conditions can induce the transient detachment of Src Y529 from the SH2 
domain without its dephosphorylation. C-E) This intermediate state allows that 
Y789 of PTPα can bind to the SH2 domain of Src. Src can adopt a favourable 
conformation to be dephosphorylated by the catalytic D1 domain PTPα. F) Src Y529 
is dephosphorylated and the phosphorylation of Y418 in the activation loop 
increases, leading to Src activation. Adapted from (204). 
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1.7.2.2 PTPε 
 
PTPε is a member of the same RPTP family as PTPα and substrate-trapping mutants 
of PTPε provide evidence that Src is a substrate of PTPε as it was shown for PTPα. 
Two major isoforms of PTPε exist and both forms are able to activate Src (299-302). 
Studies in PTPε -/- mice confirmed that PTPε is an activator of Src in vivo and a 
collaborator of Neu in mammary tumour cells, participating in the maintenance of the 
Neu-induced transformed phenotype by Src activation (303). In the same context, 
phosphorylation of Y695 was reported to direct specificity of the receptor-type PTPε 
toward Src in Neu-expressing mammary tumour cells. Y695 is located in the C-
terminal domain of PTPε and seems to be exclusively implicated in the 
dephosphorylation of Src but not in that of other substrates (299). Another study of 
the same group showed that in osteoclasts, the non-receptor form of PTPε (cyt-PTPε) 
is phosphorylated in a Src-dependent manner on Y638 and participates in the 
appropriate activation of Src downstream of integrins. Phosphorylated Y638 allows 
Src binding to PTPε, leading to Src Y529 dephosphorylation and its activation (300). 
Additional studies also demonstrated that PTPε can associate with and activate Fyn 
and Yes through the dephosphorylation of Y529 (304). 
 
1.7.2.3 CD45 
 
SFK and CD45 are important players of signal transmission downstream of immune 
receptors in B and T cells, but also in macrophages (305). CD45 was reported to 
catalyze dephosphorylation of tyrosine 529 and 418 of SFK, although the activating 
Y418 is dephosphorylated to a smaller extent than Y529, proposing a role of CD45 in 
SFK activation. Most studies performed in T cells showed that CD45 is essential for 
the dephosphorylation of Y529 of SFK, which primes the kinase to phosphorylate 
ITAM-motifs in the TCR to transmit cellular signals (306, 307). In B cells and 
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macrophages, CD45 deficiency was less severe than in T cells, providing evidence 
that CD45 is not the unique SFK activator in these cells (308, 309). CD45 was 
proposed to act concomitantly with DEP-1 (CD148) to activate Src in B cells. Double 
knockout studies of CD45 and CD148 in mice generated developmental defects in B 
cells and the myeloid lineage and also altered immune receptor signalling and 
hyperphosphorylated SFK, proposing overlapping roles for both PTPs in SFK 
activation in these cells (272). 
 
1.7.2.3 SHP-1 and SHP-2 
 
SHP-1 and SHP-2 are cytosolic PTPs containing several SH2 domains and are 
thought to contribute to growth receptor signalling pathways via SH2 domain 
interaction. Both PTPs regulate Src activity by influencing Y529 phosphorylation. In 
the case of SHP-1, it was shown to associate with Src and directly dephosphorylate 
Y529 (310). Interestingly, Src was also shown to catalyze SHP-1 tyrosine 
phosphorylation in the C-terminal tail, leading to SHP-1 activation (311). 
SHP-2 regulates Src activity in an indirect manner via the regulation of Csk 
localisation. PAG (phosphoprotein associated with glycosphingolipid-enriched 
microdomains), VE-cadherin and Paxillin are sites/proteins where Csk is recruited to 
the membrane via its SH2 domain (261, 312, 313). At these sites Csk regulates Src 
activity through the phosphorylation of Src Y529, leading to Src inactivation. SHP-2 
can be co-recruited to these sites and dephosphorylates the Csk binding sites on these 
proteins, allowing the release of Csk. The dissociation of Csk from these binding sites 
leads to the decrease of Src Y529 phosphorylation, allowing Src activation. Thus, 
SHP-2 indirectly promotes Y418 phosphorylation and Src activation through the 
regulation of Csk access to Src in response to growth factor stimulation and integrin 
signalling. 
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1.7.2.4 PTP1B 
 
PTP1B is an abundant cytosolic PTP with a major role in the regulation of 
proliferative and metabolic signals. Tyrosine 529 of SFK is a target of PTP1B 
downstream of integrin and insulin signalling as well as in several human breast 
cancer cell lines (314, 315). Moreover, the activation with SFK can also be mediated 
by distinct interaction domains such as two proline-rich regions in the C-terminal tail 
or a tandem tyrosine residue in the N-terminal of PTP1B (316). In breast cancer cells, 
activation of ErbB2 increases PTP1B expression, resulting in higher Src activation 
and the induction of a Src-dependent transformed phenotype in these cells (317). 
 
1.7.2.5 DEP-1 
 
DEP-1 is ubiquitously expressed and several studies provide evidence that DEP-1 can 
regulate Src activity. In malignant rat thyroid cells, overexpressed DEP-1 
dephosphorylates Src on tyrosine 529 leading to its activation (318). Another study 
showed that DEP-1 promotes adhesion-dependant Src activation in PDGF-stimulated 
PAE and NIH3T3 cells (319). Moreover, somatostatin (SST) was shown to activate 
DEP-1 in CHO cells stably expressing SST1 receptor (SST1R). In these cells, DEP-1 
was reported to interact with Src and to be activated by the JAK2/SHP2/Src pathway 
following somatostatin stimulation. This study did not find evidence that Src can be 
dephosphorylated by DEP-1 in response to SST (212). Thus, several studies provide 
hints that DEP-1 can interact with and activate Src in various cell types. However, it 
is not known if Src activity is affected in DEP-1 knockout models or the DEP-1 
knockin model (265, 272, 320). Our laboratory demonstrated recently that Src 
activity is increased in a DEP-1-dependent manner in VEGF-stimulated  EC, leading 
to increased cell survival (figure 14) (160). However, the mechanism of Src 
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activation via DEP-1 and the consequences on other endothelial cell functions in 
response to VEGF remain poorly defined. 
 
Figure 14: Implication of DEP-1 in the regulation of VEGFR2 
phosphorylation and VEGF-dependent downstream signalling. 
Upon VEGF stimulation, DEP-1 can target tyrosine 1054/1059 of VEGFR2 to 
reduce the general VEGFR2 phosphorylation at adherens junctions. Common 
signalling pathways including ERK1/2 and p38 are downregulated with the 
exception of the Src/Gab1/AKT pathway, which is induced under these conditions, 
leading to increased survival of EC. Adapted from (149, 160).  
 
1.8 Biological functions of Src in endothelial cells 
 
Src has a central role in cell signalling, resulting in the mediation of basal EC 
functions such as cell migration, survival and cell division (321-325). Adherens 
junctions are composed of VE-cadherin, which is linked to p120 catenin, plakoglobin 
and β-catenin via its cytoplasmic tail (326). In response to VEGF, tyrosine 
phosphorylation of adherens junction proteins is reported to increase (135). Src is 
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proposed to be responsible for the phosphorylation of VE-cadherin since VEGF-
induced VE-cadherin phosphorylation is absent in Src-/- mice (65). Src induces VE-
cadherin phosphorylation via two mechanisms in response to VEGF. On one hand, 
Src phosphorylates Vav2, resulting in the activation of Rac and PAK, which in turn 
phosphorylates serine 665 of VE-cadherin (137). On the other hand, Src mediates the 
direct phosphorylation of VE-cadherin at Y685 (327). Both Src-dependent 
phosphorylation processes induce the internalization of VE-cadherin in response to 
VEGF, resulting in the loss of junctional integrity. Moreover, Src also phosphorylates 
β-catenin on Y654, resulting in its release from VE-cadherin (328, 329). Following 
phosphorylation, the catenin-cadherin complex is abrogated and its adhesive function 
is lost, resulting in the loosening of cell-cell junctions (136, 330, 331). Decreased 
adhesive function of cell-cell contacts induces cell migration and invasion. Moreover, 
the remodelling of cell junctions induces vascular permeability through intercellular 
gap formation, allowing the passage of molecules and fluids into the interstitial space 
(129, 135, 323, 332). The entirety of induced changes of endothelial cell contacts 
upon VEGF stimulation allows the sprouting of endothelial cells to form a new 
capillary. 
VEGF also induces vascular permeability involving the eNOS pathway as 
shown in an eNOS -/- mouse model (140). Interestingly, it was reported that Src 
induces the activation of the eNOS pathway upon VEGF stimulation. The study 
showed that in basal conditions, Csk is bound to VE-cadherin and negatively 
regulates the activity of VE-cadherin-associated Src. Upon VEGF stimulation, SHP-2 
is co-recruited to VE-Cadherin, dephosphorylating the Csk binding site Y685. This 
results in the release of Csk into the cytosol and Src activation. The activated Src/VE-
Cadherin/SHP-2 complex induces the activation of the eNOS/AKT pathway, 
resulting in the disruption of cell contacts (261). 
Besides paracellular transport, Src also plays a major role in transcellular 
transport. This second transport mechanism permits the active passage of 
macromolecules into the interstitial space through the Src-mediated formation of 
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calveolae and their detachment as endocytic vesicles (331, 333). Both cellular 
transport mechanisms are implicated in physiological as well as pathological 
processes including inflammation and extravasation of tumour cells from the vascular 
space (334, 335). Indeed, the loss of functional cell-cell junctions has been associated 
with increased invasion and metastases in cancer (336). Src-mediated permeability 
allows cancer cells to invade and to metastasize into distant organs. Consistently, Src 
inhibition was shown to block metastasis formation (337-339).  
 
1.9 Biological functions of Src in cancer cells 
 
Based on the central role of Src in the regulation of multiple signalling networks, its 
activation has to be tightly regulated in a time- and space-dependent manner. 
Inappropriate Src activation is implicated in various pathologies such as cancer. Thus, 
high levels of Src expression and activity are observed in most human cancer types 
including colorectal, ovarian, pancreatic and breast cancer (340-343). However, Src 
mutations are rarely found in cancers, indicating that its activity is altered by 
upstream events including overexpression and altered activity of RTKs and PTPs.  
Consistent with these observations, v-Src, which lacks the inhibitory Y529, is a 
strong tumour promoter and it is the first oncogene identified as well as one of the 
most studied. Truncation of its C-terminal tail, which encompasses the inhibitory 
tyrosine Y529, results in a constitutively active form. In cancer cells, the 
constitutively active Src increases proliferation and cell survival to promote tumour 
mass formation. On the other hand, it also promotes the remodelling of the Actin 
cytoskeleton and cell-cell and/or cell-matrix adhesion, thereby facilitating cell 
motility and invasion (344). Activation of downstream targets of Src associated with 
higher cell motility including p190 RHOGAP leads to the loss of Actin organization 
and focal adhesion disassembly, resulting in cell detachment from the ECM (345-
348). Cancer cell invasion is an essential step to form distant metastases. The 
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“mesenchymal-type” invasion combines migration and ECM breakdown by cancer 
cells and involves Src activity to trigger expression of matrix-degrading proteases 
including MMP2 and MMP9 (349). Src was also reported to inhibit endocytosis of 
MT1-MMP, leading to its higher expression at the cell surface and hence in higher 
activation of its substrate MMP2 (350). Epithelial-to-Mesenchymal Transition (EMT) 
is a common feature of epithelial cancer cells and a dynamic process that endows 
cells with a higher capacity to migrate. It promotes the migration of single cells, 
which is a distinct feature of mesenchymal cells (351-353). In addition, Src can 
induce the phosphorylation of the E-Cadherin-β-catenin complex, leading to the 
disruption of adhesive cell contacts and the promotion of invasion and the EMT 
phenotype in cancer cells (339, 354-356). Phosphorylated β-catenin translocates to 
the nucleus to induce transcription of genes whose products such as proteases and 
vimentin are involved the promotion of EMT, invasion and tumour progression (354, 
357). Src-mediating degradation of the Rac activator Tiam1, which is implicated in 
the maintenance of cell-cell contacts, allows enhanced motility and invasiveness 
(358). Thus, Src will favour increased migration and invasion of tumour cells to 
promote their dissemination and the formation of metastases. Consistent with these 
data, Src is involved in the formation of metastases to distant organs in breast cancer 
models, especially to the bone and the lung (338, 359, 360). In conclusion, in both 
endothelial and cancer cells Src-mediated loosening and disruption of cell-cell 
contacts will contribute to tumour progression and metastasis formation. 
 
1.9.1 The role of Src in breast cancer 
 
In breast cancer, numerous genes are deregulated by heterogeneous gene copy 
numbers, expression abnormalities and mutations. Genome-wide analysis of gene 
expression in breast cancer cell lines and primary tumours led to their classification in 
various subtypes (361, 362). Common subsets were defined as basal-like, luminal-
47 
 
 
like A and B, Her2-enriched and normal-breast-like. The basal-like type is commonly 
characterized by the lack of hormone receptors for estrogen and progesterone but also 
the lack of Her2 and E-cadherin expression. In contrast, the expression of EGFR, 
basal cytokeratins, and Vimentin is amplified (363, 364). This subtype is a poor 
prognosis group based on its in generally more invasive character and its higher 
aggressiveness resulting in the formation of distant metastases (362, 365, 366). On 
the other hand the luminal-like group displays expression of ER and Her2 along with 
expression of epithelial markers such as cytokeratins and E-cadherin (363, 367). 
According to its molecular pattern, luminal-like breast cancer is in general less 
aggressive, and patients have a better outcome than those with a basal-like breast 
cancer (368). Based on heterogeneous expression patterns, subsets can also 
encompass several subset entities, as it is the case for triple-negative breast cancer. 
This subtype is negative for hormone receptors expression and Her2 expression but 
shows various molecular characteristics of basal-like as well as normal-like breast 
cancer (369).  
Src kinase activity and expression is increased in breast cancer tissue 
compared to normal breast tissue (370). Src is a mediator of many downstream 
effects of RTK and crosstalk between EGFR family and Src was shown in breast 
cancer specimens (371). Notably, Src transfection was shown to increase EGF-
mediated oncogenesis (372). For instance, SFK activity is essential for MAPK 
activation following growth factor stimulation in various breast cancer cell lines, and 
in consequence, for the induction of breast cancer cell proliferation (373). 
Furthermore, DNA synthesis in response to EGF was reported to be dependent on a 
functional Src kinase domain (374). Another study demonstrated that Src is required 
for cell motility and anchorage-independent growth in response to activation of the 
Her2-Her3 complex (375). Since bone is the preferred site for the formation of 
metastases in breast cancer, it is interesting that Src is known as an essential regulator 
of osteoclast function (359). These results demonstrated a role for Src in the 
formation of metastases to bone. In addition, increased Src expression was correlated 
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with the upregulation of mesenchymal markers such as Vimentin and N-Cadherin and 
with a higher invasive, capacity suggesting its implication in the EMT of breast 
cancer (355, 360). Altogether, these studies demonstrated an implication of Src in 
breast cancer progression, providing the rationale to target Src or to modulate its 
activity for breast cancer treatment. Some Src inhibitors such as dasatinib are 
currently in clinical trials for patients with solid tumours such as breast cancer (376). 
 
1.10 The role of PTPs in cancer 
 
Given that the Src activity is regulated by PTPs and that Src in turn regulates multiple 
signalling pathways in cancer cells, the role of PTPs in cancer recently became a 
subject of interest in cancer research.  High tyrosine phosphorylation levels are 
observed in breast cancer tissue compared to normal mammary tissue due to elevated 
tyrosine kinase activity, suggesting that the balance between RTKs signalling and 
PTP-mediated dephosphorylation is altered (377, 378). 
 
1.10.1 Tumour suppressing PTPs 
 
Since PTPs have antagonistic effects on RTKs and their dependent signalling, they 
have initially been considered as tumour suppressors. Often, PTPs are mutated and/or 
inactivated in cancer. Epigenetic alterations such as methylation are the most 
common mechanism for gene inactivation resulting in a global loss of gene 
expression compared to normal tissue (379). Further, as reported for other tumour 
suppressor genes, deletion, mutations or loss of heterozygosity (LOH) are common 
genetic alterations of PTP genes (380). The most frequent gene alterations of RPTPs 
in cancer are found in the extracellular domain. Structure-prediction studies proposed 
that a number of mutations in the extracellular domain of RPTPs could alter their 
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organization and change their interaction with other proteins. Further, point mutations 
in the catalytic domain predicted to reduce its catalytic activity were reported for 
PTPRT in colorectal cancer (381). Inactivating mutations in PTPs commonly occur 
together with activating mutations in RTK, counter-steering the general balance of 
RTK- and PTP-dependent signalling in cancer. 
 
1.10.1.1 GLEPP1/PTPRO 
 
PTPRO was reported to be inactivated by promoter methylation in human lung 
cancer. Moreover, in A549 lung cancer cells, overexpressed PTPRO reduced 
anchorage-independent growth, proliferation and the resistance to apoptosis (382). 
Furthermore, inhibiting methylation of PTPRO gene in leukaemia results in higher 
phosphorylation of BCR/Abl, increasing its transformation potential (383). In 
addition, promoter methylation of GLEPP1/PTPRO leading to the suppression of 
PTPRO expression is also seen in the breast cancer cell lines MCF-7 and MDA-MB 
231, and in many primary breast cancer tumours (384). The inhibition of PTPRO 
expression was proposed to be estrogen-dependent, consistent with results showing 
that PTPRO expression increases after treatment with the estrogen receptor antagonist 
tamoxifen. Inverse experiments showed that PTPRO overexpression increased 
tamoxifen sensitivity in MCF-7 cells (385). Thus, these data support a role for 
PTPRO as a tumour suppressor.  
 
1.10.1.2 SHP-1 
 
Epigenetic alterations such as hypermethylation of the SHP-1 promoter lead to its 
inactivation in cancer. This alteration was first described in T cell lymphomas and 
results showed that the treatment with a demethylating agent restored SHP-1 
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expression (386, 387). Re-expression of SHP-1 decreased the phosphorylation of 
JAK3 or STAT3 in this model, antagonizing the JAK3/STAT3-induced cell survival 
(388, 389). Some studies demonstrated that SHP-1 mediates somatostatin-induced 
apoptosis by increasing cellular acidification and contributes to the antiproliferative 
effect of SST2 in MCF-7 and T47D cells, supporting its negative role in cancer (390, 
391). 
 
1.10.1.3 DEP-1 
 
DEP-1 was demonstrated to be a tumour suppressor in many cancers. In various 
breast cancer cell lines, DEP-1 was shown to mediate growth inhibition in vitro 
(392). Interestingly, DEP-1 expression was associated with higher differentiation of 
several types of cancer cells, suggesting an inhibitory role for DEP-1 in cell 
transformation (392, 393). In agreement with these studies, DEP-1 expression was 
shown to suppress the malignant phenotype of transformed rat thyroid cells (394). 
Moreover, the functional PTPRJ gene was associated with the colon cancer 
susceptibility locus Scc1 in mice. Originally this locus was defined by its segregation 
with colon cancer susceptibility after crossing cancer-resistant with cancer-
susceptible mouse strains. Notably, sequence differences in DEP-1 between the 
cancer-resistant and the cancer-susceptible strain support the notion that certain DEP-
1 variants drive cancer susceptibility due to inactivating mutations (395-397). Further 
analysis of the PTPRJ gene status in human samples identified that LOH occurs in 
PTPRJ in colorectal cancer as well as breast, lung, thyroid cancer and meningiomas 
(figure 15 A-B) (395, 398). Studies in thyroid carcinoma, colon and breast cancer 
patients demonstrated that often the preferential loss of one allele occurs during 
cancer growth, indicating that the two DEP-1 alleles have different activities; the one 
remaining is potentially less active (395, 396, 399). Moreover, single nucleotide 
polymorphisms (SNPs) found in the DEP-1 extracellular domain were shown to 
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influence the susceptibility to a wide range of cancer types including colorectal, lung, 
head and neck cancer (400). As in mice, SNPs generate different allelic variants of 
PTPRJ in humans, which differ in their extracellular domain (figure 15 C) (395). 
Hence, these results suggest that DEP-1 could be less active in several cancer types 
due to the preferential loss of the more active allele and inactivating mutations in the 
remaining allele.  
Further examples strengthen the tumour suppressive role of DEP-1 in different 
cancer types. For instance, EGFR is known to drive several types of malignancy such 
as breast, head and neck as well as lung cancer (401). Thus, it is remarkable that 
DEP-1 inhibits EGFR activation at the cell surface along with inhibition of the active 
receptor transport to endosomes, supporting the tumour-suppressive function of DEP-
1 consistent with former studies (213). Also consistent with these studies, DEP-1 
expression was associated with inhibition of proliferation and motility in 
meningiomas and a colon cancer cell line (398, 402). Cytoskeletal rearrangements 
were induced by DEP-1 in colon cancer cells, leading to inhibited migration in 
comparison to DEP-1-negative colon cancer cells (402). Recently, Flt-3 
transformation of lymphoma cells in acute myeloid leukaemia (AML) was shown to 
be accompanied by the inactivation of DEP-1, suggesting that DEP-1 activity is 
required to suppress cell transformation (223). 
Some studies also provided initial evidence that DEP-1 could also have other 
functions in cancer in addition to its tumour-suppressing features. Surprisingly,   
DEP-1-/- mice grow and develop normally and show no spontaneous development of 
tumours, suggesting that additional alterations are necessary for cancer development 
(320). Recently, a missense mutation in the non-catalytic domain of DEP-1 
(K1017N) was shown to be enriched in primary breast tumours. Additionally, this 
DEP-1 variant was also found amongst the most highly enriched mutations in brain 
metastases (403). Thus, these results suggest that some DEP-1 mutations could be 
favourable for cancer progression. Interestingly, another study showed that 
expression of the DEP-1 K1016A mutant impaired the interaction between the known 
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DEP-1 substrate ERK1/2 and DEP-1. This mutant is unable to dephosphorylate 
ERK1/2, resulting in continued cell proliferation (404). It is possible that the DEP-1 
K1017N mutation found in brain metastases of breast cancer has similar functions on 
ERK1/2 as the DEP-1 K1016A mutant (380). 
 
Figure 15: Principal mechanisms of DEP-1 modification in cancer. 
A) DEP-1 is ubiquitous expressed in normal cells. B) Ruivenkamp et al., 2003 found 
loss of hetereozygosity in the PTPRJ gene, which encodes for DEP-1, in samples of 
different cancer types. LOH is a common gene modification in cancer and results in 
the loss of one allele while the other less active allele remains. C) Five single 
nucleotide polymorphisms in the fibronectin motifs of the DEP-1 extracellular 
domain were identified in colorectal cancer samples. The DEP-1 K1017N mutation 
was found enriched in breast metastases. Adapted from (380, 396, 405). 
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Oncogene activation can be induced by certain gene alterations such as chromosome 
translocation, activating point mutations (gain-of-function mutations) and gene 
amplifications. These activating alterations are frequently found in genes encoding 
for PTPs suggesting a tumour-promoting role for these PTPs in cancer. 
 
1.10.2.1 PTPα 
 
PTPα was believed to be a potential oncogenic PTP due to its ability to activate Src. 
Its positive effect on cell signalling allows PTPα to transform mouse fibroblasts, 
suggesting that PTPα can act as an oncogene itself or enhance tumorigenicity in 
collaboration with other factors (162, 406). However, Src-activating PTPα mutants 
are expressed in late stage colon and breast carcinoma (406). Depletion of PTPα 
results in decreased Src activity in mouse brain, mouse fibroblasts and several human 
cancer cell lines including breast and colon (293, 294, 407). Moreover, Src activity 
was inhibited in PTPα-depleted ER-negative breast cancer cell lines concomitantly 
with suppressed anchorage-independent growth and reduced cell survival, suggesting 
a tumour-promoting role for PTPα in these cells. In contrast, PTPα depletion did not 
inhibit Src activity in ER-positive breast cancer cell lines and its expression was 
correlated with low tumour grade and ER expression (407, 408). Together, these 
results suggest that PTPα can promote tumour progression depending on the ER 
status in breast cancer (407). Recently, it was shown that two distinct isoforms of 
PTPα exist, which both can activate Src, but differ in their capacity to transform cells 
due to a different extracellular domain, adding an interesting aspect to PTPα 
regulation (409). 
 
1.10.2 .2 PTPε 
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Expression of PTPε was shown to promote mammary hyperplasia in transgenic mice, 
and these mice developed sporadic mammary tumours more frequently than WT mice 
(410). PTPε can activate Src and promotes the transformed phenotype of Neu-
induced mammary tumour cells. Its depletion decreases cell proliferation and cells 
appear morphologically less transformed (303). This PTPε-mediated Src activation is 
essential to maintain the transformed phenotype of Neu-induced mammary tumour 
cells, demonstrating the tumour promoting role of PTPε in this model (299). 
Recently, it was shown that the expression of PTPε promotes anchorage-independent 
growth and increases survival in human breast cancer cell lines, supporting the notion 
that PTPε can act as a tumour promoter (411). 
 
1.10.2.3 SHP-2 
 
Mutations due to single-amino acid changes are found in the catalytic and the SH2 
domain of SHP-2 and increase its basal activity by preventing the inhibitory 
conformation of SHP-2. Thus, SHP-2 is defined as a proto-oncogene activating 
oncogenic tyrosine kinases in several cancers including leukemia (412-414). The 
activating mutations were detected in half of the cases of Noonan syndrome and in 
several human cancers including leukaemia, lung and colon cancer, melanoma and 
neuroblastoma (415-417). Further mutated variants encompass modified substrate 
selectivity. For instance, the activation of Ras-ERK is the principal effect of SHP-2 
mutants leading to transformation of cells (405, 412). 
 
1.10.3 Dual role of certain PTPs in cancer – PTP1B 
 
The role of PTP1B in cancer is contentious. A number of studies showed a tumour-
promoting role for PTP1B, suggesting that PTP1B can act as a proto-oncogene. In 
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contrast, it can also act as a tumour suppressor depending on the cancer type and/or 
the mutations of other genes involved in cancer development (418). 
Although PTP1B deficiency promotes oncogenic signalling due to the absent 
negative regulation of various growth receptors, PTP1B knockout mice lack 
spontaneous tumour development. Interestingly, PTP1B expression is elevated in 
most breast cancer specimens and positively correlates with ErbB2 expression. 
Consistent with this observation, PTP1B was shown to be a positive regulator of 
ErbB2 signalling, promoting the activation of the ERK- and PI3K/AKT-pathway. 
These events enhance mammary tumorigenesis and malignancy in breast cancer (419-
421). Similar results were observed in ovarian cancer, suggesting that ErbB2 and 
PTP1B could cooperate in different cancer types to promote tumorigenesis (422, 
423). Interestingly, analysis of ErbB2 mutant mice that are reported to develop 
spontaneously mammary carcinomas, were crossed with PTP1B-/- mice (424). The 
PTP1B deficiency in these mice delays tumour progression through the 
downregulation of the ERK- and PI3K/AKT-pathway and protects from lung 
metastasis formation (420, 421). Moreover, the activation of the Ras pathway was 
shown to be decreased in fibroblasts isolated from PTP1B knockout mice, indicating 
that PTP1B has a pro-oncogenic role in part due to the enhanced Ras signalling (425). 
In agreement with PTP1B knockout studies, PTP1B overexpression increases Src 
activation in colon cancer cells, further suggesting an activating role of PTP1B in 
cancer cell growth and invasion (315, 426). Consistent with this, increased PTP1B 
activity was reported to promote Src activation and invadopodia formation in breast 
cancer cells (427). 
In contrast to this positive implication of PTP1B in cancer, anti-tumorigenic 
functions of PTP1B are also reported. PTP1B overexpression was shown to decrease 
v-Src and Crk-induced ERK activation (428). Consistent with its tumour-suppressive 
role, various studies demonstrated that PTP1B promotes apoptosis through different 
mechanisms including downregulation of pro-invasive signalling, ER-stress induction 
or the increase of caspase 8/9 activity (429-432). Notably, PTP1B is also implicated 
56 
 
 
in the regulation of cell junctional integrity, reducing cell motility. It was shown to 
associate with N-cadherin to dephosphorylate β-catenin, promoting the complex 
formation between N-cadherin and β-catenin to strengthen cell-cell contacts (433, 
434). Genetic ablation of PTP1B in a p53 knockout mouse model revealed that 
PTP1B indirectly delays lymphomagenesis via the promotion of B-cell differentiation 
in these mice (435). 
Currently, a body of evidence suggests for various PTPs that the same PTP 
may behave as a tumour promoter as well as a tumour suppressor in cancer. Genetic 
and/or epigenetic alterations are suggested to act on PTP genes to modify the protein 
function depending on the cell context, resulting in this dual role in cancer. 
 
 
1.11 Previous work and objectives of this thesis 
 
DEP-1 (Density-enhanced phosphatase 1) was shown to be implicated in vessel 
remodelling and branching during development, suggesting an essential role in the 
regulation of angiogenesis. Its expression increases with cell density and was shown 
to correlate with the dephosphorylation of VEGFR2 in confluent endothelial cells. 
However, the contribution of DEP-1 in the regulation of VEGFR2 and VEGF-
dependent signalling pathways and biological responses remained ill-defined. 
Previous work in our laboratory showed that DEP-1 negatively regulates VEGFR2 
activity by the dephosphorylation of tyrosines 1054 and 1059 in the kinase activation 
loop of VEGFR2. In consequence, the global phosphorylation of VEGFR2 is 
decreased and the activation of most signalling pathways downstream of VEGFR2 is 
impaired. Consistently, DEP-1 depletion results in the global increase of VEGFR2 
phosphorylation and in the increased activation of major downstream pathways 
including the mitotic PLCγ-ERK1/2 pathway and p38. In contrast, the 
phosphorylation of Src on its inhibitory tyrosine 529 is increased in these cells 
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suggesting that DEP-1 promotes the activation of Src. Despite the negative role of 
DEP-1 on most VEGF-dependent signalling pathway, our study revealed that DEP-1 
induces the Src-Gab1-AKT pathway and promotes endothelial cell survival. 
However, the specific molecular mechanism implicated in DEP-1-mediated Src 
activation as well as the understanding of the role of DEP-1 in the regulation of the 
VEGF-dependent angiogenic program remained ill-defined. 
 
In the course of our studies, we observed that DEP-1 is phosphorylated on tyrosine 
and since it is known that the tyrosine phosphorylation of PTPs can direct them 
towards specific substrates and/or regulate PTP activity, we were interested to 
identify major phosphorylation sites in DEP-1 and to elucidate the implication of 
these sites on DEP-1 function in endothelial cells. In detail we wanted to determine:  
 
• that DEP-1 is phosphorylated in endothelial cells in response to 
VEGF on the identified tyrosines  
• that the phosphorylated tyrosines of DEP-1 are implicated in 
Src binding and activation 
• that DEP-1 and its tyrosine phosphorylation are implicated in 
the regulation of endothelial cell functions such as 
permeability, capillary formation and invasion 
• the impact of DEP-1 expression levels on Src activation and 
endothelial cell functions 
 
In this first study, we showed that Y1311 and Y1320 are the major tyrosine residues 
which are phosphorylated in the C-terminal tail of DEP-1. These residues are 
essential for Src activation and the regulation of endothelial cell functions including 
permeability, invasion and capillary formation. Subsequently, we identified also a 
threonine residue proximal to Y1320 which displays a potential phosphorylation site.  
 
58 
 
 
The aim of this second study was to define the role of T1318 on DEP-1 tyrosine 
phosphorylation and consequently in Src activation and endothelial cell functions. 
The results are presented in chapter III: 
 
• Confirmation of DEP-1 phosphorylation on threonine 
• Evaluation of DEP-1 T1318 phosphorylation in endothelial 
cells  
• Impact of DEP-1 T1318 phosphorylation on Y1311 and Y1320 
phosphorylation 
• Role of DEP-1 T1318 phosphorylation on Src binding and Src 
activation  
•  Consequence of DEP-1 T1318 phosphorylation on the   
phosphorylation of VE-cadherin and endothelial cell  
permeability 
• Identification of the kinase responsible for DEP-1 T1318 
phosphorylation 
 
In this second study, we demonstrated that DEP-1 is constitutively phosphorylated on 
T1318 in endothelial cells. Upon VEGF stimulation, T1318 phosphorylation is 
decreased concomitantly with induced DEP-1 phosphorylation on Y1311 and Y1320. 
Mutation of DEP-1 T1318 impairs phosphorylation of Y1311 and Y1320, Src 
activation and endothelial cell permeability. First hints provide evidence that DEP-1 
T1318 is phosphorylated by CK2 in endothelial cells.  
 
Src is known as tumor oncogene, promoting cancer progression via the induction of 
cell transformation, pro-invasive cell signalling and cell functions. Since DEP-1 has a 
major role in Src activation in endothelial cells, we were interested in understanding 
the role of DEP-1 in Src regulation in breast cancer cells. The results of this third 
study are presented in chapter IV: 
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• Evaluation of DEP-1 expression in a panel of basal-like and 
luminal-like breast cancer cell lines 
• Implication of DEP-1 in Src regulation in this panel of breast 
cancer cell lines 
• Effect of DEP-1 on cell signalling events (induction of pro-
invasive pathways) in basal-like breast cancer cells 
• Determination of the role of DEP-1 on biological cell functions 
in basal-like versus luminal-like breast cancer cell lines  
• Confirmation of our model in a bone metastatic subpopulation 
of MDA-MB 231 (variant 1833) 
• Evaluation of DEP-1 expression in human breast cancer 
specimen (TMA) and its impact on the clinical outcome of 
breast cancer patients 
 
In this study we showed that in basal-like breast cancer cell lines DEP-1 expression is 
elevated in contrast to luminal-like breast cancer cell lines. DEP-1 activates Src and 
Src-dependent pro-invasive signalling in basal-like breast cancer cell lines. 
Consistently, DEP-1 is required for the proper localisation of proteins implicated in 
the mediation of cell motility and in the promotion of migration and invasion in 
basal-like breast cancer cell lines. Importantly, DEP-1 expression is correlated with 
reduced overall survival of patients in human breast cancer. 
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Abstract 
 
DEP-1/CD148 is a receptor-like protein tyrosine phosphatase with anti-proliferative 
and tumor-suppressive functions. Interestingly, it also positively regulates Src family 
kinases in hematopoietic and endothelial cells, where we showed it promotes VE-
cadherin-associated Src activation and endothelial cell survival upon VEGF 
stimulation. However, the molecular mechanism involved and its biological functions 
in endothelial cells remain ill-defined. We demonstrate here that DEP-1 is 
phosphorylated in a Src- and Fyn-dependent manner on Y1311 and Y1320, which 
bind the Src SH2 domain. This allows DEP-1-catalyzed dephosphorylation of Src 
inhibitory Y529 and favors the VEGF-induced phosphorylation of Src substrates VE-
cadherin and Cortactin. Accordingly, RNAi-mediated knockdown of DEP-1 or 
expression of DEP-1 Y1311F/Y1320F impairs Src-dependent biological responses 
mediated by VEGF including permeability, invasion and branching capillary 
formation. In addition, our work further reveals that above a threshold expression 
level, DEP-1 can also dephosphorylate Src Y418 and attenuate downstream signaling 
and biological responses, consistent with the quiescent behavior of confluent 
endothelial cells that express the highest levels of endogenous DEP-1. Collectively, 
our findings identify the VEGF-dependent phosphorylation of DEP-1 as a novel 
mechanism controlling Src activation, and show this is essential for the proper 
regulation of permeability and the promotion of the angiogenic response. 
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Introduction 
 
DEP-1/CD148 (also called PTPη or PTPRJ) is a receptor-like protein tyrosine 
phosphatase (PTP) expressed in several cell types including epithelial, endothelial 
and hematopoietic cells (436). It encompasses an extracellular domain containing 
eight fibronectin type III-like motifs, a transmembrane domain, a single intracellular 
catalytic domain, and a short C-terminal tail (234). Initial studies demonstrated that 
its expression increases with cell density and suggested a function in cell contact-
mediated growth inhibition (234, 394). Overexpression of DEP-1 in cancer cells was 
also reported to inhibit their growth, while thyroid cell transformation was associated 
with its decreased expression, indicative of a role for DEP-1 as a tumor suppressor 
(392-394, 402, 437). DEP-1 was further identified as the gene associated with the 
mouse colon cancer susceptibility locus (Scc1), and was found to be frequently 
deleted and mutated in human cancers (438). These growth inhibitory functions of 
DEP-1 are consistent with the nature of some of its reported substrates, which include 
the PDGF, HGF (Met), and VEGF (VEGFR2) receptors as well as Src family kinases 
(SFKs), ERK1/2 and the p85 subunit of PI3K (149, 160, 173, 272, 274, 275, 318, 
439, 440). DEP-1 also dephosphorylates proteins from the cell-cell junctional 
complexes including p120catenin, occludin and ZO-1, which might impact biological 
functions dependent on the loosening/strengthening of intercellular contacts (274, 
275, 441). 
VEGFR2 is a potent activator of the angiogenic response and is the main 
mediator of the mitogenic, chemotactic, permeability and survival effects of VEGF in 
normal and tumor-associated vessels (108). VE-cadherin adhesion complexes are 
important sites of VEGF-dependent signaling in confluent cells, as activated 
VEGFR2 associates to these complexes to mediate AKT activation and cell survival 
(269). DEP-1 was shown to co-localize to these sites and to attenuate the 
phosphorylation of VEGFR2, resulting in the impaired activation of ERK1/2 and the 
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contact-inhibition of endothelial cell proliferation (149, 442). However, DEP-1 was 
also reported to positively regulate VE-cadherin-associated Src and AKT and to 
promote VEGF-dependent endothelial cell survival (160). Consistent with these 
distinct in vitro functions, inactivation of DEP-1 in mice via the swapping of its 
catalytic domain and C-terminal tail with GFP revealed both positive and negative 
regulatory effects in vascular development, and resulted in defective vessel 
remodeling and branching in addition to increased endothelial cell proliferation (265).  
SFKs promote cell survival, invasion, remodeling of cell-cell junctions and 
permeability which are essential cellular functions that contribute to vessel sprouting 
and neovascularization (18, 114, 158, 443, 444). In their inactive state, SFKs adopt a 
closed conformation where the SH2 domain is linked to the phosphorylated C-
terminal tyrosine residue (Y529 in human Src). To become active, the SH2 domain 
must engage with higher affinity binding sites on other molecules to release the Src 
C-terminal tyrosine residue and allow its dephosphorylation by PTPs (phospho-
displacement mechanism). This then induces conformational changes that result in 
trans-phosphorylation of the catalytic tyrosine residue (Y418 in human Src) and SFK 
activation (445). DEP-1 has been shown to dephosphorylate Src Y529 and Y418 in 
vitro, but to preferentially target Y529 and activate Src when overexpressed in 
thyroid tumor cells (318). Conversely, the silencing of DEP-1 in endothelial cells 
results in the increased phosphorylation of VE-cadherin-associated Src on Y529, 
consistent with the observed inhibition of its activity and decreased Y418 
phosphorylation in response to VEGF (160). Recent genetic studies demonstrated that 
DEP-1/CD148 is also an important activator of SFKs in hematopoietic cells, and 
promotes immunoreceptor signaling, B cell and myeloid lineage development, 
phagocytosis, as well as platelet activation and thrombosis (272, 436, 446). 
Despite their broad implication in the activation of SFKs, the molecular 
mechanism underlying the ability of most PTPs to activate Src remains incompletely 
understood. The phosphorylation of receptor-type PTPε and PTPα has been suggested 
to regulate their ability to activate Src (204, 206, 299). We show here that VEGF 
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induces the tyrosine phosphorylation on DEP-1 Y1311 and Y1320 in endothelial 
cells. This is essential for Src Y 529 dephosphorylation and the promotion of Src-
dependent angiogenic responses (114, 129, 443). However, we also found that when 
expressed above a threshold level, such as that observed in confluent and quiescent 
cells, DEP-1 rather inhibits Src and downstream responses. This study therefore 
identifies for the first time regulatory events allowing the control of DEP-1-mediated 
Src activation and further defines the molecular mechanisms underlying the 
promotion of VEGF-dependent permeability and angiogenesis. 
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Methods 
 
Antibodies and Reagents 
PY99, Myc (clone 9E10), and DEP-1 (clone 143-41; for IP) antibodies were 
purchased from Santa Cruz Biotechnology. Antibodies detecting VEGFR2 pY1059, 
FAK, PLCγ, GST, and Src (mouse clone GD11 for IP and blotting) were obtained 
from Upstate/Millipore. DEP-1 goat (for blotting) and mouse (clone 143-41; for IP 
and blotting) antibodies were from R&D System. Phospho-specific antibodies against 
Src pY418, VE-cadherin pY658, FAK pY861 and Alexa Fluor 488 goat anti-mouse 
antibody were from Invitrogen. Horseradish peroxidase (HRP)-conjugated anti-
mouse or anti-rabbit IgGs, VE-cadherin, Src (rabbit clone 36D10 for blotting), and 
Src pY529 antibodies were purchased from Cell Signaling Technology, New England 
Biolabs. β-catenin antibody was from BD Transduction Laboratories. Anti-Fyn 
polyclonal antibody was provided by André Veillette, Institut de Recherches 
Cliniques de Montréal, Canada. VE-cadherin pS665 antibody was generated as 
described (137). Phospho-specific antibodies against DEP-1 Y1311 and Y1320 were 
generated by GenScript against the following peptides: CQKDSKVDLI[pY1311]QNT 
and CKDSKVDLIYQNTTAMTI[pY1320]EN, respectively. VEGF was obtained from 
the BRB Preclinical Repository of the NCI-Frederick Cancer Research and 
Development Center. PP2 and pNPP were purchased from Calbiochem and Sigma, 
respectively. 
 
cDNA constructs 
The plasmids encoding WT DEP-1, the C/S and D/A mutants were provided by 
Nicholas Tonks (Cold Spring Harbor Laboratory, NY, USA).(234) The WT and 
mutant Myr-DEP-1 cDNA constructs were generated as previously described.(160) 
All of the Y/F and E/Q DEP-1 mutants were made using the QuikChange XL site-
directed mutagenesis kit (Stratagene). The mutagenic primers used are described 
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below. The Src Y527F and Src Y527F/R175L plasmids were provided by Jeroen den 
Hertog (Hubrecht Institute, Utrecht, Netherlands), whereas the SrcRF 
(K295R/Y527F) and WT Src cDNA constructs used in these studies were obtained 
from Drs. Joan Brugge (Harvard Medical School, USA) and Stéphane Laporte 
(McGill University Health Centre, Montreal, Canada), respectively (206). WT pRK5-
Fyn is from Filippo Giancotti (Sloan-Kettering Institute for Cancer Research, New 
York, USA) and was obtained through Addgene. The GST-Src SH2 and GST-Src 
SH3 domain constructs (in pGEX-2TK) were generated using standard PCR 
procedures. 
 
Generation of Y/ F mutants in Myr-DEP-1 D/A and full-length DEP-1 
The mutagenic primers (Invitrogen) used to generate the various Myr-DEP-1 D/A 
Y/F mutants were the following: 
5’-AACTGAAGACAGGCTTCTTGTCCATCGTCATGGATCC-3’(Y1045F), 5’-
GTCAAGGGAAAGACTTCGTTGGAGCAATCCCTGTGGAT-3’ (Y1094F), 5’-
GAAGCTCCTGAAGATCTGTTTAAGGACTTCCTGACC-3’ (Y1161F), 5’-
CTGTGACTTTGGCTTGGCCCGGGATATTTTTAAAGATCCAG-3’ (Y1268F), 
5’-GATATTTATAAAGATCCAGATTTTGTCAGAAAAGGAGATGCTCGC-3’ 
(Y1288F), 5’- TGCTCAGCAGGATGGCAAAGACTTCATTGTTCTTCCGA-
3’(Y1311F), 5’-GACCCCAAATTCCATTTTGACAACACAGCAGGAATCAGTC-
3’ (Y1320F). The Y1311F/Y1320F mutant was made on the Y1311F mutant using 
the Y1320F mutagenic primer. Y1311F, Y1320F and Y1311F/Y1320F mutations 
were also generated on the full-length WT DEP-1 expressing vector. The E1321Q 
mutation was generated in DEP-1 WT using the following mutagenic primer: 5’-
GCGATG ACAATCTATCAAAACCTTG-CGCCCGTG -3’ (E1321Q). The 
presence of all mutations was confirmed by DNA sequencing. 
 
 
Cell culture 
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HEK 293, HEK 293T, SYF mouse embryonic fibroblasts (MEFs) and bovine aortic 
endothelial cells (BAECs from Lonza; passages 1 to 8) were cultured in high-glucose 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum 
(FBS; Invitrogen) and 50 µg/ml gentamycin. Human umbilical vein endothelial cells 
(HUVECs; Cascade Biologics, Invitrogen) were cultured (passages 1 to 4) on gelatin 
(0.2%)-coated tissue culture dishes in M200 (Invitrogen) supplemented with 2% FBS, 
hydrocortisone, EGF, bFGF, heparin (LSGS kit; Invitrogen) and 50 µg/ml 
gentamycin.  
 
DNA transfection conditions  
Transfections were performed using either the standard calcium phosphate method  or 
Lipofectamine 2000/Lipofectin according to the manufacturer's recommendations 
(447). In general, 5-10 µg of cDNA constructs were transfected in HEK 293 cells. In 
HEK 293T cells, 2 µg of DEP-1 constructs were co-transfected with 1 µg of 
SrcY527F (Figures 2E, 2F, Supplemental Figures 1A and 2B), while 3 or 4 µg were 
transfected to study the phosphorylation of endogenous Src and of transfected DEP-1 
and VEGFR2 (Figure 3B, C and E). MEFs were transfected with DEP-1 D/A (10 µg) 
alone or with WT Src or Fyn constructs (5 µg). BAECs and HUVECs were 
transfected with 6-8 µg/10 cm-dish and 10 µg/6 cm-dish, respectively.  
 
Immunoprecipitation and Western blotting 
Cell lysates (200-500 µg) were incubated with antibodies for 1.5h at 4oC, followed by 
incubation with protein A- or G-conjugated Sepharose beads (Amersham 
Biosciences/GE Healthcare) for an additional 1.5h. Beads were washed 3 times with 
lysis buffer and then denatured in 1x Laemmli sample buffer. In vitro Src kinase 
assay was performed using the Millipore kit as described.(160) Proteins were 
resolved by SDS-polyacrylamide gel electrophoresis, transferred onto Hybond-C 
extra membranes (Amersham Biosciences/GE Healthcare) and immunoblotted 
according to standard procedures as previously described (160). 
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GST pull-down assay 
GST fusion proteins were purified as described (160). Five μg of GST, GST-Src SH2 
or GST-Src SH3 fusion proteins were incubated for 30 min at 4 °C with Glutathione-
conjugated Sepharose beads (Amersham Biosciences/ GE Healthcare). After three 
washes with lysis buffer, GST proteins coupled to beads were incubated for 1.5h at 4 
°C with lysates (500 µg) of transfected HEK 293 cells. Protein complexes were 
washed 3 times with lysis buffer, resolved by SDS-PAGE and detected by Western 
blotting. 
 
Cell adhesion assay 
Twenty-four well plates were coated with Matrigel (200 µg/well) for 2h at 37°C, 
washed twice with PBS and then blocked with BSA (0.5mg/ml in PBS) for 1h at 
37°C. Transfected HUVECs (5 × 104 cells) were seeded in duplicates in M200 
medium and allowed to adhere in the presence of VEGF (10 ng/ml) for 30 min at 
37°C. Cells were fixed with formalin for 20 min and then stained with crystal violet 
(0.1%) in 20% (v/v) methanol overnight. For quantification, cell counts were 
performed for each condition on 6 photographs/well taken at ×10 magnification using 
a Nikon Eclipse TE300 microscope and a Photometrics CoolSNAP camera.  
 
 
DNA transfection, cell stimulation and lysis  
HEK 293 and HEK 293T cells were seeded at 0.8 and 1.2 × 106 cells/10-cm dish, 
respectively, and transfected using the standard calcium phosphate method. Cells 
were lysed 48h post-transfection in a 50 mM HEPES [pH 7.5] buffer (160), as for all 
other experiments described below. MEFs (1.7 x 106 cells/10-cm dish) were 
transfected in OptiMEM (Invitrogen) using Lipofectamine 2000. BAECs (2 × 106 
cells/10-cm dish) and HUVECs (5.25 – 6.3 × 105 cells/6-cm dish) were transfected in 
OptiMEM with Lipofectamine 2000 and Lipofectin, respectively. See Supplemental 
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data section for amounts of DNA used. Medium was replaced the next morning with 
supplemented DMEM (BAECs) or M200 (HUVECs). Cells were serum-starved the 
next day for 16h (BAECs), or 42h later for 6h (HUVECs), and then stimulated with 
VEGF 50 ng/ml for the indicated times before cell lysis. Alternatively, HUVECs 
were collected for biological assays.  
 
RNAi transfection 
HUVECs (3 × 104 cells/cm2 for cell signaling experiments and 2.2 – 2.5 × 104 
cells/cm2 for biological assays) were transfected with DEP-1 (Hs_PTPRJ_3_HP) and 
AllStars control siRNAs from Qiagen at a final concentration of 75 nM in M200 
medium using Dharmafect reagent #4 (Dharmacon). Medium was replaced 16h post-
transfection with supplemented M200. At 42h post-transfection, cells were serum-
starved for 6 hours in M200 and stimulated with VEGF as described above. 
Alternatively, cells were submitted to biological assays.  
 
In vitro phosphatase assay 
Immunoprecipitated DEP-1 was resuspended in 50 µl of a 50 mM HEPES [pH 7.4] 
assay buffer containing BSA (0.1 mg/ml) and DTT (3mM) and transferred into a 96-
well plate. Paranitrophenyl phosphate (pNPP; 50 µl of a 50 mM stock in water) was 
added to the wells and incubated 5-15 min at room temperature. Absorbance was read 
at 405 nm with a Victor3 V fluorescence reader (PerkinElmer). pNPP hydrolysis after 
5 min of reaction is reported in the graph of Figure 3D. 
 
 
 
Capillary-like formation on Matrigel 
Ice-cold Matrigel (BD Biosciences; 50 l/well) was added to flat-bottomed 96-well 
plates and allowed to solidify 1h at 37oC. HUVECs (2 × 104 cells/well) were seeded 
in duplicates on Matrigel and incubated 5-6h at 37°C in supplemented M200. 
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Capillaries were fixed in formalin buffer and photographs were taken (6/well) at ×10 
magnification. The complexity of the network was quantified by measuring the length 
of tubes formed and the number of branches at connecting nodes.  
 
Matrigel Invasion 
Transwell filters (polycarbonate membrane, 8 µm-pore size; Corning Brand, Fisher) 
were coated with 50 µl/filter of Matrigel (2 mg/ml) that was allowed to solidify for 2h 
at 37oC. Transfected HUVECs (5 × 105 cells) were resuspended in 400 µl of M200 
medium without LSGS and seeded in duplicate in the top chamber. The lower 
chamber was filled with M200 medium containing VEGF (50 ng/ml). Cells were 
incubated for 20h and then fixed with phosphate-buffered formalin for 20 min before 
staining with crystal violet (0.1% in 20% (v/v) methanol) for a minimum of 60 min. 
The Matrigel layer and cells remaining on top of the filter were wiped off. Only cells 
that went through the filter pores were visualized and counted.  
 
Endothelial permeability assay 
Six hours after transfection, HUVECs were seeded onto Transwell permeability 
inserts (6,5mm diameter, 1,0 µm pore size; BD Falcon, BD Biosciences) pre-coated 
with rat tail collagen type I (50µg/ml). After 46h, the cells were serum-starved for 1h 
in M200 medium and then stimulated with VEGF (50ng/ml) in the presence of FITC-
Dextran (40 kDa size, 1 mg/ml). Permeability was determined by measuring the 
fluorescence at 520 nm (498 nm excitation) that was emitted from 50 µl-medium 
aliquots taken from the bottom chambers and diluted with 200 µl of M200 medium. 
Fluorescence was detected with a Victor3 V fluorescence reader (Perkin-Elmer).  
In vitro DEP-1/Src associatio 
Purified GST-DEP-1IC encompassing the intracellular domain (a.a. 997-1337) was 
cleaved with Thrombin (Calbiochem, Millipore) for 1h at R.T. Thrombin was 
removed from the eluate using p-aminobenzamidine-agaraose beads (Sigma) for 30 
min at 4oC. Approximately 0.3 µg of DEP-1IC was incubated or not with 10 ng of 
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purified recombinant Src (Millipore) and submitted to a cold kinase assay (according 
to Millipore’s instructions) for 20 min at 30oC. Lysis buffer was added at the end of 
the reaction and proteins were incubated for 2h with DEP-1 goat antibodies, which 
recognize the intracellular domain, and then further incubated with Protein G 
Plus/Protein A- Agarose beads blocked with BSA (Calbiochem, Millipore) for an 
additional 2h. Co-immunoprecipitating Src was revealed following Western blotting 
with Src antibodies.  
 
Immunofluorescence microscopy 
HUVECs (2 × 105 cells) were plated onto gelatin-coated glass coverslips in 24-well 
inserts 6h after RNAi transfection. Cells were further incubated 24h, serum-starved in 
M200 for 2h and then stimulated with VEGF (50 ng/ml) for 30 min before fixation in 
formaldehyde (3,7% (v/v) in PBS) for 20 min and a 10 min-permeabilization in 
Triton X-100 (0. 2%). Cells were next blocked 30 min in FBS (8% solution (v/v) in 
PBS) and incubated 1h with the β-catenin antibody (1:50), followed by a 45 min 
incubation with the Alexa Fluor 488-coupled mouse secondary antibody (1:1000). 
Coverslips were mounted in ProLong Gold antifade reagent containing DAPI 
(Invitrogen/Molecular Probes). 
 
Data analysis 
Statistical significance was evaluated with the Mann-Whitney rank sum test using the 
SPSS software. P-values of less than 0.05 were considered to be significant.  
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Results 
 
DEP-1 is tyrosine-phosphorylated in a Src family kinase-dependent manner. 
 
Activation of Src by the protein tyrosine phosphatase PTPε has been linked to its 
tyrosine phosphorylation and its capacity to associate with the kinase (299, 304). In 
order to determine if a similar mechanism was involved in the ability of DEP-1 to 
activate Src, we first confirmed that DEP-1 was tyrosine phosphorylated and 
identified the kinases potentially involved. As shown in Figure 1, WT Myr-DEP-1 
and a catalytically inactive and substrate trapping mutant (Myr-DEP-1 D/A), which 
encompass the intracellular portion of DEP-1 fused to the myristylated sequence of 
Src, were constitutively phosphorylated when expressed in HEK 293 cells (Figure 
1A-B). However, the phosphorylation of WT Myr-DEP-1 was much weaker, 
indicating that it was subject to auto-dephosphorylation, similarly to what was 
observed for PTPε  (299). Consistent with these observations, the phosphorylation of 
full-length WT DEP-1 was enhanced when cells were incubated with pervanadate, a 
general PTP inhibitor (Figure 1C). To determine if SFKs were implicated in this 
constitutive phosphorylation event, HEK 293 cells expressing Myr-DEP-1 D/A were 
treated with a pharmacological SFK inhibitor (PP2), DMSO as vehicle control, or co-
transfected with a dominant negative mutant form of Src (RF-Src). As shown in 
Figure 1D, PP2 treatment or expression of RF-Src decreased the tyrosine 
phosphorylation of DEP-1, while co-transfection of a constitutively active Src mutant 
(Src Y527F) with either full-length WT DEP-1 or the DEP-1 C/S mutant increased 
their phosphorylation (Figure 1E). The C/S mutant is catalytically inactive but has 
virtually no ability to trap substrates compared to the DEP-1 D/A mutant,(160) and 
thus is not similarly protected from dephosphorylation by other endogenous 
phosphatases (448). Lastly, Figure 1F shows that phosphorylation of full-length DEP-
1 D/A is barely detectable in Src/Yes/Fyn-null fibroblasts (SYF MEFs), but rescued 
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by re-expression of WT Src or Fyn. These results thus demonstrate that DEP-1 can be 
tyrosine-phosphorylated in a SFK-dependent manner. 
 
 
Figure 1: DEP-1 is tyrosine phosphorylated in a SFK-dependent manner. 
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(A) Structure of full-length DEP-1 and Myc-tagged Myr-DEP-1. (B) Myr-DEP-1 
WT and inactive Myr-DEP-1 D/A mutant were expressed in HEK 293 cells. 
Tyrosine phosphorylation of immunoprecipitated DEP-1 was analyzed by 
immunoblotting (IB) with the PY99 phosphotyrosine antibody (PY). The 
membrane was stripped and reprobed with the Myc antibody to detect equivalent 
levels of immunoprecipitated Myr-DEP-1. (C) Tyrosine phosphorylation of full-
length WT DEP-1 is increased by pervanadate (PV) treatment of HEK 293T cells 
transfected with empty vector (pmT2) or full-length WT DEP-1. At 48h post-
transfection, cells were incubated or not with PV (100 µM) for 20 min before cell 
lysis. DEP-1 was immunoprecipitated (IP) with the clone 143-41 mouse antibody, 
and its tyrosine phosphorylation determined by immunoblotting with the PY99 
antibody. The membrane was stripped and reprobed with the DEP-1 antibody 
(clone 143-41) to show similar levels of immunoprecipitated DEP-1. (D) Tyrosine 
phosphorylation of Myr-DEP-1 D/A is impaired by PP2 or by a Src dominant 
negative mutant. HEK 293 cells were transfected with Myr-DEP-1 D/A and 
incubated with either PP2 (5 µM; 30 min) or vehicle (DMSO), or co-transfected 
with a Src dominant negative mutant (RF-Src). Tyrosine phosphorylation of 
immunoprecipitated DEP-1 was detected as described in B. Src-RF expression was 
determined following immunoprecipitation with the mouse Src antibody (GD11 
clone) and immunodetection with the rabbit clone 36D10. (E) Tyrosine 
phosphorylation of DEP-1 is increased by co-expression of a constitutively active 
Src mutant. HEK 293T cells were transfected with empty vector (pmT2), WT DEP-
1, or the C/S mutant in the presence or not of active Src Y527F. Tyrosine 
phosphorylation of immunoprecipitated DEP-1 was determined as described above. 
Immunoblotting of total cell lysates with the Src antibody (clone GD11) reveals 
equivalent Src Y527F expression levels. (F) WT Src and Fyn promote DEP-1 D/A 
tyrosine phosphorylation. SYF MEFs were transfected with empty vector (pmT2), 
the DEP-1 D/A mutant alone, or in combination with either WT Src or Fyn 
encoding vectors. Phosphorylation of immunoprecipitated DEP-1 is revealed as 
described above. Immunoblotting of total cell lysates with the indicated antibodies 
demonstrate similar amounts of DEP-1 and SFKs in the various conditions. All 
results are representative of 3 independent experiments. 
 
DEP-1 C-terminal Y1311 and Y1320 are phosphorylation sites and associate 
with Src. 
 
To identify DEP-1 phosphorylated site(s), residues corresponding to SFK consensus 
phosphorylation sites and/or potential SH2-domain binding sites were mutated in 
Myr-DEP-1 D/A (Figure 2A). The resulting Y/F mutants were expressed in HEK 293 
77 
 
 
cells and their phosphorylation level relative to the "non-mutated" Myr-DEP-1 D/A 
was evaluated by immunoblotting total cell lysates with the anti-phosphotyrosine 
antibody PY99. Figure 2B reveals that the Myr-DEP-1 D/A Y1311F and Y1320F 
mutants were the least phosphorylated. Consistently, mutation of both residues led to 
the complete abrogation of Myr-DEP-1 D/A tyrosine phosphorylation (Fig. 2C). 
These two tyrosine residues were the only tyrosine-phosphorylated sites detected by 
mass spectrometry analysis performed on Myr-DEP-1 D/A (data not shown).  
Analysis of the amino acid sequences downstream of Y1311 and Y1320 
suggested that these sites might be Src SH2-domain binding sites. To test this, we 
first performed in vitro association experiments and investigated the ability of GST 
alone, GST-Src-SH2 or GST-Src-SH3 fusion proteins coupled to Glutathione-
Sepharose beads to associate with Myr-DEP-1 WT, Myr-DEP-1 D/A or the Myr-
DEP-1 D/A Y/F mutants from transfected HEK 293 cell lysates. The highly tyrosine-
phosphorylated Myr-DEP-1 D/A associated with the GST-Src-SH2 fusion proteins 
with a strong affinity, while mutation of Y1311 and Y1320 residues abolished this 
interaction (Fig. 2D). We further showed that recombinant Src directly associated 
with the purified phosphorylated intracellular domain of DEP-1 in vitro (Figure 2E), 
supporting the conclusion that DEP-1 phosphorylated on Y1311 and Y1320 directly 
associates with the Src SH2 domain. 
To demonstrate that the phosphorylated DEP-1 Y1311 and Y1320 are also 
implicated in the binding of Src in vivo, DEP-1 C/S and the C/S Y1311F, Y1320F, 
and Y1311F/Y1320F mutants were co-expressed in HEK 293T cells with 
constitutively active Src (Src Y527F) to enhance the phosphorylation of DEP-1, as 
previously done (Fig. 1E). Figure 2F shows that full-length DEP-1 C/S co-
immunoprecipitated with Src. Mutations of Y1311 or Y1320 resulted in the decreased 
association of DEP-1 to Src, with the mutation at Y1320 having a slightly stronger 
effect. In the converse experiment, DEP-1 C/S failed to associate with a Src SH2 
domain mutant (Y527F/R175L), further confirming that DEP-1 associates with Src 
through its SH2 domain (Fig. 2G). Altogether, these results demonstrate that the 
78 
 
 
tyrosine phosphorylation of DEP-1 on Y1311 and Y1320 can mediate the association 
of Src via its SH2 domain, and that Y1320 may be a slightly preferred binding site. 
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Figure 2: DEP-1 Y1311 and Y1320 are major phosphorylation sites that 
associate with Src via its SH2 domain.  
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(A) Diagram representing the potential SFKs tyrosine phosphorylation sites in the 
intracellular domain of DEP-1 according to published consensus sequences or 
Scansite predictions (http://scansite.mit.edu/). FN, Fibronectin type III-like repeats; 
EC, extracellular; TM, transmembrane; IC, intracellular (B) HEK 293 cells were 
transfected with "non-mutated" (-) Myr-DEP-1 D/A or the various Y/F mutants. 
Their tyrosine phosphorylation was detected by immunoblotting (IB) total cell 
lysates (TCL) with the PY99 antibody (PY). Expression levels of transfected Myr-
DEP-1 were detected with a Myc antibody. (C) HEK 293 cells were transfected with 
Myr-DEP-1 mutated at both Y1311 and Y1320, which is not detectably tyrosine 
phosphorylated. (D) DEP-1 associates with the Src SH2 domain via its 
phosphorylated Y1311 and Y1320 residues. Lysates of HEK 293 cells transfected 
with the indicated constructs were incubated with GST-Src-SH2, GST-Src-SH3 or 
with GST alone. Association of DEP-1 with Src domains was detected by 
immunoblotting with the MYC antibody. The equivalent amount of GST fusion 
proteins used in the pull-down-assay is detected with a GST antibody. Lower panel, 
Lysates of transfected HEK 293 cells were immunoblotted with the MYC antibody 
to show the similar expression level of DEP-1 constructs. (E) In vitro association of 
recombinant Src with the purified intracellular domain of DEP-1 (DEP-1IC) 
previously phosphorylated by Src in vitro. DEP-1IC was immunoprecipitated with 
DEP-1 goat antibodies and associated Src was immunodetected using the 36D10 
clone. (F) The association of DEP-1 C/S and DEP-1 C/S Y/F mutants to Src was 
investigated in HEK 293T cells co-transfected with constitutively active Src, to 
induce maximal tyrosine phosphorylation of DEP-1. The co-precipitation of Src with 
DEP-1 and the equal expression of Src Y527F were detected by immunoblotting 
with a Src antibody (GD11 clone). (G) Mutation in the Src SH2 domain abrogates its 
ability to associate with DEP-1. HEK 293T cells were co-transfected with DEP-1 
C/S and activated Src Y527F or the Src Y527F/R175L SH2 domain mutant. Src was 
immunoprecipitated with the mouse GD11 mouse clone, and associated DEP-1 was 
detected with the goat antibody. Immunoblotting of total cell lysates with the DEP-1 
goat antibody or the Src GD11 antibody reveal that equal amounts of Src and DEP-1 
constructs were expressed. All results are representative of at least 3 independent 
experiments. 
 
Mutation of Y1311 and Y1320 impairs DEP-1-mediated activation of Src in 
HEK 293T cells, without affecting PTP activity. 
 
To determine if the binding of the Src SH2 domain to phosphorylated DEP-1 Y1311 
and Y1320 could be involved in a phospho-displacement mechanism leading to Src 
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activation, we first investigated the ability of WT DEP-1 and the Y/F mutants to 
activate Src in HEK 293T cells. Figure 3A shows that transfection of increasing 
amounts of WT DEP-1 led to the progressive dephosphorylation of inhibitory Y529 
while increasing the phosphorylation of Y418 and kinase activity. Interestingly, as 
levels of expression reached a maximum, Y418 phosphorylation and kinase activity 
also started to decrease, suggesting that DEP-1 can also dephosphorylate Src on Y418 
in these conditions, as previously observed in vitro (318). This experiment thus 
indicated that the level of DEP-1 expression is crucial in determining its substrate 
specificity and function. We next investigated the consequences of expressing DEP-1 
Y/F mutants on Src phosphorylation using optimal transfection conditions resulting in 
the activation of Src by WT DEP-1, as determined in Figure 3A. Results show that 
Src Y418 phosphorylation was slightly decreased upon expression of the DEP-1 
Y1311F mutant when compared to cells expressing WT DEP-1, while changes in the 
phosphorylation status of Src Y529 were barely visible. In contrast, expression of the 
DEP-1 Y1320F or Y1311F/Y1320F mutants strongly impaired phosphorylation of 
Y418 and dephosphorylation of Y529, in a manner comparable to that observed 
following expression of the catalytically inactive DEP-1 C/S mutant (Figure 3B). 
Using a validated phosphospecific DEP-1 antibody recognizing phosphorylated 
Y1320 (see Supplemental Figure 1), the constitutive phosphorylation of WT DEP-1 
and of the Y1311F mutant was detected in HEK 293T cells and correlated with their 
ability to upregulate Src Y418 phosphorylation (Figure 3C). The DEP-1 C/S 
catalytically inactive mutant was also constitutively phosphorylated, demonstrating 
that tyrosine phosphorylation is not sufficient for Src activation and that the catalytic 
activity of DEP-1 is also required. These results thus suggest that phosphorylated 
DEP-1 Y1311 and Y1320 associate with Src, and that this is required for Src 
activation. However, as phosphorylation of PTPs can modulate their catalytic 
activity,(449) the consequences of mutating Y1311 and Y1320 on the catalytic 
activity of DEP-1 were also investigated. For this, WT DEP-1 and the various Y/F 
mutants were co-transfected with activated Src (Y527F) in HEK 293T cells to 
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promote tyrosine phosphorylation of WT DEP-1 (as shown in Figure 1E). An in vitro 
PTP assay using pNPP as a substrate was performed on immunoprecipitated DEP-1. 
The results reveal that the Y1311F, Y1320F or double Y1311F/Y1320F mutations 
did not significantly interfere with the catalytic activity of DEP-1 in these 
experimental conditions (Figure 3D). To further confirm this result, 
dephosphorylation of VEGFR2, previously identified as a DEP-1 substrate, (149, 
160) was monitored in VEGF-stimulated HEK 293T cells co-expressing VEGFR2 
with either WT DEP-1, DEP-1 Y1311F/Y1320F or the C/S mutant in conditions 
similar to those of Figure 3B. Immunoblotting with a general phosphotyrosine 
antibody showed that the DEP-1 Y1311F/Y1320F mutant was as efficient as WT 
DEP-1 at reducing the phosphorylation of VEGFR2, while the C/S mutant had no 
effect, as expected (Figure 3E). On the basis of these results, we conclude that the 
phosphorylation of DEP-1 on Y1311 and Y1320 is not involved in the regulation of 
its catalytic activity. This then strongly suggests that the decreased 
dephosphorylation/activation of Src in cells expressing the DEP-1 Y1311F/Y1320F 
mutant is not due to reduced catalytic activity of the mutant but rather to its lost 
ability to associate with Src.  
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Figure 3: Mutation of Y1311 and Y1320 impairs DEP-1-mediated activation of 
Src in HEK 293T cells, without affecting PTP activity. 
IP: VEGFR 2
pmT2 WT YY/FF C/S
VEGFR 2 +
IB: PY
IB: VEGFR 2
TCL
IB: DEP-1
IB: DEP-1
Y1
31
1F
Y1
32
0F
Y1
31
1/2
0F
C/S
+ Src 527F
pm
T2
WT
IP: DEP-1
TCL
IB: Src
IB: pY418Src
IB: DEP-1
IB: pY529Src
TCL
IB: Src
pm
T2
WT
 DE
P-1
Y1
31
1F
Y1
32
0F
Y1
31
1F
/20
F
DE
P-1
 C/
S
DEP-1 WT
0.5     1      2     3     4      5     10
IB: pY418 Src
IB: Src
IB: pY529 Src
IB: DEP-1
TCL
(µg DNA)
0
1
2
3
0, 5 1 2 3 4 5 100,5     1,0      2,0      3,0       4,0     5,0     10,0 (μg DNA)
1
0
2
3
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
A
B
C
D
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
IB: DEP-1
IB: PY1320 DEP-1
TCL
pm
T2
DE
P-1
 W
T
Y1
31
1F
Y1
32
0F
Y1
31
1F
/20
F
C/S
E
pN
P
P
hy
dr
ol
ys
is
0
500
1000
1500
2000
2500
pN
P
P
hy
dr
ol
ys
is
pmT 2
WT
Y1311F
Y1320F
Y1311/ 20F
C/ S
D
R
el
at
iv
e 
S
rc
 a
ct
iv
ity
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
R
el
at
iv
e 
Sr
c 
ac
tiv
ity
(x
-fo
ld
)
pN
P
P
hy
dr
ol
ys
is
pN
P
P
hy
dr
ol
ys
is
R
el
at
iv
e 
S
rc
 a
ct
iv
ity
84 
 
 
(A) HEK 293T cells were transfected with increasing amounts of WT DEP-1 cDNA 
vector. The phosphorylation level of Src on Y529 and Y418 was determined by 
immunoblotting total cell lysates (TCL) with the corresponding phosphospecific 
antibodies. Lower panel, Src was immunoprecipitated from the corresponding cell 
lysates shown in A with the Src GD11 antibody and its kinase activity determined in 
vitro using a Src peptide substrate with [γ-32P]ATP as previously done (160). Based 
on these results, all other transfection experiments were performed with 3-4 µg of 
DEP-1 plasmids to achieve optimal Src activation in these cells. This result is 
representative of 4 independent experiments. (B) HEK 293T cells were transfected 
with empty vector (pmT2), WT DEP-1 and the indicated mutants, and the 
phosphorylation level of Src on Y529 and Y418 analyzed as described above. (C) 
DEP-1 is constitutively tyrosine phosphorylated in HEK 293T cells. Total cell 
lysates of HEK 293T cells transfected with equal levels of WT DEP-1 and the 
various mutants were immunoblotted with a phosphospecific antibody detecting 
pY1320 DEP-1. (D) The catalytic activity of DEP-1 is not affected by the various 
mutations reducing its tyrosine phosphorylation. WT DEP-1 and mutants were co-
expressed with activated Src Y527F in HEK 293T cells to enhance DEP-1 
phosphorylation. DEP-1 was immunoprecipitated from 200µg of HEK 293T cell 
lysates (not containing phosphatase inhibitors) and submitted to the pNPP assay as 
described in the Material and Methods section. Empty vector (pmT2) and DEP-1 
catalytically inactive C/S mutant represent negative controls. pNPP hydrolysis after 
5 min of reaction is reported in this graph. This result represents the average of 3 
independent experiments. Lower panel, Western blot analysis reveals similar levels 
of expressed WT DEP-1, mutants, and constitutively active Src in the various 
conditions tested. *P<0.05 (E) Mutant DEP-1 is as effective as WT DEP-1 at 
dephosphorylating VEGFR2. HEK 293T cells co-transfected with VEGFR2 and 
either empty vector (pmT2), WT DEP-1, DEP-1 Y1311F/Y1320F (YY/FF) or the 
C/S mutant were stimulated with VEGF (50 ng/ml) for 5 min. Phosphorylation of 
immunoprecipitated VEGFR2 was detected using a general phosphotyrosine 
antibody (PY99). Similar DEP-1 expression levels are shown. This result is 
representative of 2 independent experiments. 
 
DEP-1 Y1311 and Y1320 are required for VEGF-dependent Src activation in 
endothelial cells. 
We previously demonstrated that DEP-1 is required for VEGF-induced Src activation 
in primary cultures of endothelial cells (160). Overexpression of DEP-1 reveals here 
that similarly to what was observed in HEK 293T cells (Figure 3A), moderate versus 
high expression levels of DEP-1 in endothelial cells also led to opposite effects on 
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Src activation and phosphorylation of its substrate VE-cadherin (Supplemental Figure 
2A) (135, 450). This is consistent with the notion that higher expression of 
endogenous DEP-1 is observed in post-confluent or quiescent endothelial cells in 
vitro and in vivo, while its expression is decreased to moderate levels in growing and 
migrating cells (149, 262). To find out if Src activation also relied on DEP-1 Y1311 
and Y1320 in VEGF-stimulated endothelial cells, we therefore investigated the 
consequences of expressing moderate amounts of WT and DEP-1 Y/F mutants in 
primary cultures of bovine aortic endothelial cells (BAECs). Figure 4A shows that 
VEGF stimulation of control cells (pmT2-transfected) led to the dephosphorylation of 
Src Y529, while this was observed constitutively in cells overexpressing WT DEP-1. 
In contrast, a progressive decrease in Y529 dephosphorylation induced by VEGF was 
observed when Y1311F, Y1320F and Y1311F/Y1320F mutants were expressed, the 
latter being the most efficient at inhibiting Src Y529 dephosphorylation. In these 
same conditions, the VEGF-induced phosphorylation of ERK1/2 was similarly 
decreased in cells overexpressing WT DEP-1 or the mutants, demonstrating that 
impaired dephosphorylation of Src in cells expressing the DEP-1 mutants was not due 
to differential VEGFR2-dependent signaling or to reduced phosphatase activity. Our 
results also demonstrated that the Y1311F and Y1320F mutants but even more 
strikingly the double Y1311F/Y1320F mutant abolished the Src-dependent 
phosphorylation of VE-cadherin in response to VEGF stimulation, confirming the 
role of DEP-1 Y1311/Y1320 in VEGF-dependent Src activation (Figure 4B). To 
strengthen this observation, the sequence downstream of Y1320 (Y1320ENL), 
corresponding to a potent Src SH2 binding site, was mutated to Y1320QNL 
(Supplemental Figure 3). Results show that the association of Src with the DEP-1 C/S 
E1321Q mutant was much reduced and correlated with the impaired ability of VEGF 
to induce the dephosphorylation of Src Y529 and the phosphorylation of VE-cadherin 
in endothelial cells expressing this mutant. These experiments thus reveal the 
requirement of DEP-1 Y1311 and Y1320 for Src association and activation in VEGF-
stimulated endothelial cells. 
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We next investigated if endogenous DEP-1 was phosphorylated in response to 
VEGF using DEP-1 phosphospecific antibodies. Figure 4C shows that 
phosphorylation of DEP-1 on Y1311 and Y1320 was rapid and transient, with 
maximal increases occurring within 2 minutes. A concurrent increase in Src Y418 
phosphorylation was also observed over this time period. Importantly, similar kinetics 
of DEP-1 phosphorylation on Y1320 were observed in VEGF-stimulated BAECs 
overexpressing WT DEP-1, but phosphorylation was virtually absent in VEGF-
stimulated cells overexpressing the Y1311F/Y1320F mutant where Src activation was 
found to be abrogated (Figure 4D). These results are thus consistent with our model-
hypothesis that tyrosine phosphorylation of DEP-1 is part of the mechanism leading 
to Src activation, and that a phospho-displacement mechanism may be involved. 
 
Figure 4: VEGF-dependent phosphorylation of DEP-1 on Y1311 and Y1320 
mediate Src activation in endothelial cells. 
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(A) Bovine aortic endothelial cells (BAECS) were transfected with empty vector 
(pmT2), WT DEP-1 and the indicated mutants, serum-starved, and then stimulated 
with VEGF (50 ng/ml) for 7 min. Src dephosphorylation on Y529 was detected 
using a phosphospecific antibody recognizing phosphorylated Y529. VEGF-
dependent signaling was monitored by detecting the activation of ERK1/2 using an 
antibody recognizing phosphorylated T202/Y204. Equivalent signaling is observed 
in cells expressing WT DEP-1 and mutants. (B) BAECs were treated as in C. The 
phosphorylation of VE-cadherin and FAK Y861 was investigated following the 
immunoprecipitation of VE-cadherin and its immunodetection with the PY99 
antibody, and by immunoblotting total cell lysates with a FAK phosphospecific 
antibody recognizing Y861. These results are representative of 3 independent 
experiments. (C) HUVECs were serum-starved and stimulated with VEGF for the 
indicated times. Phosphorylation of endogenous DEP-1 is detected in total cell 
lysates (TCL) using phosphospecific antibodies detecting pY1311 and pY1320. The 
phosphorylation/activation status of Src on Y418 is determined by immunoblotting 
total cell lysates with the pY418Src antibody. Results suggest that VEGF-induced 
DEP-1 tyrosine phosphorylation is concomitant with Src activation. (D) The VEGF-
mediated tyrosine phosphorylation of DEP-1 on Y1320 is enhanced in BAECs 
overexpressing WT DEP-1, but abrogated in cells expressing the Y1311F/Y1320F 
mutant (YY/FF).  
 
DEP-1 promotes the VEGF-dependent remodeling of intercellular junctions and 
endothelial permeability via Y1311 and Y1320. 
 
VEGF-dependent remodelling and loosening of intercellular adhesions are required to 
facilitate tip cell migration and invasion during sprouting angiogenesis, (18) but also 
represent key steps in the promotion of vascular permeability (443). Src is a major 
regulator of these processes, in part through the direct tyrosine phosphorylation of 
adhesion proteins including VE-cadherin, but also via the induction of a Src-VAV2-
Rac-PAK pathway, resulting in the serine phosphorylation of VE-cadherin and its 
cellular internalization (114, 135, 137, 450, 451). To test if DEP-1 was implicated in 
the remodelling of cell-cell junctions in response to VEGF stimulation, the 
phosphorylation of VE-cadherin was first investigated in DEP-1-depleted HUVECs 
compared to control cells using antibodies recognizing VE-cadherin phosphorylated 
on Y658 and S665 (137, 450, 451). Consistent with decreased Src Y418 
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phosphorylation, Figure 5A shows that the VEGF-induced tyrosine phosphorylation 
of VE-cadherin, as detected with the pY658VE-cadherin antibody, was reduced in 
DEP-1-depleted cells. In addition, the Src-dependent phosphorylation/activation of 
the Rac GDP exchange factor VAV2 was similarly decreased and correlated with the 
inhibited phosphorylation of VE-cadherin on Serine 665 (Antibody specificity in 
Supplemental Figure 4). As phosphorylation of VE-cadherin correlates with its 
increased internalization and the weakening of its intracellular association with 
Catenins at cell-cell junctions, the above results suggested that the remodelling of 
cell-cell junctions and endothelial permeability might be defective in cells lacking 
DEP-1 expression (137, 450). Accordingly, immunostaining of HUVECs with a β-
Catenin antibody revealed a “hairy” phenotype and the appearance of intercellular 
gaps representative of loosened cell-cell contacts upon stimulation of control cells 
with VEGF, while DEP-1-silenced cells maintained stable cell-cell junctions (Figure 
5B). In agreement with this, HUVECs transfected with control siRNAs cells showed 
a significant increase in permeability in response to VEGF, while this was completely 
blocked in DEP-1-depleted cell monolayers (Figure 5C). Importantly, overexpression 
of WT DEP-1 in HUVECs promoted VEGF-dependent endothelial cell permeability 
compared to cells transfected with empty vector (pmT2) (Figure 5D). However, 
overexpression of the Y1311F/Y1320F mutant decreased permeability below the 
level detected in control cells, thus behaving as a dominant negative mutant. These 
results are consistent with a role for DEP-1 and its phosphorylated C-terminal tail in 
Src activation and the consequent phosphorylation of VE-cadherin in VEGF-
stimulated endothelial cells, and highlight the role of DEP-1 in the control of 
endothelial permeability. 
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Figure 5: DEP-1 and its C-terminal Y1311 and Y1320 are essential mediators of 
VEGF-dependent endothelial permeability. 
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(A) DEP-1 promotes VEGF-dependent VE-cadherin phosphorylation. HUVECs 
were transfected with control (CTL) or DEP-1 siRNAs. Forty-two hours later, cells 
were serum-starved for 6h and stimulated with VEGF for the indicated times. The 
phosphorylation level of Src, VE-cadherin, and Vav2 was determined by 
immunoblotting with the indicated phosphospecific antibodies. Results are 
representative of at least 3 independent experiments. (B) DEP-1 is required for 
VEGF-induced loosening of cell-cell junctions. Control (CTL) and DEP-1-depleted 
cells were stimulated with VEGF (50 ng/ml) for 30 min and stained with β-Catenin 
and anti-mouse Alexa 488-secondary antibodies. Lower panel, RNAi-mediated 
decrease in DEP-1 expression levels. (C) DEP-1 mediates VEGF-induced 
endothelial permeability. Control (CTL) and DEP-1-silenced cells were plated on 
collagen-coated inserts until the formation of a tight monolayer. Forty-six hours 
later, cells were serum-starved for 2h and then stimulated or not with VEGF 
(50ng/ml) for 30 minutes in the presence of FITC-dextran (in the upper chamber). 
VEGF-induced permeability was measured by detecting the fluorescence emitted by 
FITC-dextran present in aliquots that were collected from the bottom chambers. 
Data is presented as fold changes over unstimulated control (CTL) cells. Essays 
were conducted in triplicates and results are representative of 4 independent 
experiments. *p<0.05 (D) HUVECs transfected with pmT2 empty vector, WT DEP-
1, the Y1311F/1320F (YY/FF) or C/S mutants were plated on collagen-coated 
inserts, serum-starved for 1h and then stimulated for 30 min with VEGF in the 
presence of FITC-dextran, as described above. Data is presented as fold changes 
over stimulated control (pmT2) cells. Assays were conducted in triplicates and 
results are representative of 3 independent experiments. 
 
Efficient endothelial cell invasion and capillary formation require DEP-1 and its 
phosphorylated C-terminal tail 
 
Src is also a key promoter of endothelial cell invasion and neovascularization.(114, 
129) One potential candidate substrate mediating these effects is Cortactin, which 
allows branched actin polymerization and the stabilization of membrane protrusions 
during cell migration and invasion.(452) It is enriched in membrane protrusions of 
endothelial cells in a Src-dependent manner and is essential for VEGF-induced 
migration and in vivo angiogenesis.(453-455) Importantly, Cortactin tyrosine 
phosphorylation also correlates with its ability to promote cell migration and 
invasion.(452, 455, 456) Consistent with the role of DEP-1 via Y1311/Y1320 in the 
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activation of Src, the depletion of DEP-1 in HUVECs or the expression of the DEP-1 
Y1311F/Y1320F mutant in BAECs resulted in the decreased tyrosine 
phosphorylation of Cortactin, as detected using a pY421Cortactin antibody (Figures 6A 
and 6B). In contrast, Cortactin phosphorylation was stimulated by overexpression of 
WT DEP-1 (Figure 6B). As previously reported,(454) Figure 6C shows that Cortactin 
was enriched in the membrane protrusions of control endothelial cells stimulated with 
VEGF, but this localization was impaired in the DEP-1-depleted HUVEC population. 
In agreement with these observations, the VEGF-dependent invasion of DEP-1-
silenced HUVECs into Matrigel was strongly impaired (Figure 6D). Conversely, 
overexpression of WT DEP-1 stimulated this response over control cells (pmT2-
transfected), while expression of the Y1311F/Y1320F or C/S mutants were unable to 
do so (Figure 6E). These results thus show that DEP-1 via Y1311/Y1320 is required 
for the proper tyrosine-phosphorylation and localization of Cortactin to membrane 
protrusions, and is an essential mediator of endothelial cell invasion triggered by 
VEGF. It is interesting to note here that VEGF-stimulated endothelial cells 
expressing high levels of DEP-1, which rather mimic the status of quiescent/post-
confluent endothelial cells,(262, 457) were unable to invade compared to pmT2-
transfected cells or cells expressing moderate amounts of DEP-1(Supplemental 
Figure 2B). These results are thus consistent with the opposite capacity of moderate 
versus high levels of DEP-1 to activate Src. 
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Figure 6: DEP-1 promotes VEGF-induced Cortactin tyrosine phosphorylation and 
endothelial cell invasion through Y1311 and Y1320. 
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(A) HUVECs were transfected with control (CTL) and DEP-1 siRNAs and then stimulated 
with VEGF (50 ng/ml) as indicated in legend to Figure 5A.  Cortactin tyrosine 
phosphorylation was monitored by immunoblotting total cell lysates (TCL) with the 
pY421Cortactin antibody. DEP-1 expression and Cortactin protein levels were detected with 
the DEP-1 goat and Cortactin (4F11clone) antibodies, respectively. (B) BAECs were 
transfected with WT and mutant DEP-1 constructs, serum-starved and then stimulated 5 
min with VEGF (50 ng/ml). Cortactin tyrosine phosphorylation and protein levels were 
monitored as described above. (C) DEP-1 is required for the localization of Cortactin in 
membrane protrusions. HUVECs transfected with control (CTL) or DEP-1siRNAs were 
plated on gelatin-coated glass coverslips, serum-starved, and then stimulated with VEGF 
(10 ng/ml) for 5 min before cell fixation. Immunostaining with Cortactin (4F11 clone) and 
Alexa Fluor 594-coupled mouse secondary antibodies is shown. The percentage of cells 
with enriched localization of Cortactin in membrane protrusions was evaluated in control 
and DEP-1-depleted cells in 4 microscopic fields at the 40 × magnification. *p<0.05 (D) 
HUVECs were transfected with control (CTL) or DEP-1 siRNAs and seeded in duplicates 
48 h post-transfection on Transwell filter inserts previously coated with 50 µl of Matrigel (2 
mg/ml). Cells were allowed to invade for 24h, and then processed to visualize and count 
cells on the lower side of the filter. Results ± SD have been normalized using the average 
from the control condition. *p<0.05 (E) HUVECs transfected with empty vector (pmT2), 
WT DEP-1, DEP-1 Y1311F/Y1320F (YY/FF) or DEP-1 C/S were plated in duplicates on 
Matrigel-coated filter inserts and processed as described above. Results are representative 
of 5 independent experiments. *p<0.05 All other results shown in this figure are 
representative of 3 independent experiments. 
 
As could be expected based on the inhibition of Src and Cortactin phosphorylation, 
the plating of DEP-1-silenced HUVECs on Matrigel resulted in their impaired ability 
to reorganize and elongate branched capillary-like structures (Figure 7A). Expression 
of the DEP-1 Y1311F/Y1320F or C/S mutants also reduced the length of capillaries 
forming and significantly impaired branching compared to cells overexpressing WT 
DEP-1 (Figure 7B). Of note, there was no difference in the capacity of DEP-1-
silenced cells or cells expressing the DEP-1 Y1311F/Y1320F mutant to adhere to 
Matrigel with that of control cells, demonstrating that the impaired invasion and 
capillary formation observed were not a consequence of decreased adhesion 
(Supplemental Figure 5). Altogether, the results presented herein demonstrate for the 
first time the central implication of endogenously expressed DEP-1 in the mediation 
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of Src-dependent angiogenic responses and reveal the essential contribution of DEP-1 
Y1311 and Y1320 in the proper regulation of these events. 
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Figure 7: DEP-1, via Y1311 and Y1320, mediates the formation of branching 
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capillary-like structures. 
(A) HUVECs transfected with CTL or DEP-1 siRNAs were plated 48h post-
transfection on Matrigel (in duplicates) to promote the formation of capillary-like 
structures. The length of tubes formed as well as the number of branches at 
connecting nodes were quantified after 5-6h from 6 field/well. Results ± SD have 
been normalized using the average from the control condition and are representative 
of 3 independent experiments. *p<0.05 (B) HUVECS transfected with the indicated 
constructs were plated in duplicates on Matrigel to evaluate their ability to form 
branching capillary-like structures. Quantification was done as described above and 
is representative of 3 independent experiments. *p<0.05 (C) Representative DEP-1 
expression level in RNAi-transfected cells. (D) Comparable expression level of 
DEP-1 and mutants in transfected HUVECs. 
 
Discussion 
Previous studies from our laboratory demonstrated that the knockdown of DEP-1 
expression in endothelial cells impaired Src activation in response to VEGF and FGF 
(160). We further showed that this was a consequence of the defective 
dephosphorylation of the Src inhibitory Y529 in the VE-cadherin-associated fraction, 
which was identified as the major pool of activated Src in VEGF-stimulated 
endothelial cells (261). We now show that the VEGF-induced activation of Src is 
mediated through the phosphorylation of DEP-1 on the C-terminal Y1311 and 
Y1320, which allow its interaction with the Src SH2 domain and the 
dephosphorylation of the displaced inhibitory Y529. Consistent with the central role 
played by Src in angiogenesis, our studies further reveal the major function of DEP-1 
and its C-terminus in the VEGF-dependent phosphorylation of VE-cadherin and 
Cortactin, (453, 458) and consequently, in the remodeling of intercellular junctions, 
permeability, cell invasion, and the formation of branching capillary-like structures. 
We thus propose that a phospho-displacement mechanism engaging DEP-1 pY1311 
and pY1320 with the SH2 domain of Src is required for its activation in response to 
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VEGF stimulation, and that this is critical for the angiogenic response of endothelial 
cells. 
The impaired capacity of DEP-1 Y/F mutants to associate with Src and promote its 
activation (Figures 2-4) reveals the importance of VEGF-dependent phosphorylation 
of DEP-1 as a mechanism controlling Src activation in this cell system. Supporting 
this conclusion, we found that the phosphorylation kinetics of DEP-1 overlapped with 
those of VEGF-induced Src Y418 phosphorylation (Figure 4). In addition, while 
phosphorylation of overexpressed WT DEP-1 on Y1320 was above that seen in 
control cells upon VEGF stimulation, no residual phosphorylation was detected in 
cells overexpressing the DEP-1 Y1311F/Y1320F mutant where Src activation was 
abrogated (Figure 4). On these bases, we then propose that the VEGF-dependent 
phosphorylation of Y1311/Y1320 controls the moment at which DEP-1 can interact 
with Src to dephosphorylate Y529, but without altering its ability to dephosphorylate 
other substrates not associating with DEP-1 via these residues. This mechanism is 
somewhat similar to what was reported for PTPε whereby tyrosine phosphorylation 
of the carboxy-terminal Y695 is essential for the specific dephosphorylation of Src on 
Y529, but not for the ability of PTPε to dephosphorylate other substrates (299). 
Importantly, we also demonstrated that the impaired ability of mutant DEP-1 to 
dephosphorylate Src was not due to its decreased catalytic activity, since it was as 
active as WT DEP-1 in a pNPP assay or following its co-expression with another 
substrate, VEGFR2 (Figure 3). Our results therefore identify growth factor-mediated 
phosphorylation of DEP-1 as another level of regulation of its functions, by 
determining both substrate specificity and kinetics of dephosphorylation.  
We have shown in HEK 293T cells that DEP-1 is constitutively phosphorylated, and 
that this is dependent on the basal activity of SFKs (Figures 1, 3C). However, it is not 
clear yet how VEGF leads to this initial phosphorylation of DEP-1 in endothelial 
cells. As we have concluded from our work in HEK 293T cells, DEP-1 can auto-
dephosphorylate or get dephosphorylated by other PTPs (Figure 1). Thus, it is 
tempting to speculate that a VEGF-induced event leading to the attenuation of PTP 
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catalytic activity could contribute to the increased phosphorylation of DEP-1. In that 
respect, reactive oxygen species (ROS), which have inhibitory effects on PTPs, might 
perhaps be involved (449). Coupled with a relatively high basal activity of Src in 
endothelial cells, the VEGF-induced increase in ROS (451) could lead to a decrease 
in DEP-1 activity, thus enabling the accumulation of phosphorylated DEP-1 and the 
consequent activation of Src. In agreement with this idea, it is interesting that ROS 
production in endothelial cells contributes to VEGF-induced Src activation and 
phosphorylation of VE-cadherin, and to the promotion of capillary formation and 
permeability (451, 459). 
To further prove the contribution of DEP-1 Y1311/Y1320 to VEGF-mediated Src 
activation, we demonstrated that the phosphorylation of two well-known Src 
substrates, VE-cadherin and Cortactin, (450, 452) was abrogated in cells expressing 
the Y1311F/Y1320F, E1321Q or C/S mutants, similarly to what was observed in 
DEP-1-silenced cells (Figures 4-6 and Supplemental Figure 3). VE-cadherin tyrosine 
and serine phosphorylation is associated with the loosening of cell-cell junctions that 
promotes increased vessel permeability and the initiation of vessel sprouting and 
elongation (18, 460). In the case of Cortactin, its tyrosine phosphorylation promotes 
the local polymerization of branched actin that is important for stabilization of 
nascent membrane protrusions during cell migration and invasion (452, 456, 461). Its 
expression and tyrosine phosphorylation are also essential for VEGF-dependent 
migration (453, 455).  In this context, the decreased phosphorylation of VE-cadherin 
and Cortactin, as well as the impaired localization of Cortactin at membrane 
protrusions, are highly consistent with the inability of DEP-1-silenced or mutant-
expressing cells to remodel cell-cell junctions and regulate permeability in response 
to VEGF, or to invade and form a well-organized network of branching capillary-like 
structures (Figures 5-7). These data thus demonstrate for the first time a promoting 
role for endogenous and moderately overexpressed DEP-1 in the induction of pro-
angiogenic functions of endothelial cells and also highlight the key role played by the 
C-terminal Y1311/Y1320. These findings also suggest that the defective vessel 
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remodeling and branching characterized in the DEP-1 mutant mouse (265) might 
partly be explained by impaired Src-dependent pathways. The reported localization of 
DEP-1 at endothelial cell-cell junctions (442) and its association with constituents of 
the VE-cadherin complex (160, 274, 275) strongly support its critical role in the 
activation of Src at this site (261) (Figures 4B, 5A). However, as DEP-1 also 
promotes cell-substratum adhesions, (318) its possible involvement to these sites as 
well is not excluded. 
The results presented herein also importantly revealed that the expression level of 
DEP-1 is a critical factor dictating its substrate specificity and function. Moderate 
overexpression of DEP-1 increased Src activation associated with Y529 
dephosphorylation, while higher levels also led to Y418 dephosphorylation and 
blocked VEGF-dependent tyrosine phosphorylation of VE-cadherin and endothelial 
cell invasion (Figures 3-4, Supplemental Figure 2). Thus, depending on DEP-1 
expression levels, the dephosphorylation of Src might be inappropriate for the 
promotion of biological activities such as permeability and invasion. In that context, 
it is interesting to consider that similarly to the in vitro situation, the expression of 
DEP-1 in vivo is decreased in proliferating and migrating cells during vessel repair 
compared to adjacent quiescent endothelial cells (149, 262). This then suggests that 
DEP-1 might have bivalent functions, where moderate levels would promote VEGF-
dependent Src activation in actively growing and invading endothelial cells, while its 
upregulated expression at confluence and the recruitment of VEGFR2 (269) would 
result in the downregulation of both Src and VEGFR2 activity (149, 160) to promote 
vessel quiescence and stabilization. Interestingly, a similar dual function of the 
receptor-like PTP CD45 was previously reported, where higher versus lower 
expression levels led to the differential dephosphorylation and activation of the SFK 
Lck, inducing both positive and negative regulatory functions in T cell signaling 
(462). In all cases, these regulatory mechanisms might be necessary to allow the 
downregulation of SFK signaling and the attenuation/termination of biological 
responses associated to cell quiescence.  
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In conclusion, these studies bring novel insights into the molecular mechanisms 
underlying the VEGF-dependent regulation of Src, which is a key promoter of 
angiogenesis and vascular permeability, and importantly recognize DEP-1 Y1311 and 
Y1320 as positive regulators of the angiogenic response. 
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Supplemental Figures  
 Supplemental Figure 1: Characterization of DEP-1 phosphospecific antibodies 
recognizing pY1311 and pY1320. 
 
(A) HEK 293T cells were co-transfected with either empty vector (pmT2), DEP-1 
C/S, C/S Y1311F or C/S Y1320F, with or without active Src (SrcY527F) to induce 
their tyrosine phosphorylation. Phosphorylated DEP-1 is detected in total cell lysates 
using phosphospecific antibodies recognizing pY1311 and pY1320 in cells 
expressing C/S DEP-1, but not when encompassing the Y1311F or Y1320F 
mutations, respectively. Immunodetection of DEP-1 and Src with the corresponding 
antibodies shows equal protein levels between conditions. (B) HUVECs were 
transfected with control (CTL) and DEP-1 siRNAs. Cells were serum-starved for 6h 
and incubated with pervanadate (100 µM) for 3 min before adding or not VEGF (50 
ng/ml) for 2 min. Phosphorylation of endogenous DEP-1 is detected in VEGF-
stimulated CTL cells with anti-DEP-1 pY1311 and pY1320, but not in DEP-1-
silenced cells. Immunoblotting with DEP-1 and Src antibodies shows decreased 
expression of DEP-1 in the DEP-1 RNAi-transfected cells, but equivalent levels of 
Src, confirming constant protein loading.  
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Supplemental Figure 2: VEGF-induced Src activation and downstream 
responses are differentially regulated by moderate versus high overexpression 
of DEP-1. 
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(A) BAECs were transfected with either 5 (moderate) or 15 (high) µg of empty 
vector (pmT2) or WT DEP-1. The activation status of Src as well as the 
phosphorylation of its substrate VE-cadherin were monitored by immunoblotting 
total cell lysates (TCL) with the indicated antibodies. Results are representative of 3 
independent experiments. (B) BAECs were transfected with moderate versus high 
amounts or DEP-1 cDNA plasmids as described above. Their ability to invade 
Matrigel was performed as described in the Methods section. Lower panels, 
immunoblotting of DEP-1 shows moderate and high expression levels while PLCγ 
detection demonstrates equal protein loading. Results are representative of 2 
independent experiments. 
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Supplemental Figure 3: Mutation of a Src consensus binding site downstream of 
Y1320 is sufficient to block optimal Src activation. 
(A) The consensus Src binding site Y1320ENL was mutated to Y1320QNL to disrupt Src 
binding. (B) Empty vector (pmT2), DEP-1 CS and DEP-1 C/S E1321Q were expressed 
in HEK 293T cells, in the presence or not of active Src Y527F. DEP-1 was 
immunoprecipitated and the associated Src detected by immunoblotting with the Src 
GD11 antibody. Immunoblotting of total cell lysates with the Src GD11 antibody shows 
equal amounts of transfected Src. (C) BAECS were transfected with empty vector 
(pmT2), WT DEP-1 and the E1321Q mutant. Forty-eight hours later, serum-starved 
cells were stimulated with VEGF (50 ng/ml) for 7 min, and the activation status of Src 
was probed with the phosphospecific antibody detecting the inhibitory phosphorylation 
of Y529. Immunoblotting with phosphospecific antibodies detecting activated VEGFR2 
and ERK1/2 shows that their level of phosphorylation are equivalent in cells expressing 
WT or the E1321Q mutant. (D) BAECs were treated as described in C. The 
phosphorylation of VE-cadherin was investigated following the immunoprecipitation of 
VE-cadherin and immunodetection with the PY99 antibody. All results are 
representative of at least 3 independent experiments. 
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Supplemental Figure 4: Specificity of pS665VE-cadherin antibodies. 
(A) Indicated amounts of the phosphorylated or non-phosphorylated VE-cadherin 
peptide (658-YDVSVLNSVRRGG-670) were immobilized on nitrocellulose 
membrane using dot-blot apparatus (Bio-Rad) and then blotted against pS665VE-
cadherin antibodies. (B) HEK-293T cells were transfected with cDNA constructs 
encompassing intracellular portions of VE-cadherin (amino acids 621-784, 621-728 
and 703-784). GFP transfected cells serve as negative control. Lysates were 
processed for Western blotting using pS665VE-cadherin and GFP antibodies. (C) 
Alternatively, cells were transfected with wild-type (WT), non phosphorylable 
(S665V) and phospho-mimetic (S665D) mutants of VE-cadherin. Cell lysates were 
processed as in (B). 
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Supplemental Figure 5: The expression level of DEP-1 has no influence on the 
ability of endothelial cells to adhere to Matrigel. 
(A) HUVECs transfected with control (CTL) or DEP-1 siRNAs were plated in 
Matrigel-coated wells in duplicates and left to adhere in the presence of VEGF for 
30 min. Adhesion was quantified by counting the cells remaining attached after 
staining with crystal violet (6 fields/well were counted). Results are representative of 
3 independent experiments. (B) HUVECs transfected with empty vector (pmT2), 
WT DEP-1, DEP-1 Y1311F/Y1320F (YY/FF) or DEP-1 C/S were processed as 
described above. Results are representative of 3 independent experiments.  
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Supplemental Figure 6: Analysis of phosphorylated DEP-1 D/A by mass 
spectrometry. 
Myc-tagged Myr-DEP-1 D/A was immunoprecipitated with the Myc antibody from 
lysates of transfected HEK 293T cells. The Myr-DEP-1 D/A corresponding band 
was excised from the gel and subjected to in-gel trypsin digestion before analysis by 
electrospray mass spectrometry (ES MS/MS) at the Proteomics platform of the 
Centre génomique de Québec. Peptide sequences were determined using the 
software program MASCOT and validated using SCAFFOLD and ASCORE. The 
modification of 80 mass units to tyrosine as well as serine and threonine was 
included in the database searches to determine phosphopeptides. Following analysis, 
peaks could discriminate between phosphorylated tyrosine.  
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Abstract 
 
DEP-1 is a receptor-type protein tyrosine phosphatase with antiproliferative and 
tumor suppressive functions. Hence, several DEP-1 substrates include cell growth-
promoting receptor tyrosine kinases and ERK1/2. However, we and others have also 
reported its ability to positively regulate Src family kinases and biological functions 
in endothelial and immune cells. We further demonstrated that upon VEGF 
stimulation of endothelial cells, phosphorylation of DEP-1 Y1311 and Y1320 in its 
C-terminal tail is required for the optimal activation of Src and promotion of crucial 
angiogenic cell functions via their interaction with the SH2 domain of Src. Here, we 
show that DEP-1 T1318 is a new phosphorylation site, important for the regulation of 
the Src pathway. Interestingly, we find that DEP-1 tyrosine phosphorylation is 
impaired when T1318 is mutated, suggesting that T1318 has a regulatory control over 
DEP-1 tyrosine phosphorylation. Consistent with these findings, DEP-1 T1318A has 
a decreased ability to bind and activate Src in HEK 293T cells. Similarly, the 
phosphorylation of both Y1311 and Y1320 is impaired upon VEGF stimulation of 
endothelial cells expressing DEP-1 T1318A, which is unable to promote the 
activation of Src and the phosphorylation of its substrate VE-cadherin. Consequently, 
VEGF-induced endothelial cell permeability is impaired when DEP-1 T1318A is 
overexpressed. As T1318 is in a CK2 consensus phosphorylation site, incubation of 
endothelial cells with the CK2 inhibitor TBCA or CK2 overexpression demonstrate 
that DEP-1 T1318 is phosphorylated in a CK2-dependent manner. Treatment of 
endothelial cells with TBCA also impedes VEGF-induced DEP-1 tyrosine 
phosphorylation and Src activation. Overall, our results support the conclusion that 
the CK2-dependent phosphorylation of DEP-1 T1318 regulates the tyrosine 
phosphorylation of its C-terminal tail. Phosphorylation of DEP-1 T1318 may thus 
work as a regulatory switch directing the activity of DEP-1 towards its substrate Src 
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in a spatio-temporal manner to allow optimal Src activation and the promotion of 
angiogenic endothelial cell responses. 
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Introduction 
 
Angiogenesis, or the formation of new blood vessel from already existing vessels, is 
essential for life. Blood vessels constitute the first functional organ providing the 
organism with oxygen and nutrients during development. In adults, angiogenesis is 
implicated in the regulation of female reproductive functions and wound healing; 
however, it can also contribute to the development of various pathologies including 
rheumatoid arthritis and cancer (463-465). Thus, angiogenesis is defined as a 
hallmark of cancer, promoting tumor growth and metastases formation (58). 
Neovascularisation in normal and pathological conditions is driven by the ability of 
endothelial cells to respond to angiogenic factors. One of the most important 
angiogenic factor is VEGF, which mediates most biological functions of endothelial 
cells including vascular permeability, cell migration and capillary formation via its 
receptor VEGFR2 (108, 466). Tight coordination and regulation of VEGFR2 activity 
is essential to maintain appropriate VEGF-dependent signalling and cell functions. 
The regulation of VEGFR2 is mediated by several mechanisms including protein 
tyrosine phosphatases (PTPs) such as DEP-1/PTPRJ/CD148, which dephosphorylate 
VEGFR2 to attenuate or inhibit VEGF-induced signalling (149, 467).  
The expression of the receptor-like PTP DEP-1 was initially reported to 
increase with cell density, suggesting that it was regulating cell contact-mediated 
growth inhibition (234). Consistent with these findings, DEP-1 expression was also 
demonstrated to promote breast cancer cell differentiation and to inhibit cancer cell 
proliferation (392, 394, 437, 468). Several reports of loss of heterozygozity of DEP-1 
in human cancers further suggest a role for DEP-1 as a negative regulator of growth 
and as a tumor suppressor (396). Interestingly, increased endothelial cell proliferation 
and impaired vessel remodelling and branching were observed in DEP-1 knock-in 
mutant mice in which the catalytic domain and C-terminal tail of DEP-1 were 
substituted for GFP (265). As VEGFR2 is a major mediator of angiogenic responses, 
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these results suggested that DEP-1 was implicated in its regulation. Accordingly, in 
confluent endothelial cells, DEP-1 is found to associate with VE-cadherin and 
VEGFR2 at sites of cell-cell contact (adherens junctions) and to mediate contact 
inhibition via the dephosphorylation of VEGFR2 and inhibition of the MAPK/ERK 
pathway (149, 150, 469). Previous work in our laboratory demonstrated that DEP-1 
dephosphorylates Y1054/1059 of VEGFR2 resulting in the global attenuation of 
VEGFR2 activity and consequently of major signalling pathways downstream of 
VEGFR2 (160). However, unexpectedly, DEP-1 also promotes the Src-Gab1-AKT 
pathway under these conditions via the dephosphorylation of VE-cadherin-associated 
Src at inhibitory Y529, thereby promoting Src activation and the induction of VEGF-
mediated endothelial cell survival (160).  
Phosphatases are usually regulated by a number of mechanisms to control 
their activity and to maintain appropriate cell signalling. Posttranslational 
modifications such as phosphorylation on tyrosine as well as serine/threonine 
residues were described to influence phosphatase activity (449). For instance, 
phosphorylation of CD45 on tyrosine increases its catalytic activity in T cells (202). 
Similarly, serine phosphorylation of PTPα was reported to increase its catalytic 
activity and also to regulate its substrate specificity towards Src (206, 470). DEP-1 
tyrosine phosphorylation on tyrosine 1311 and 1320 was recently reported by our 
group (471). In VEGF-stimulated endothelial cells, the binding of Src to these 
residues results in the dephosphorylation of Src Y529 by DEP-1 and its activation.  
Src is implicated in the induction of a number of endothelial cell biological functions 
including permeability and angiogenesis (18, 114, 129, 158). The remodelling of 
adhesive endothelial cell contacts, which is essential for the induction of vascular 
permeability and sprouting angiogenesis, is mediated by the Src-dependent 
phosphorylation of VE-cadherins directly on Y658 and Y731 (327, 450). We recently 
demonstrated that via its phosphorylated Y1311 and Y1320 and its ability to regulate 
Src activation, DEP-1 regulates VE-cadherin phosphorylation, endothelial cell 
permeability, invasion and capillary tube formation in response to VEGF (471). 
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In this paper, we identify a novel regulatory phosphorylation site in the C-
terminal tail of DEP-1. DEP-1 T1318 is essential for the proper tyrosine 
phosphorylation of DEP-1 and therefore modulates its ability to activate Src and 
downstream endothelial biological responses. We also find that CK2 is a potential 
kinase regulating T1318 phosphorylation and the activation of this crucial angiogenic 
pathway. 
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Materials and Methods 
 
Cell culture 
Human umbilical vein endothelial cells (HUVECS, Cascade Biologics, purchased 
from Invitrogen were cultured (passages 1 to 4) on 0.2% gelatin-coated tissue culture 
dishes and maintained in M200 medium (Invitrogen) supplemented with LSGS and 
gentamycin 50μg/ml (Wisent). Bovine aortic endothelial cells (BAEC) and HEK 
293T cells were cultured in Dulbecco modified Eagle medium (DMEM) 
supplemented with 10% fetal bovine serum and gentamycin (50 μg/ml).  
 
Reagents and antibodies 
Recombinant human VEGF-A was obtained from the Biological Resources Branch 
Preclinical Repository of the National Cancer Institute Frederick Cancer Research 
and Development Center. 4-para-nitro-phenyl phosphate (pNPP) was from Sigma. 
Rat tail collagen type I was bought from Sigma. Anti-Src rabbit antibody (clone 
36D10), p-Threonine antibody, pY658 VE-Cadherin, VE-cadherin, pY421 Cortactin 
and Cortactin antibodies were from Cell Signaling Technologies. Anti-pY418 Src 
rabbit antibody was from Invitrogen. Mouse anti-DEP-1 (143-41) and goat anti-DEP-
1 antibodies were from R&D Technologies. Anti-DEP-1 (143-41) and PY99 anti-
phospho-tyrosine mouse antibodies were from Santa Cruz Technology, and anti-Src 
(clone GD11) mouse antibodies were from Upstate/Millipore. Phosphospecific 
antibodies against DEP-1 pY1311 and pY1320 were generated by Genscript and have 
been described before (471). Antibodies to DEP-1 pT1318 were generated by 
GenScript against the CKDSKVDLIYQNTTAM[pT1318]IYEN peptide. Secondary 
(HRP-conjugated) anti-rabbit and anti-mouse antibodies were from Cell Signaling 
and HRP-conjugated anti-goat antibody was from Santa Cruz.  
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cDNA constructs 
Plasmids encoding human DEP-1 WT and C/S mutant (in pmT2) were kindly 
provided by Nicholas Tonks (Cold Spring Harbor Laboratory, NY, USA). The DEP-1 
T1318A and DEP-1 C/S T1318A mutants were generated with the QuikChange XL 
site-directed mutagenesis kit (Stratagene). The Src Y527F plasmid was provided by 
Marc Prentki (CRCHUM, Montreal, Qc, Canada) and the CK2 construct with its 
corresponding empty vector pc/CMV by David Litchfield (University of Western 
Ontario, London, ON, Canada). 
 
Cell transfection 
3,5 x 104 cells/cm2 of BAEC plated in 100 mm dishes were transfected with 6 µg of 
DEP-1, DEP-1 T1318A or C/S using Lipofectamine 2000 (ratio 1:2,5) following 
manufacturer’s instructions (Invitrogen). Twenty-four hours post transfection, cells 
were starved O/N in serum-free DMEM. Stimulation was performed 48h post-
transfection with VEGF (50 ng/ml). HEK 293T cells were seeded at 1,2 × 106 
cells/10-cm dish and transfected 24 h later using the standard calcium phosphate 
method. Empty pmT2 vector or DEP-1 constructs (2 µg) were co-transfected with 
active Src (1 µg). Cells were lysed 48h following transfection. HUVECs were plated 
at 40 000 cells/cm2 and transfected 20h later with 8 µg of pmT2, DEP-1 WT and 
DEP-1 T1318A mutant using 20 µl of lipofectin (Invitrogen) in OptiMEM medium 
(Invitrogen), or 8 µg of CK2 and its corresponding empty vector per 60 mm-dish. For 
the CK2 experiment, medium was replaced the next day and cells were starved for 6h 
in M200 48h post-transfection. Cells were then stimulated with VEGF for the 
indicated time points and then lysed as mentioned below. Alternatively, transfected 
HUVECs were collected 6h after transfection and processed for the permeability 
assay.  
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Cell lysis, immunoprecipitation and Western blotting 
Cells were solubilized in a 50mM Hepes  pH 7,5 lysis buffer containing 0,5% Triton 
X-100, 0,5% Nonidet P40, 10% glycerol, 1mM EDTA, 150mM NaCl, 1mM 
phenylmethanesulfonyl fluoride (PMSF), 1mM sodium vanadate (Na3VO4), 5mM 
Sodium Fluoride (NaF), Aprotinin (10μg/ml) and Leupeptin (10μg/ml). For Src 
binding experiments in HEK 293T cells (Fig. 2A), DEP-1 was immunoprecipitated 
from cell lysates (200μg) with 2 µl of anti- DEP-1 antibody (R&D Systems) for 1,5h 
at 4°C, and further incubated for 1,5h at 4°C with 30 µl of a 40% Protein G-
Sepharose bead suspension. Beads were then washed 3X with lysis buffer and 
immunoprecipitates, or total protein extracts (40-50 µg), were subjected to SDS-
PAGE, and transferred onto Hybond-C Extra nitrocellulose membranes (Amersham 
Biosciences/GE Healthcare). Similarly, VE-cadherin was immunoprecipitated from 
BAEC cell lysates (200 µg) using 2 µl of antibody. Western blotting and antibody 
detection was carried out using appropriate HRP-conjugated secondary antibodies 
and chemioluminescence-based detection systems according to the manufacturer’s 
recommendations (ECL; Amersham or Visualizer kit; Millipore). 
 
Permeability assay 
Transfected HUVECs (4 x 104 cells/cm2) were seeded onto Transwell permeability 
inserts (6,5mm diameter, 1,0 μm pore size; BD Falcon, BD Biosciences) pre-coated 
with rat tail collagen type I (50μg/ml). After forty-six hours, the cells were serum-
starved for 1h in M200 medium and then stimulated by adding VEGF (50ng/ml) with 
FITC-Dextran (40 kDa size, 1 mg/ml) in the upper chamber for 30 min. Permeability 
was determined by measuring the fluorescence at 520 nm (498 nm excitation) in 50 
μl-medium aliquots taken from the bottom chambers, which were diluted with 200 μl 
of M200 medium. Fluorescence was detected with a Victor3 V fluorescence reader 
(Perkin-Elmer). 
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pNPP assay 
DEP-1 immunoprecipitated from transfected HEK 293T cells was resuspended in 50 
μl of a 50 mM HEPES [pH 7,4] assay buffer containing BSA (0,1 mg/ml) and DTT 
(3mM) and transferred into a 96-well plate. DEP-1 activity was tested against the 
phospho-peptide 4-para-nitro-phenyl phosphate (pNPP; 50 μl of a 50 mM stock in 
water), which was added to the wells and incubated 5-15 min at room temperature. 
The coloured product pNp was detected by readings at 405 nm using a Victor3 V 
fluorescence reader (PerkinElmer). pNPP hydrolysis after 5 min of reaction is 
reported in the graph of Fig. 2C. 
 
 
VEGF stimulation of non-transfected HUVECs 
HUVECs were plated at confluence (3 x 104 cells/cm2) for 42h and starved for 6h. 
Cells were stimulated with VEGF 50 ng/ml for the indicated time points and lysed as 
described above. 
 
 
 
 
 
 
 
 
120 
 
 
 
Results 
 
DEP-1 is phosphorylated on T1318 in the C-terminal tail. 
 
Previous work in our laboratory identified Y1311 and Y1320 as major 
phosphorylation sites in the C-terminal tail of DEP-1 (471). Biochemical and 
biological characterization determined that these sites are critical for VEGF-mediated 
Src activation and the promotion of major angiogenic functions including the 
remodelling of cell-cell junctions and permeability, invasion and branching capillary 
formation (471). In an attempt to further identify novel regulatory sites, mass 
spectrometry analysis performed on constitutively tyrosine phosphorylated DEP-1 led 
to the identification of T1318 as a new phosphorylated residue (471). As this site is 
proximal to Y1320, we reasoned it might be involved in the regulation of the Src 
pathway and we began investigating its phosphorylation status in HEK 293T cells. As 
it was first discovered on tyrosine phosphorylated DEP-1, these investigations were 
carried out in cells co-transfected with active Src together with DEP-1 or DEP-1 
T1318A encompassing the C/S mutation, which renders DEP-1 catalytically inactive 
and inapt to auto-dephosphorylate. Using a general anti-phosphothreonine antibody, 
Figure 1A shows that DEP-1 C/S is indeed phosphorylated in HEK 293T cells, while 
the DEP-1 C/S T1318A mutant shows reduced phosphorylation. Threonine 
phosphorylation of DEP-1, but not that of the T1318A mutant, is also revealed using 
a specific pT1318 DEP-1 antibody, further demonstrating that T1318 is a true 
phosphorylation site (Fig. 1B). To find out if T1318 phosphorylation had an impact 
on DEP-1 tyrosine phosphorylation in this cell system, total cell lysates of HEK 293T 
cells transfected with DEP-1 C/S or the T1318A mutant were immunoblotted with 
pY1311 and pY1320 specific DEP-1 antibodies. Figure 1C shows that in these 
conditions, the phosphorylation of proximal Y1320, but not that of Y1311, is 
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decreased when T1318 is mutated. These results thus demonstrate that DEP-1 T1318 
is phosphorylated and can regulate the phosphorylation of Y1320 in HEK 293T cells.  
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Figure 1: DEP-1 is phosphorylated on T1318 in the C-terminal tail. 
(A) HEK293T cells co-transfected with active Src and either DEP-1 C/S or the C/S 
T1318A mutant (C/S = catalytically inactive mutant; unable to dephosphorylate 
itself). DEP-1 was immunoprecipitated with DEP-1 antibody and immunoblotted 
with a general p-Thr antibody. Immunoblotting with Src antibody reveals equal 
protein loading in both conditions. (B) HEK293T cells were transfected as in (A). 
Cell lysates were immunobloted with the pT1318 DEP-1 antibody. (C) Western blot 
analysis shows the DEP-1 tyrosine phosphorylation levels (PY1311 and PY1320) of 
pmT2, DEP-1 C/S or DEP-1 C/S T1318A mutant expressed in HEK293T cells. Cell 
lysates were immunoblotted with phosphospecific antibodies PY1311 and PY 1320 
DEP-1. 
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Impaired ability of DEP-1 T1318A to bind and activate Src in HEK 293T cells. 
 
Our previous studies demonstrated that Src binds via its SH2 domain to the 
phosphorylated Y1311 and Y1320 of DEP-1 (471). This binding releases the 
inhibitory interaction of Src pY529 from its own SH2 domain, and induces 
conformational changes that allow dephosphorylation of Y529 and increased 
phosphorylation of Y418 consistent with optimal Src activation (284). Since Y1320 
phosphorylation seems to depend on T1318 phosphorylation (Fig. 1), we then next 
investigated the ability of DEP-1 T1318A mutant to bind and activate Src in 
HEK293T cells. Figure 2A shows that the DEP-1 T1318A mutant is impaired in its 
capacity to bind Src, as shown by immunoprecipitation experiments in transfected 
HEK 293T cells. This reduced Src binding results into decreased phosphorylation of 
the Src activatory site Y418 and higher phosphorylation of inhibitory Y529 in HEK 
293T cells expressing DEP-1 T1318A compared to cells expressing WT DEP-1, 
consistent with decreased Src activity (Figure 2B). Similarly, catalytically inactive 
DEP-1 C/S is unable to dephosphorylate Src Y529 and activate Src (Figure 2B). 
Importantly, a phosphatase assay performed in the presence of pNPP as substrate 
revealed that the decreased ability of DEP-1 T1318A to activate Src is not due to its 
decreased catalytic activity (Figure 2C). The difference in PTP activity is not 
significant in vitro (p-value 0.2). These results demonstrate that the decreased 
activation of Src in HEK 293T cells expressing DEP-1 T1318 is due to the impaired 
tyrosine phosphorylation of Y1320 and decreased Src binding. Phosphorylation of 
T1318 is therefore required for DEP-1-mediated Src activation in HEK 293T cells.   
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Figure 2: Impaired ability of DEP-1 T1318A to bind and activate Src in HEK 
293T cells. 
(A). Lysates of HEK293T cells co-transfected with DEP-1 C/S or the DEP-1 C/S 
T1318A mutant and constitutive active Src were immunoprecipitated with DEP-1 
antibody. Association of DEP-1 with Src was detected by immunoblotting using Src 
antibody. (B) HEK 293T cells were transfected with DEP-1 WT, the WT T1318A 
mutant or DEP-1 C/S and Src phosphorylation was evaluated with a pY418 Src 
antibody. (C) Lysates of transfected HEK293T cells were immunopreciptated (IP) 
with DEP-1 antibody and IPs were used in a PTP activity assay. pNPP was used as a 
substrate to evaluate the PTP activity of DEP-1. Equal DEP-1 expression levels were 
determined by immunoblotting of immunoprecipitated DEP-1 using DEP-1 
antibody. Results are representative of 3 independent experiments. 
 
DEP-1 T1318 phosphorylation regulates VEGF-induced DEP-1 tyrosine 
phosphorylation and Src activation in endothelial cells. 
 
To investigate the kinetics of endogenous DEP-1 T1318 phosphorylation in 
endothelial cells, HUVECs were grown to confluence and stimulated with VEGF 
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(Fig. 3A). T1318 phosphorylation of DEP-1 is observed in basal condition, and this is 
maintained or slightly induced until 1 minute upon VEGF stimulation, demonstrating 
that in these conditions, DEP-1 is constitutively phosphorylated on T1318 and that 
VEGF treatment rapidly downregulates the phosphorylation of this residue. In 
contrast, DEP-1 Y1311 and Y1320 phosphorylation is induced by VEGF treatment, 
as early as 30 sec post-stimulation, and reverts to basal levels after 7 min of 
stimulation. Interestingly, Src phosphorylation on tyrosine 418 is also rapidly induced 
after VEGF stimulation and overlaps with the induction of DEP-1 threonine and 
tyrosine phosphorylation (Fig. 3A).  
To determine if DEP-1 T1318 phosphorylation has a regulatory impact on 
Y1311 and Y1320 phosphorylation in VEGF-stimulated endothelial cells, the 
phosphorylation status of these residues was investigated in HUVECs transfected 
with WT and T1318A DEP-1, or with empty vector (pmT2). Figure 3B shows that 
overexpression of WT DEP-1 results in higher levels of T1318 phosphorylation, 
especially before VEGF stimulation. Similarly, DEP-1 tyrosine phosphorylation is 
also increased compared to control (pmT2) cells, but mainly after VEGF stimulation. 
The elevated signal of DEP-1 phosphorylation on T1318 in DEP-1 T1318A mutant 
expressing cells could be due to higher DEP-1 expression levels in these cells 
compared to pmT2 expressing cells. However, in contrast to DEP-1 WT expressing 
cells, the phosphorylation of both Y1311 and Y1320 was reduced in these cells. 
Consistent with these results, Src phosphorylation on Y418 is impaired in VEGF-
stimulated cells overexpressing DEP-1 T1318A compared to WT DEP-1-expressing 
cells (Fig. 4A, lower panel). These results thus suggest that T1318 phosphorylation 
promotes DEP-1 tyrosine phosphorylation and Src activation in VEGF-stimulated 
endothelial cells.  
126 
 
 
Figure 3: DEP-1 T1318 phosphorylation regulates VEGF-induced DEP-1 
tyrosine phosphorylation and Src activation in endothelial cells. 
(A) HUVECs plated at 3 x 104 cells/cm2 for 42h were serum-starved for 6h and 
stimulated with 50 ng/ml VEGF for the given time points. Phosphorylation levels of 
DEP-1 phosphorylation were detected with the pY1311, pY1320 and pT1318 
antibodies. Src phosphorylation was revealed using pY418 antibody. (B) HUVECs 
were plated at 4 x 104 cells/cm2 and transfected with pmT2, DEP-1 WT or the DEP-
1 T1318A mutant. Forty-two hours post transfection, cells were starved for 6h and 
stimulated with 50 ng/ml VEGF at given time points. Western blot analysis shows 
DEP-1 tyrosine phosphorylation levels of pY1311 and pY1320 and DEP-1 threonine 
phosphorylation levels of pT1318 in transfected cells. Arrows mark the upper band 
of DEP-1. 
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DEP-1 T1318 phosphorylation promotes the phosphorylation of VE-cadherin 
and the induction of endothelial cell permeability in response to VEGF. 
 
The adhesion protein VE-cadherin is phosphorylated in a Src-dependent manner 
directly on Y658 and Y731 (327). Moreover, activation of a Src-Vav2-PAK pathway 
leads to the phosphorylation of serine 665 of VE-cadherin. Phosphorylation of VE-
cadherin promotes its internalization and the remodelling of endothelial cell contacts 
(137). The VEGF-induced loosening of endothelial cell-cell contacts reduces the 
endothelial cell barrier function and increases vascular permeability (135, 332). Src 
has a prominent role in the mediation of vascular permeability and our previous 
studies demonstrated that DEP-1, via Y1311 and Y1320, is implicated in the 
remodelling of endothelial cell-cell junctions and the mediation of vascular 
permeability through the activation of Src (471). In this context, we investigated the 
impact of DEP-1 T1318 on these processes. BAECs were transfected with WT DEP-
1, DEP-1 T1318A and the C/S mutants, as well as with empty vector, and then 
stimulated with VEGF. The tyrosine phosphorylation of VE-cadherin 
immunoprecipitated from WT DEP-1-expressing cells was strongly induced in 
response to VEGF stimulation, while this was completely blocked in cells expressing 
the DEP-1 T1318A mutant (Fig. 4A; upper panel). Moreover, Src-dependent VE-
cadherin phosphorylation on Y658 was also decreased in HUVECs expressing the 
DEP-1 T1318A mutant compared to cells expressing WT DEP-1 (Fig. 4B). These 
results thus suggest that endothelial cells expressing the T1318A mutant maintain the 
integrity and rigidity of their intercellular contacts even in the presence of VEGF.  
DEP-1 T1318 phosphorylation would thus be required to induce the Src-dependent 
remodelling of endothelial cell-cell junctions. To test this hypothesis, we performed a 
vascular permeability assay with cells transfected with either the empty vector 
(pmT2), WT DEP-1 or the DEP-1 T1318A mutant. Figure 4C shows that 
permeability is induced in control cells following stimulation with VEGF, and that a 
similar induction is observed in cells overxpressing WT DEP-1. However, 
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permeability of the cell monolayer overexpressing the DEP-1 T1318A mutant is 
decreased below the basal level observed in non-stimulated control cells, suggesting 
that DEP-1 T138A mutant has a dominant negative function in this context. 
Altogether, these results demonstrate that DEP-1 T1318A is required to induce the 
remodelling of endothelial cell-cell junctions and endothelial cell permeability, 
suggesting a crucial role for DEP-1 T1318 in the appropriate regulation of endothelial 
barrier integrity in response to VEGF stimulation. 
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Figure 4: DEP-1 T1318 phosphorylation promotes phosphorylation of VE-
cadherins and induction of endothelial cell permeability in response to VEGF. 
(A) BAEC cells were plated at 3,8 x 104 cells/cm2 and transfected with pmT2, DEP-
1 WT, DEP-1 C/S or the DEP-1 T1318A mutant. Cells were serum-starved o/n and 
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for 7 minutes stimulated with VEGF (50 ng/ml). Total cell lysates were 
immunoblotted with the pY418-specific Src antibody to show activation levels of 
Src. The phosphorylation levels of VE-cadherin were determined following 
immunoprecipitation using a VE-cadherin antibody. Immunoprecipitates were 
immunoblotted with a general PY antibody. Results show that the DEP-1 T1318A 
mutant impairs VE-cadherin phosphorylation on tyrosine. (B) HUVECs were plated 
at 4 x 104 cells/cm2 and transfected with pmT2, DEP-1 WT and DEP-1 T1318A 
mutant. 48h post transfection cells were starved and VEGF treatment induces 
Y1311, Y1320 and T1318 phosphorylation of DEP-1 concomitantly with 
phosphorylation of Y658 of VE-cadherin. (C) With pmT2, DEP-1 WT and DEP-1 
T1318A transfected HUVECs (3 x 104 cells/cm2, transfection for 6h) were submitted 
to a permeability test. Cells were plated on collagen type I coated inserts. After 
forty-six hours cells were starved for 1h and permeability was induced by 50 ng/ml 
VEGF. 50 µl aliquots were taken and diluted with 200 µl of M200 medium to 
measure the fluorescence level of the bottom chamber. Experiments were done in 
triplicate and means of relative permeability are shown. 
 
 
DEP-1 T1318 is phosphorylated via CK2 in HEK392T and endothelial cells. 
 
The T1318 sequence (T-X-Y-E) is a putative consensus sequence for the 
phosphorylation by the constitutively active serine/threonine kinase CK2 (T-X-X-
D/E/pS/pY) (472, 473). Due to its implication in several cellular signalling events in 
response to diverse growth factors, CK2 can regulate a variety of biological functions 
(473, 474). Very interestingly, CK2 was reported to interact with the Cadherin 
complex, where DEP-1 co-localizes, and to regulate the integrity of cell-cell contacts 
(475, 476). In addition, CK2 inhibitors were also shown to inhibit the retinal 
angiogenic process (477). Therefore, we were interested in investigating the role of 
CK2 in DEP-1 threonine phosphorylation.  
Treatment of transfected HEK 293T cells with TBCA (Tetrabromocinnamic 
acid), a potent specific CK2 inhibitor, resulted in the inhibition of DEP-1 threonine 
phosphorylation, as revealed with a general anti-phosphothreonine antibody (Fig. 
5A). As showed before (Fig. 1B), the specific phosphorylation of DEP-1 on T1318 
can be detected in control cells (vehicle-treated cells) expressing DEP-1 C/S, but not 
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in cells expressing the T1318A mutant (Fig. 5B). In these conditions, treatment of the 
cells with TBCA reduces the phosphorylation of DEP-1 on T1318 (Fig. 5B). Similar 
results were also observed following the incubation of endothelial cells with TBCA 
prior to VEGF stimulation (Fig. 5C). Indeed, compared to controls, DEP-1 T1318 
phosphorylation was reduced in TBCA-treated endothelial cells. Densitometry 
analysis of DEP-1 T1318 western blot revealed that TBCA reduces basal and VEGF-
induced DEP-1 T1318 phosphorylation levels in endothelial cells compared to the 
control cells (1.7 fold reduction of DEP-1 T1318 phosphorylation at basal levels and 
1.5 fold or 2.4 fold reduction at one or seven minutes after VEGF, respectively). 
Concomitant with this reduction of DEP-1 T1318 phosphorylation, VEGF-induced 
Y1311 and Y1320 phosphorylation was also impaired. Accordingly, Src Y418 
phosphorylation was greatly reduced in these conditions (Fig. 5 C). Thus, these 
results demonstrate that TBCA treatment decreases DEP-1 phosphorylation on T1318 
concomitantly with decreased DEP-1 tyrosine phosphorylation and Src activation. 
The converse experiment, where CK2 or empty vector were transfected in endothelial 
cells, showed that CK2 increases the basal and VEGF-induced phosphorylation of 
DEP-1 T1318 (Fig. 5D). Higher T1318 phosphorylation correlated with elevated 
tyrosine phosphorylation, especially of Y1320, in CK2 overexpressing cells. 
Consequently, Src Y418 phosphorylation is increased along with phosphorylation of 
its substrate Cortactin in response to VEGF. Therefore, our results strongly suggest 
that CK2 is involved in the phosphorylation of DEP-1 T1318 in endothelial cells and 
regulates the DEP-1-dependent activation of the Src pathway in response to VEGF 
stimulation. 
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Figure 5: DEP-1 1318 is phosphorylated via CK2 in VEGF-stimulated 
endothelial cells. 
(A) HEK293T cells transfected with DEP-1 were treated with 50 µM TBCA 
(Tetrabromocinnamic acid) or the empty vehicle (Ethanol) for 1h to inhibit CK2 
activity. Cell lysates were immunobloted with pThr antibody. (B) HEK293T cells 
transfected with DEP-1 C/S or the C/S T1318A mutant were treated with 50 µM 
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TBCA or with the empty vehicle for 1h to inhibit CK2 activity. Cell lysates were 
immunobloted with DEP-1 pT1318 antibody. (C) HUVECs were plated at 3 x 104 
cells/cm2 for 42h, starved for 6h and treated at given time points with TBCA (50 
µM) or empty vehicle for 1h. VEGF treatment induces T1318 phosphorylation of 
DEP-1 concomitantly with Src activation. Arrows mark the upper band of DEP-1. 
(D) HUVECs were plated at 3 x 104 cells/cm2 and transfected with HA-tagged CK2 
and the respective empty vector (pc/CMV). CK2 overexpression was determined 
with a HA-antibody. Phosphorylation levels of Src and its substrate Cortactin were 
determined with either pY418 Src or pY421 Cortactin antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
134 
 
 
Discussion 
 
In this study we identified a threonine residue in the C-terminal tail of DEP-1 that is 
localized proximal to Y1320. DEP-1 is phosphorylated in a CK2-dependent manner 
on T1318 in non-stimulated endothelial cells and this phosphorylation is rapidly 
decreased after VEGF treatment. Importantly, the phosphorylation status of DEP-1 
T1318 overlaps with that of Y1311 and Y1320 in VEGF-stimulated cells, 
concomitantly with Src Y418 phosphorylation. DEP-1 T1318 phosphorylation 
promotes the transient VEGF-induced phosphorylation of Y1311 and Y1320, and is 
therefore critical for VEGF-mediated Src activation, VE-cadherin phosphorylation 
and endothelial cell permeability (Figure 6). 
 
Figure 6: CK2-mediated DEP-1 T1318 phosphorylation and DEP-1 tyrosine 
phosphorylation in endothelial cells. 
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CK2 is translocated to cell-cell contacts proximal to the VEGFR2-DEP-1 complex. 
CK2 induces the phosphorylation of DEP-1 on threonine 1318 in endothelial cells. In 
response to VEGF, T1318 phosphorylation decreases slightly and Y1311 and Y1320 
phosphorylation is induced concomitantly. DEP-1 T1318 phosphorylation increases 
the binding affinity of Src to DEP-1 Y1320 resulting in DEP-1-mediated 
dephosphorylation of the Src inhibitory Y529, resulting in Src activation. Activated 
Src promotes biological functions of endothelial cells. 
 
This is the first report showing that DEP-1 threonine phosphorylation 
regulates its tyrosine phosphorylation. Given the consequences of this on Src 
activation and downstream signalling, this suggests that DEP-1 T1318 
phosphorylation represents a novel regulatory mechanism directing DEP-1 substrate 
specificity towards Src with consequent Src activation in response to VEGF. 
Sequence analysis of phospho-mimicking mutations of T1318 (T1318E or T1318D) 
with Scansite software (http://scansite.mit.edu/) reveals that a negative charge at 
position 1318 would increase the affinity of Y1320 as a Src substrate (478). Thus, 
this suggests that the phosphorylation of T1318 might have direct impact on the 
phosphorylation of Y1320 by Src and perhaps by other Src-like kinases previously 
shown to phosphorylate DEP-1 (212, 471). This would lead to the increased binding 
of Src to Y1320, with consequent enhancement of Src activation.  
We have observed that the T1318A mutation mainly affects Y1320 
phosphorylation in HEK 293T cells expressing constitutively active Src. In contrast, 
the phosphorylation of both DEP-1 tyrosine residues is impaired by the mutation of 
DEP-1 T1318 in endothelial cells. We postulate that the decreased phosphorylation of 
Y1311 when T1318 is mutated could be a direct consequence of the decreased 
activation of Src in endothelial cells. Thus, by decreasing Src activation through 
decreased tyrosine phosphorylation of Y1320, T1318 would also indirectly affect the 
phosphorylation of Y1311 in endothelial cells. 
Posttranslational modifications such as serine/threonine phosphorylation are known 
to regulate the activity or the substrate specificity of some phosphatases. Indeed, 
serine phosphorylation of PTPα was demonstrated to regulate its activity (470). It was 
136 
 
 
also suggested that the dephosphorylation of Ser204 in the juxtamembrane domain 
increases the binding affinity of Src to PTPα (206). Dephosphorylation of this residue 
is thus proposed to direct PTPα substrate specificity towards Src to promote its 
activation during mitosis (206). However, in the case of DEP-1, it is the increased 
phosphorylation of T1318 that directs its substrate specificity towards Src due to the 
increased ability of Src to bind tyrosine phosphorylated DEP-1 in these conditions. It 
is possible that DEP-1 phosphorylation on T1318 could influence the steric 
conformation of DEP-1. Based on our results, we show that DEP-1 phosphorylation 
on T1318 and Y1320 could be present at the same time early after VEGF stimulation. 
In this case, two negative charged phosphate groups would be in proximity to each 
other. Initially, we thought that the localization of two phosphate groups (PO42-) leads 
to steric hindrance in the molecular protein structure due to their negative charges. 
The negative charge of DEP-1 T1318 phosphorylation could hinder the binding of a 
phosphate group to DEP-1Y1320 due to electrostatic repulsion between the two 
phosphate groups. Interestingly, scansite analysis of DEP-1 T1318E mutant (mutant 
which mimics phosphorylation on T1318) and our results of DEP-1 phosphorylation 
in endothelial cells provide opposed evidences.  
The analysis of DEP-1 T1318E mutant revealed that this mutation improve 
the recognition of the consensus site for Src-mediated phosphorylation and Src 
binding in contrast to the uncharged threonine residue of DEP-1 WT. The better 
recognition of the consensus site by Src is due to the negative charged glutamatic acid 
mimicking the phosphorylated threonine 1318 (-ME1318IYEN-). Interestingly, this 
mutation approximates the T1318 surrounding sequence closer to the optimal Src 
consensus sequence (–EEIYE-). Thus, the peptide sequence surrounding Y1320 has a 
higher affinity towards Src due to the phosphorylation on DEP-1 T1318 resulting in a 
better recognition of Y1320 by Src and/or a higher accessibility of Y1320 for Src-
mediated phosphorylation. 
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The VEGF-dependent modulation of DEP-1 T1318 phosphorylation therefore 
represents a new regulatory mechanism controlling the intensity and kinetics of Src 
activation in VEGF-stimulated endothelial cells.  
 Based on the sequence surrounding T1318, we identified CK2 as a potential 
kinase. The multifunctional serine/threonine kinase CK2 is implicated similarly as 
Src in a wide range of signalling pathways downstream of various growth factor 
receptors (473). It is a tetrameric protein composed of two catalytic (α and α’) and 
two regulatory subunits (β). Several studies proposed that CK2 is constitutively 
active, but the mechanism regulating this basal activity is ill-defined (472, 479). Of 
note, using inhibitors, CK2 was demonstrated to be involved in endothelial cell 
responses in a mouse model of proliferative oxygen-induced retinal 
neovascularization (477). CK2 was further described as a “master regulator” of 
angiogenesis due to its important role in the mediation of endothelial cell 
proliferation, survival, migration, tube formation and sprouting in vitro (480). 
Consistent with these positive roles for CK2 in angiogenic responses, we show here 
that CK2-mediated phosphorylation of DEP-1 T1318 is implicated in the promotion 
of Src-dependent endothelial cell functions such as endothelial cell permeability. 
Interestingly, CK2 was reported to localize at adherens junctions where DEP-
1 co-localizes (149, 274, 475). It was also shown to phosphorylate E-cadherin and 
lead to increased cell-cell adhesion (475, 476). Based on this, it is tempting to 
speculate that in order for VEGF to promote cell-cell junction loosening and 
endothelial cell permeability, CK2 activity would need to decrease or to dissociate 
from the VE-cadherin complex. Such scenarios would then be consistent with the 
detection of basal T1318 phosphorylation of DEP-1 in confluent unstimulated 
endothelial cells, and its rapid decrease upon VEGF stimulation. As CK2 localization 
is one way to regulate its activity on proximal substrates, its de-localization from VE-
cadherin complexes could represent one mechanism to regulate its access to DEP-1, 
which co-localizes to these structures (481, 482). Alternatively, as CK2 was shown to 
be inactivated by ROS in a mouse model of cardiac hypertrophy (483), the localized 
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production of ROS at intercellular junctions upon VEGF stimulation could also be 
involved in the fast decline of CK2 activity at this site (484, 485). 
In conclusion, we show herein that DEP-1 phosphorylation on T1318 is 
mediated by CK2 and promotes VEGF-induced DEP-1 phosphorylation on tyrosine, 
Src activation and endothelial cell functions. Thus, we report for the first time that 
DEP-1 T1318 phosphorylation displays a regulatory mechanism over DEP-1 tyrosine 
phosphorylation and DEP-1 mediated cell signalling.  
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Abstract 
 
Tight control of protein tyrosine kinase-dependent activities by protein tyrosine 
phosphatases (PTP) is essential for the induction of proper biological responses. 
DEP-1 is a PTP known for its antiproliferative and tumour suppressive functions. 
Indeed, many of its identified substrates are growth factor receptors, and it is 
frequently deleted and/or mutated in several human cancers including that of the 
breast. We have previously shown that DEP-1 plays an essential role in Src activation 
and the mediation of pro-angiogenic functions in endothelial cells. Since Src 
activation is also critical for breast cancer cell invasion and metastasis, we 
investigated if DEP-1 expression was related to the activation of the Src in breast 
cancer cells. We show here that DEP-1 expression is higher in the invasive MDA-MB 
231, HS578T and BT-549 basal-like breast cancer cell lines compared to the less 
invasive MCF7, T47D and SK-BR3 luminal-like breast cancer cell lines. We 
demonstrate that the knockdown of DEP-1 decreases Src phosphorylation on Y418 in 
the basal-like cells, but not in luminal-like cell lines. Phosphorylation of the Src 
substrates Cortactin and FAK, which are associated with pro-invasive signalling, is 
also decreased in DEP-1-silenced MDA-MB 231 and HS578T cells. Consistent with 
these results, DEP-1 mediates the migration of these cell lines and the proper 
localization of Src, Cortactin and Actin at the leading edge of migrating cells. 
Furthermore, DEP-1 promotes the invasion of MDA-MB 231 and HS578T cells into 
Matrigel, but not that of T47D and SK-BR3 cells. In addition, we find that DEP-1 
levels are further elevated in a MDA-MB 231 metastatic derivative cell line 
compared to the parental cell line, and that this correlates with higher 
phosphorylation of SrcY418, Cortactin and FAK, as well as increased invasion. 
Importantly, immunohistochemistry analysis of 141 breast tumour samples reveals 
that DEP-1 expression correlates with the decreased overall survival of patients and 
anterior breast cancer history. Collectively, our findings support the novel idea that 
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DEP-1 can act as a promoter of breast cancer progression, via Src activation and the 
induction of an invasive cell program.  
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Introduction 
 
Protein-tyrosine phosphatases (PTP) are important antagonists of receptor tyrosine 
kinases (RTK) in cell signalling events. The expression of most tumour suppressive 
PTPs is altered in cancer, due to epigenetic and/or genomic modifications including 
mutations, deletions or amplifications (405). In particular, DEP-1/PTPRJ/CD148 is a 
PTP that has been reported to be mutated or deleted in several human cancers 
including those of the breast, colon, lung and thyroid cancer (396, 398). In addition, 
SNPs (single nucleotide polymorphisms) found in the extracellular domain of DEP-1 
were associated with thyroid carcinomas, the risk to develop colorectal cancer, breast 
cancer and childhood ALL, suggesting a prominent role of DEP-1 in tumorigenesis 
(486, 487). Recently, DEP-1 was also shown to suppress EGFR-induced proliferation 
by limiting endocytosis of activated EGFR, supporting the idea that DEP-1 has a 
tumour suppressive role (213). 
Breast cancer is the most frequently diagnosed cancer in women and most 
breast cancer deaths are due to the formation of metastases at distant organs, in 
preference into the bone, the lung and the brain (488-490) . Based on gene expression 
profiling two groups of breast cancer can be defined: Luminal-like breast cancer is 
reported to be Estrogen receptor positive (ER+) and represents the largest number of 
breast cancer cases. In contrast, basal-like breast cancer is ER- and represents only 
15% of breast cancer (362, 363, 368). This subtype of breast cancer is generally more 
aggressive and highly express genes associated with proliferation, suppression of 
apoptosis, migration and invasion (365, 366, 491). Consistently, patients affected by 
the basal-like type of breast cancer have a poor clinical outcome.  
Src and the other members of the Src family kinases (SFK) represent the 
largest group of non-receptor membrane-associated kinases (492) . Further, Src can 
promote many cellular processes such as proliferation, migration/invasion and 
survival of cancer cells (373, 375, 493, 494). Its activity is mainly regulated by the 
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phosphorylation level of the inhibitory tyrosine residue Y530 (in human). This 
residue is highly phosphorylated and bound intra-molecularly to Src’s SH2 domain 
when Src is inactive and in a closed conformation. Dephosphorylation of Y530 leads 
to Src activation which is often accompanied by autophosphorylation of tyrosine 419 
in the activation loop of Src. Based on its central role in several cell signalling 
pathways, Src can induce pro-invasive pathways that promote cancer progression 
(495). It is often over expressed or overactivated in many human cancers including 
that of the breast (340, 495-497). It is known as an essential player in survival and 
establishment of bone metastases mediating osteoclast activation and bone resorption 
(360). 
One of the well-characterized Src substrates associated with the migratory and 
invasive capacity of cancer cells is Cortactin. Cortactin has regulatory and scaffolding 
roles in cytoskeletal organization by stabilizing Actin structures, but also in the 
regulation of membrane trafficking (498-500). Stabilized Actin supports the 
formation of protrusion and lamellipodia at the leading edge of migrating cells where 
Cortactin was shown to localize. FAK is another Src substrate contributing to the pro-
invasive phenotype of cancer cells (501, 502). FAK resides at focal adhesion and in 
some instances at cell adherens junctions, where it is involved in the promotion of 
cell motility, via Actin assembly, and the formation of lamellipodia (503-506).  
Here, we show that DEP-1 promotes Src activation, migration and invasion of 
basal-like breast cancer cells, which in contrast to luminal-like breast cancer cell 
lines, express higher levels of DEP-1. Importantly, consistent with a role in cancer 
progression, the expression of DEP-1 is found to be further increased in a derivative 
metastatic of basal-like cells in vitro, and correlates with reduced overall survival in 
breast cancer patients and the occurrence of an anterior breast cancer history. In 
conclusion, we identify DEP-1 as a novel and essential player in the promotion of 
pro-invasive signalling in basal-like breast cancer cell lines and as a potential 
predictor of the risk to develop metastases.  
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Material and methods 
 
Cell culture and reagents 
Breast cancer cells were cultured in DMEM, supplemented with 10% FBS and 50 
µg/ml Gentamycin. Primary Antibodies for anti-pY421 Cortactin, anti-pY418 Src, 
anti-pY861 FAK, FAK (Invitrogen), anti-Cortactin, clone 4F11 (Millipore), anti-
DEP-1 (R&D), Src, clone 36D10 (Cell signalling) were used for Western blots. Anti-
PTPRJ Prestige Antibody (Sigma) was used for immunohistochemistry. 
 
siRNA and cDNA Transfection and cell stimulation  
For siRNA transfection experiments MDA-MB 231 and HS578T cells were plated at 
2 x 104 cells/cm² SK-RBR3 and T47D cells were plated at 3 x 104 cells/cm². Cells 
were transfected 20h post-plating with DEP-1 (Hs_PTPRJ_3_HP) or Allstars control 
siRNAs (Qiagen) at a final concentration 25 nM using Lipofectamine 2000 
(Invitrogen) following the manufacturer’s instructions. For cDNA overexpression, 
cells were plated at 2,2 x 104 cells/cm² and transfected with 1,2 µg of cDNA/35 mm 
and 5 µl of Lipofectamine 2000. Twenty-four hours post-transfection, cells were 
starved O/N in serum-free medium and stimulated 40h post-transfection with 5% 
FBS. Cells were lysed in a 50mM Hepes pH 7,5 lysis buffer containing 0,5% Triton 
X-100, 0,5% Nonidet P40, 10% glycerol, 1mM EDTA, 150mM NaCl, 1mM 
phenylmethanesulfonyl fluoride (PMSF), 1mM sodium vanadate (Na3VO4), 5mM 
Sodium Fluoride (NaF), Aprotinin 10μg/ml and Leupeptin 10μg/ml. Cells were lysed, 
subjected to SDS-PAGE and immunoblotted using standard protocols (160). 
 
Invasion assay 
MDA-MB 231 and MDA-MB 231 1833 variant cells were plated at 5 x 103 cells/cm2; 
HS 578Tcells were plated at 2 x 104 cells/cm²; and SK-BR3 and T47D cells at 3 x 104 
cells/cm². siRNA were transfected as mentioned above. For overexpression 
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experiments, MDA-MB 231 cells were plated at 2,2 x 104 cells/cm² and transfected as 
described above. Forty hours post-transfection, cells were trypsinized and centrifuged 
at 1000 rpm for 5 min. Cells (1 x 104) were seeded on a polycarbonate membrane 
(Costar Transwell Corning, pores 8µm) pre-coated with 50 µl of Matrigel (BD) at a 
final concentration of 3,8 mg/ml (MDA-MB 231, siRNA experiments), 3,7 mg/ml 
(HS578T),  2 mg/ml (T47D) and 1 mg/ml (SK-BR3)  for 2 h at 37° C (siRNA 
experiments), and 50 µl of Matrigel (3,55 mg/ml) for MDA-MB 231 cells 
overxpressing DEP-1 cDNA. Cells were allowed to invade the Matrigel for 16-18 h. 
Cells were then fixed with formalin for 20 min and stained O/N with Crystal violet 
(1,2% in 20% methanol). Stained cells on the lower side of the polycarbonate 
membrane (cells that invaded the Matrigel and crossed the membrane) were counted. 
Experiments were done in duplicate.  
 
Scratch wound healing assay 
MDA-MB 231 and HS 578T cells were plated at 5 x 104 cells/cm² and 2 x 104 
cells/cm² respectively and transfected as described in the above section. Medium was 
replaced after 16h and cells were incubated until they reached 100% confluence.  
Forty hours post-transfection, the cell monolayer was scratched with a yellow tip to 
create 3 lines. Photos were taken immediately after scratching at 2 microscope 
fields/scratch (at t=0). Cells were allowed to migrate for 22h and when the wound 
was closed at 80-90%, cells were fixed with formalin and stained O/N with crystal 
violet. Images of the microscope fields photographed at t=0 were taken at t=22h. 
Wound closures were quantified using Image Pro Plus Software (Version 5.1; 
MediaCybernetics, Bethesda, MD) and Microsoft Excel. Gap width at t0 and tfinal 
were taken and the ratio t0/tfinal calculated in control and DEP-1-depleted cells. The 
gap width ratios of control cells were compared to those of DEP-1 knockdown cells. 
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Immunofluorescence 
MDA-MB 231 were plated at 2 x 104 cells/cm² and transfected with siRNA as 
described above. Twenty-four hours post-transfection, cells were plated on glass 
coverslips (2 x105 cells/2cm²) and grown for 2 days. The cell monolayer was 
scratched and cells were allowed to migrate for 6h before fixation in Formalin-
buffered solution for 20 min. Slides were washed three times with PBS and 
permeabilized for 5 min with TritonX-100 (0,25% in PBS). Slides were washed three 
times with PBS and then blocked with FBS (8% in PBS) for 30 min. Antibodies 
detecting DEP-1 (clone 143-41 R&D, 1:50), Src (clone 36D10, 1:100), Cortactin 
(clone 4F11, Millipore 1:100), and Phalloidin-AlexaFluor 594 (1:150) were used to 
stain proteins of interest. Secondary antibodies were diluted 1:800 in FBS (8% in 
PBS). Slides were mounted with ProLong Gold antifade reagent containing DAPI 
(Invitrogen/Molecular Probes). The quantitative analysis of the membrane 
localization of Src, Cortactin and Actin was performed in 6 microscopic fields at 40 x 
magnification. Cells with localization of Src, Cortactin and Actin at the membrane 
were counted in control cells and the number compared to cells treated with DEP-1 
siRNA. Experiments were done in triplicate and in every experiment 100-200 cells 
were evaluated in every experiment. 
 
Tissue array and immunohistochemistry (IHC) 
TMAs were constructed as previously described (Svotelis et al., 2011). 
Immunohistochemical studies were performed on representative tumor areas 
annotated by a pathologist. The tissue microarray contains a total of 141 cases of 
breast cancer. The original data set was filtered to eliminate incompletely stained 
cores (5 of 141). The samples were stained with Prestige DEP-1 antibody (Sigma) 
diluted 1:20 and incubated for 60 minutes at 37oC. Immunohistochemistry was 
performed using the Ventana Benchmark XT automated immuno-stainer (Ventana 
Medical Systems, Tucson, AZ, USA). We used the ultraView Universal DAB 
detection kit (#760-500) with 30 minutes antigen retrieval in cell conditioning 
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buffer#2. TMA slides were scanned on the VS-110 (Olympus Corporation, Japan), 
using the VS-ASW FL 2.4 software (Olympus, Germany). 
Three independent observers evaluated DEP-1 expression levels in the TMA. The 
immunohistochemical data were transformed into positive (1) and negative (0) 
staining for DEP-1. 
 
Statsitical analysis  
Survival curves were calculated according to the Kaplan Meier method coupled with 
a log-rank test for survival analysis. Overall survival was computed from the date of 
diagnosed primary tumour to the date of death or the last follow up. The correlation 
of clinical data with DEP-1 expression was done with Pearson/Spearman correlation. 
All statistical analysis were performed with SPSS 16.0 (SPSS Inc., Chicago, IL, 
USA).  
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Results 
 
Higher DEP-1 expression in basal-like breast tumor cell lines mediates Src 
activation. 
 
DEP-1 has been characterized as an inhibitor of cell proliferation and a tumor 
suppressor in many cancer types (234, 392-394, 437). However, despite these 
negative regulatory roles, we previously demonstrated that DEP-1 could also 
positively modulate Src activity and biological functions such as invasion in 
endothelial cells (160, 471). Since Src activity is associated with breast cancer 
progression and increased invasiveness, we thus wondered about the expression 
status of DEP-1 in breast cancer cell lines and if it was involved in the regulation of 
the Src pathway (493, 495). 
 
As a starting point to test this possibility, we evaluated the expression level of 
DEP-1 in a series of human breast cancer cell lines known for their high invasive 
character (basal-like cell lines; MDA-MB 231, HS578T and BT549), or displaying 
low invasiveness (luminal-like cell lines; SK-BR3, T47D and MCF-7). Surprisingly, 
we observed higher DEP-1 expression levels in basal-like cell lines compared to 
luminal-like cell lines under the same culture conditions (Fig. 1A). To test if DEP-1 
expression in highly invasive cell lines correlates with Src phosphorylation on 
tyrosine 418, DEP-1 expression was knocked-down by RNAi transfection. Results 
shown in figure 1B demonstrate that Src tyrosine 418 phosphorylation is decreased in 
DEP-1-silenced basal-like cell lines, whereas no changes or slightly induced 
phosphorylation are observed in lower invasive cell lines. These findings demonstrate 
that highly invasive basal-like cell lines express higher levels of DEP-1, which are 
critical for the optimal phosphorylation/activation of Src. 
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Figure 1: Higher DEP-1 expression in basal-like breast tumour cell lines 
mediates Src activation. 
(A) Breast tumour cell lysates (50 µg) were immunoblotted with DEP-1 antibody. 
Immunoblotting with Tubulin antibody was used for loading control. (B) All breast 
cancer cell lines tested in A) for DEP-1 expression were transfected with control or 
DEP-1 siRNA and cell lysates were immunoblotted with DEP-1 and pY418 Src 
antibodies. Results representative for 2-4 independent experiments. 
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DEP-1 promotes Src activation and pro-invasive signaling in MDA-MB 231 and 
HS578T cells.  
 
Activated Src can induce a pro-invasive signaling pathway in cancer cells, via the 
phosphorylation of its downstream targets Cortactin and FAK (498, 502, 505, 507). 
To find out if DEP-1 expression was regulating this pathway, DEP-1 was depleted in 
the MDA-MB 231 and HS578T basal-like cells. As shown in Figure 1B, Src 
phosphorylation on Y418 is decreased in the basal condition and following FBS 
stimulation (Fig. 2A, B). Consistent with this result, the phosphorylation of Cortactin 
on the Src-dependent tyrosine residue 421 and of FAK on tyrosine 861 were similarly 
impaired in DEP-1-depleted cells compared to the control (CTL) MDA-MB 231 and 
HS578T cells.  Altogether, these results demonstrate that in invasive breast cancer 
cells, DEP-1 regulates Src activation and the activation of Src-dependent downstream 
pathways associated with a pro-invasive phenotype. 
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Figure 2:  DEP-1 promotes Src activation and pro-invasive signaling in MDA-
MB 231 and HS578T cells. 
(A) MDA-MB 231 cells transfected with control (CTL) or DEP-1 siRNAs, serum-
starved O/N and stimulated with FBS (5%) at given time points. Immunoblotting 
with Src Y418, Cortactin pY421 and FAK pY861 antibodies determined the 
phosphorylation level of Src, Cortactin and FAK. DEP-1 silencing correlates with 
inhibition of Src, Cortactin and FAK phosphorylation. (B) HS578T cells were 
treated as mentioned in (A) and stimulated with 5% FBS at given time points. 
Phosphorylation levels of Src, Cortactin and FAK were determined as in A). Results 
are representative for 4 individual experiments. 
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DEP-1 promotes the migration of invasive breast cancer cells and regulates the 
localization of Src and Cortactin and the Actin organization at the leading edge 
of migrating cells. 
 
Cell migration and invasion are key steps in metastases formation and consequently 
in cancer progression. Several signalling pathways lead to the Src-dependent 
activation of Cortactin and FAK and consequently to increased cell 
migration/invasion (498, 502, 505). As we find that DEP-1 is required for the Src-
dependent   phosphorylation/activation of Cortactin and FAK (Fig. 2), we next 
investigated the implication of DEP-1 in the mediation of breast cancer cell migration 
in a scratch assay. Figure 3 shows that closure of the gap was delayed In DEP-1-
depleted MDA-MB 231 and HS578T cells compared to their corresponding controls, 
suggesting that DEP-1 is required for the appropriate migration of these invasive 
breast cancer cell lines. Cell counts of DEP-1-depleted or control cells were similar 
24 h post transfection, suggesting that inhibition of proliferation could not be inferred 
as a cause of delayed wound closure of DEP-1-depleted cells (Supplemental Figure 
1). 
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Figure 3: DEP-1 promotes the migration of invasive breast cancer cells. 
 
(A) MDA-MB 231 or (B) HS578T cells transfected with control (CTL) or DEP-1 
siRNAs. Cell monolayers were scratched 40h after transfection and cells were 
allowed to close the gap for 20h. Cells were then fixed and stained with crystal 
violet. 2 photos per gap were taken immediately after the scratch (t0) and the end 
point of gap closure after 20h (tfinal). Gap width at t0 and tfinal were measured with 
ImageProPlus and the gap width calculated t0/tfinal. The gap width ratio of control 
cells were compared to DEP-1 knockdown cells. Immunoblots show the level of 
DEP-1 silencing in both cell lines and PLCγ was used to show equal protein loading. 
Results shows the average of 4 experiments, * p< 0.05. 
 
 
Cortactin promotes the appropriate arrangement of the cytoskeleton resulting 
in directed cell movement (499). Since we observed a defect in cell migration and 
Cortactin phosphorylation/activation, we next investigated if Src and Cortactin were 
properly localized at the leading edge of migrating MDA-MB 231 cells. Interestingly, 
we found that DEP-1 is enriched at the membrane of the migrating front (Fig. 4A, C). 
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This is consistent with reports that DEP-1 is localized at membrane ruffles in 
macrophages (508). Further, we demonstrate that Src, Cortactin and Actin are also 
enriched at the membrane of the front migrating cells (Fig.4 A-D). Conversely, Actin 
is about 30% less organized at the membrane in DEP-1-depleted cells (Fig. 4B, D). In 
addition, the enrichment of Src and Cortactin is also decreased by about 50% at this 
site in DEP-1-depleted cells (Fig. 4 A-D). These results suggest that the presence of 
DEP-1 at the leading edge of moving cells is essential for the appropriate localization 
of Src and Cortactin to promote directed and coordinated cell migration.  
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Figure 4: DEP-1 regulates the localization of Src, Cortactin and the 
arrangement of Actin at the leading edge of migrating cells. 
(A), (B) MDA-MB 231 were transfected with CTL or DEP-1 siRNA. Cells were 
plated 24h later on glass cover slips. The cell monolayer was scratched 42h after 
plating on the coverslips. Cells were allowed to migrate for 6h into the gap. Cells 
were fixed after 6h, stained with anti-DEP-1 and anti-Src antibodies (A) or anti-
Cortactin and Phalloidine-Alexa Fluor594 (B). DAPI staining was used to mark the 
cell nucleus. (C), (D) Quantification of at the leading edge localized DEP-1, 
Cortactin, Src and Actin in wound-edge cells were evaluated in control and DEP-1 
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siRNA cells. (E) Western blot shows inhibition of DEP-1 expression in MDA-MB 
231 cells. Results shown are means ± SEM of cells which localized these proteins at 
the leading edge and are representative for 3 independent experiments. p-values were 
calculated with Mann-Withney U-test * p< 0.05 
 
 
DEP-1 promotes invasion of basal-like breast cancer cells. 
 
Since breast cancer cell invasion is a process dependent on Src and the ability of cells 
to move, we next asked if invasion was also affected in DEP-1-depleted basal-like 
cells. Fig. 5A and B show that DEP-1-silencing strongly decreased the invading 
capacity of MDA-MB 231 and HS578T cell lines into Matrigel. However, the 
invasive capacity of DEP-1-depleted luminal-like breast cancer cell lines (SK-BR3, 
T47D) was similar to control cells, or was slightly increased in the case of DEP-1-
silenced SK-BR3 cells (Fig. 5C, D). Altogether, these results show that DEP-1 
promotes invasion of the basal-like cell lines MDA-MB 231 and HS578T, but has no 
effect or slightly suppresses invasion in the luminal-like cell lines T47D and SK-
BR3. Collectively, our results highlight for the first time that DEP-1 can promote the 
pro-invasive cell functions of highly invasive basal-like breast cancer cell lines. 
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Figure 5: DEP-1 promotes invasion in basal-like breast cancer cells. 
(A) MDA-MB 231 cells transfected with control (CTL) or DEP-1 siRNAs were 
submitted to Matrigel invasion assay (n=3). Inserts were coated with 3,8 mg/ml 
Matrigel. 1 x 105 cells were seeded in the upper invasion chamber. DMEM-5% FBS 
was added to the bottom chamber and cells were allowed to invade Matrigel for 20h. 
(B) HS578T cells transfected with control (CTL) or DEP-1 siRNAs were submitted 
to Matrigel invasion assay (n=3) as in (A). Inserts were coated with 3,7 mg/ml 
Matrigel. (C) T47D and (D) SK-BR3 cells were treated as in (A) and plated to 
inserts coated with 2 mg/ml or 1mg/ml Matrigel, respectively. 105 cells were seeded 
in the upper invasion chamber. DMEM-5% FBS was added to the bottom chamber 
and cells were allowed to invade Matrigel for 20h. Results shown are means ± SEM 
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of cells that invaded Matrigel and that are on the lower side of the polycarbonate 
membrane of the insert. Results are representative for 3 independent experiments. p-
value were calculated with Mann-Withney U-test * p< 0.05 
 
 
Overexpression of DEP-1 YY/FF mutant in MDA-MB 231 cells correlates with 
decreased Src and Cortactin activation and impaired invasion. 
 
Our laboratory previously demonstrated that DEP-1 promotes Src activation and Src-
dependent biological functions in endothelial cells in response to VEGF (160, 471). 
We further showed that DEP-1 phosphorylation on Y1311 and Y1320 is required for 
the mediation of these events. To demonstrate that DEP-1 indeed regulates biological 
cell functions via Src activation in breast cancer cells, MDA-MB 231 cells were 
transiently transfected with a moderate quantity of empty vector (pmT2), DEP-1 WT 
and DEP-1 Y1311F/Y1320F (YY/FF), which was previously shown to block Src 
activation (471). Figure 6A shows that following FBS stimulation, phosphorylation of 
Src and Cortactin is impaired in cells expressing the DEP-1 YY/FF mutant compared 
to cells transfected with empty vector of expressing WT DEP-1. Thus, DEP-1 
mediates Src activation and the induction of pro-invasive signalling via tyrosine 1311 
and 1320 in MDA-MB 231 cells. The capacity of MDA-MB 231 cells overexpressing 
a subtle quantity of empty vector (pmT2), DEP-1 WT or DEP-1 YY/FF mutant to 
invade Matrigel was also tested (Fig. 6B). Similarly, we found that the expression of 
DEP-1 YY/FF decreased the invasion of MDA-MB 231 compared to cells expressing 
pmT2 or WT DEP-1. Our results therefore demonstrate that subtle overexpression of 
WT DEP-1 leads to the increased activation of Src, Src-dependent pro-invasive 
signalling and mediates invasion in MDA-MB 231 cells. They also show that Y1311 
and Y1320 of DEP-1, which are required for the promotion of Src activation, are 
involved in the induction of Src-dependent functions in MDA-MB 231. These results 
thus support the conclusion that DEP-1 contributes to the invasive phenotype of 
MDA-MB 231 cells through the activation of the Src pathway. 
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Figure 6: Overexpression of DEP-1 YY/FF mutant in MDA-MB 231 cells 
correlates with decreased Src and Cortactin activation and impaired invasion. 
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(A) MDA-MB 231 cells were plated at 3 x 104 cells/cm² and transfected with empty 
vector (pmT2), DEP-1 WT or DEP-1 YY/FF mutant. Forty hours post transfection, 
cells were stimulated with 5% FBS at given time points, lysed and immunoblotted 
for DEP-1 expression, Src Y418 and Cortactin pY421 phosphorylation. 
Overexpression of DEP-1 YY/FF mutant inhibited Src Y418 and Cortactin pY421 
phosphorylation. (B) Cells transfected as in (A) were submitted to Matrigel invasion 
assay (n=3). 105 cells were seeded on a Matrigel coated polycarbonate membrane 
with a concentration of 3,55 mg/ml. DMEM-5% FBS was added to the bottom 
chamber and cells were allowed to invade Matrigel for 20h. Cells were then fixed 
and stained with crystal violet. Cells that invaded Matrigel and were found at the 
lower polycarbonate membrane were counted and DEP-1 YY/FF overexpressing 
cells compared to DEP-1 WT overexpressing cells. * p< 0.05 
 
DEP-1 expression promotes the pro-invasive phenotype of the metastatic MDA-
MB 231 cell variant 1833.  
 
An essential step for cancer progression is the ability of tumour cells to form 
metastases at distant sites. In breast cancer, the most preferred site of metastases 
formation is the bone (509, 510). Interestingly, Src activity was reported to be 
increased in the metastatic explants (variant 1833) of MDA-MB 231, which formed 
bone metastases in a Src-dependent manner (360). Based on our results obtained in 
MDA-MB 231 cells correlating DEP-1 expression to the activation of the Src 
pathway and cell invasion, we were therefore interested in determining if DEP-1 
expression was similarly increased in this metastatic cell line. Figure 7A shows that 
increased phosphorylation of Src Y418 was observed in 1833 cells compared to the 
parental cells, as previously reported. Importantly, higher expression of DEP-1 as 
well as activation of Cortactin and FAK were also detected in the 1833 metastatic 
variant, consistent with its increased ability to invade Matrigel compared to the 
parental MDA-MB 231 cells (Fig. 7B). To  determine the implication of DEP-1 in the 
invasive capacity of 1833 cells, MDA-MB 231 and 1833 cells were transfected with 
control or DEP-1 siRNAs. Figure 7C shows that DEP-1 silencing led to decreased 
invasion of both the parental MDA-MB 231 and 1833 cell lines compared to controls, 
although the reduction was more pronounced in the parental cells (Fig.  7C). Thus, in 
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the bone metastatic MDA-MB 231 subpopulation 1833, the higher amount of DEP-1 
expression induces a stronger Src-dependent pro-invasive signalling leading 
consequently to more invasive 1833 cells compared to the parental MDA-MB 231 
cells.  
 
 
Figure 7: DEP-1 expression promotes the pro-invasive phenotype of the 
metastatic MDA-MB 231 cell variant 1833.  
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(A) MDA-MB 231 cells and the bone-metastatic explant 1833 were plated at 2 x 
104 cells/cm² for 4d and then lysed. DEP-1 expression level and the 
phosphorylation levels of Src Y418, Cortactin Y421 and Y861 FAK were 
determined. The enhanced phosphorylation of Src and Cortactin correlates with 
higher DEP-1 expression in the metastatic explant 1833. (B) Cells were submitted 
to Matrigel invasion assay (n=3). Inserts were coated with 50 µl Matrigel (3,8 
mg/ml). 105 cells were seeded in the upper invasion chamber. DMEM-5% FBS was 
added to the bottom chamber and cells were allowed to invade Matrigel for 20h. 
Cells were fixed and stained with crystal violet. Cells which invaded Matrigel and 
were located at the lower membrane of the insert were counted. (C) MDA-MB 231 
and the metastatic explant 1833 were plated at 5 x 103 cells/cm2 and transfected 
with control (CTL) or DEP-1 siRNA. Forty-two hours post transfection cells were 
submitted to Matrigel invasion assay (n=3). Inserts were coated with 3.8 mg/ml 
Matrigel and invasion test was done as described in (B). Results shown are 
representative for 3-4 independent experiments. * p-value < 0.05, Mann-Withney-
U-test. 
 
Expression of DEP-1 in human breast tumours is associated with an anterior 
breast cancer and might be unfavourable for patient’s outcome. 
 
The results presented above suggest that DEP-1 expression is implicated in the 
promotion of migration and invasion in high invasive breast cancer cell lines. To 
determine the clinical relevance of our observations, we analyzed DEP-1 expression 
by immunohistochemistry on a tissue microarray (TMA) encompassing tumour 
samples from 128 patients. Tumour specimens were evaluated with respect to the 
presence or absence of DEP-1 expression (Fig. 8A). Analysis of the data revealed that 
DEP-1 expression was also associated with a previous history of breast cancer in the 
same or the opposite breast, which was diagnosed more than five years before the 
actual malignancy (p-value 0,024, Pearson correlation). Moreover, DEP-1 expression 
seems by trend to be associated with lower overall survival of breast cancer patients 
(p-value 0.1, Pearson correlation). Further analysis also highlighted that patients with 
DEP-1 positive tumours showed by a trend reduced overall survival compared to the 
group with DEP-1 negative tumours (Fig. 8B), suggesting that DEP-1 expression is 
unfavourable for clinical outcome of the patients. Altogether, our results suggest for 
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the first time an oncogenic role for DEP- 1 in invasive breast cancer, potentially 
promoting cancer progression and the formation of metastases. Accordingly, DEP-1 
expression might be unfavourable for the clinical outcome of breast cancer patients 
and could be a novel therapeutic target in breast cancer. 
 
 
Figure 8: Expression of DEP-1 in human breast tumours is associated with an 
anterior breast cancer and might be unfavourable for patient’s outcome. 
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(A) Representative cores of a tissue microarray of breast cancer samples illustrate 
negative and positive DEP-1 staining. Table1 shows the p-values of 
Pearson/Spearman correlation of an anterior breast cancer history. (B) Kaplan-Mayer 
analysis coupled with a log Rank-test revealed a trend to reduced overall survival of 
patients with DEP-1 expressing tumours (grey line) versus patients with DEP-1 
negative tumours (black line). 
Supplemental Figures 
Supplemental Figure 1: Cell proliferation in DEP-1-depleted and control MDA-
MB 231 and HS578T cells. 
(A) MDA-MB 231 cells were plated between 20000 cells/cm2 and 30000 cells/cm2 
20 h before transfection. Cells were transfected as mentioned in Material and 
Methods. Twenty-four hours post-transfection cells were trypsinized and counted. 
Ratio between control and DEP-1-depleted cells was shown as x-fold increase. 
Results are representative of 9 individual experiments. (B) HS578T cells were plated 
between 20000 cells/cm2 20 h before transfection with DEP-1 or control siRNA. 
Twenty-four hours post transfection cells were trypsinized and counted. Ratio 
between control and DEP-1-depleted cells was shown as x-fold increase. Results are 
representative of 3 individual experiments. 
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Discussion 
 
In this study we demonstrate that DEP-1 expression is higher in basal-like breast 
cancer cell lines compared to the luminal-like cell lines tested. DEP-1 depletion 
correlates with decreased Src Y418 phosphorylation in basal-like cells. Further 
analysis of two basal-like breast cancer cell lines (MDA-MB 231 and HS578T) 
revealed that DEP-1 promotes migration and the proper localisation of Cortactin and 
Src at the leading edge of migrating cells. We showed further that invasion is 
decreased when cells express the DEP-1 YY/FF mutant suggesting that DEP-1 
tyrosines are impliqued in Src activation in MDA-MB 231 cells. Importantly, DEP-1 
expression levels are increased along with elevated Src, Cortactin and FAK activity 
in the metastatic MDA-MB 231 cell variant 1833, suggesting that DEP-1 is 
implicated in the metastatic process of MDA-MB 231 cells. Notably, clinical data 
indicate that DEP-1 expression correlates with an anterior breast cancer and seems to 
be by trend associated with reduced overall survival of breast cancer patients, 
confirming our in vitro results and signifying that DEP-1 expression may be a marker 
to predict the risk to develop metastases.  
 
In this work we showed that DEP-1 expression is elevated in highly invasive basal-
like breast cancer cells compared to luminal-like cell lines. These results were 
unexpected since DEP-1 is reported to behave as a tumor suppressor (392, 394, 399). 
However, despite the fact that several studies reported that DEP-1 expression inhibits 
the proliferation of different cancer cell types including breast cancer cells (213, 392, 
402), our results nonetheless suggest the novel idea that DEP-1 could also promote 
tumor progression. In agreement with this hypothesis, we demonstrated that DEP-1 
mediates the migration and invasion of breast cancer cells via its ability to activate 
Src, a well-characterized promoter of cancer cell migration, invasion and metastases 
formation (493-495, 511). Moreover, it was shown that Src preferentially promotes 
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the establishment and survival of latent breast cancer metastases to the bone, favoring 
the activation of the CXCL12-CXCR4-AKT pathway and the resistance to TRAIL-
induced apoptosis (360). Interestingly, we also previously revealed a role for DEP-1 
in endothelial cell survival, via the activation of a Src-Gab1-AKT pathway (160). As 
supplementary evidence, our results also show that a metastatic explant of MDA-MB 
231 cells express higher DEP-1 levels compared to the parental MDA-MB 231 cell 
line, and that this correlates with higher phosphorylation of Src on Y418 as well as 
higher invasive capacity. In light of all of these observations, our data therefore 
suggest that elevated DEP-1 expression in breast cancer cells could promote cancer 
progression and the formation of metastases. 
 To further support this hypothesis and investigate the clinical relevance of our 
observations, we performed IHC analysis of DEP-1 expression in 128 tumor samples 
of human breast cancers. Interestingly, as could have been expected based on its 
known tumor suppressive functions, we did not find an association between 
decreased DEP-1 expression and advanced breast cancer stages. In contrast, we found 
that its expression correlates with an anterior breast cancer history and seems to be 
associated with reduced overall survival of breast cancer patients. The latter results 
thus support the results from our in vitro studies and suggest that DEP-1 expression 
could contribute to cancer progression and the metastatic process in breast cancer.  
 We also showed that DEP-1 is localized at the leading edge of migrating cells, 
allowing the recruitment and the localisation of Src, Cortactin and Actin to these 
sites. Src-dependent activation of Cortactin maintains the Actin assembly at the 
leading edge, promoting the formation of protrusions and lamellipodia (499, 500). 
Thus, DEP-1 localisation at the leading edge very likely promotes local Src activation 
and cytoskeletal organization required for the formation of lamellipodia (Fig. 4). In 
addition, Cortactin has also been reported to regulate membrane trafficking and the 
secretion of ECM-degrading proteins through the delivery of MMPs and proteases at 
the cell-substratum interface (498, 512). Consistent with these functions, and 
similarly to what was reported for Src, elevated expression of Cortactin was shown to 
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increase the number of bone metastases (360, 507). Based on these results, it can be 
speculated that a DEP-1-Src-Cortactin signalling pathway initiates organized and 
directed cell movement leading to cancer cell invasion and the formation of distant 
metastases (499, 500). Likewise, DEP-1 also increased the phosphorylation of FAK 
in basal-like breast cancer cells, which is another Src substrate involved in the 
promotion of cell migration and invasion that is overexpressed and amplified in 
breast cancer (513, 514). FAK is phosphorylated on several residues including 
tyrosines and serine/threonines. Phosphorylation on these residues can be induced by 
several stimuli including growth factors as VEGF and PDGF as well as phorbol ester 
(515-517). FAK possesses six tyrosine and four serine residues located in different 
domains. When FAK is inactive, its conformation is closed. Following integrin-
mediated binding to ECM the FERM domain will be replaced and allow the 
autoposphorylation at Y397 and the binding of SH2-domain including kinases such 
as Src to this residue. Y397 is located adjacent to the kinase domain of FAK and is 
the major tyrosine phosphorylation site. Src binding to Y397 via its SH2 domain 
induces Src activation which leads to the phosphorylation of additional FAK residues 
such as Y576, Y577 and Y861 resulting in full activation of FAK (121, 518-521). 
Y925 was also identified as residue phosphorylated by Src and is associated with E-
cadherin deregulation and integrin adhesion dynamics in EMT (494, 522).  
  Altogether, these results therefore support the correlation made between 
higher invasiveness and aggressiveness of basal-like breast cancer cells in relation 
with the expression of DEP-1, and that its ability to regulate the Src pathway may in 
part be responsible for these characteristics.  
 The apparent discrepancy between our observations and those of previous 
studies that highlighted the tumor suppressor role of DEP-1 suggests that during 
cancer progression, the tumour suppressive functions of DEP-1 must be reduced or 
inactivated. Consistent with this idea, it is important to consider that LOH (loss of 
heterozygosity) of the PTPRJ gene leads to reduced amounts of PTP activity in the 
cells, which we have shown are appropriate for the optimal activation of Src (471). In 
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addition, a number of mutations in the extracellular and intracellular domain of DEP-
1 have been identified in human cancers, and these could also contribute to modifying 
the growth suppressive functions of DEP-1 (395, 399, 400, 403). Indeed, a missense 
mutation in the KIM domain of DEP-1 (K1017N) was found in primary breast 
tumors, but most enriched in brain metastases, suggesting that this mutation of DEP-1 
is advantageous to cancer progression (403). The KIM domain (aa 1013-1024) allows 
DEP-1 to associates with and dephosphorylate ERK1/2, which are major activators of 
proliferation (149, 275, 404). Thus, the K1017N DEP-1 variant found in breast cancer 
metastases might be inactivated with respect to its ability to dephosphoyrlate ERKs 
and inhibit proliferation, but still able to activate the pro-invasive Src pathway. In 
addition, as PTPs are regulated by oxidation and that this is increased in most cancer 
cells, it is also conceivable that oxidation might contribute to the attenuation of PTP 
activity to reduce the ability of DEP-1 to inactivate growth promoting pathways, but 
still be sufficient to allow the dephosphorylation and activation of Src. Consistent 
with this idea, FLT3-ITD-induced cell transformation in AML was recently shown to 
depend on high Src activation and the oxidative inactivation of DEP-1 (523). Thus, 
alterations of DEP-1 activity via the presence of inactivating mutations or via 
increased oxidation could represent an advantage for tumor cells, allowing them to 
respond to the selective pressure towards Src activation and metastasis formation.  
Interestingly, other PTPs that can activate Src are also believed to display 
oncogenic potential. PTPε, PTP1B and PTPα are examples of PTPs which can 
activate Src and potentially promote cancer progression (162, 315, 406, 426, 427). 
However, results of PTPα in cancer are in part controversial. For instance, PTPα 
expression was shown to correlate with a low tumour grade and cell growth 
inhibition, while another study recently demonstrated that PTPα expression promotes 
Src activation and subsequently anchorage-independent growth and cell survival in 
ER-negative breast cancer and colon cancer cell lines (340, 407, 408). Consistently, 
the closely related PTPε was also found to be overexpressed in various transgenic 
mouse mammary tumor models that are Her2/Neu- or HRas-induced (523). 
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Moreover, it was recently demonstrated that PTPε expression promotes anchorage-
independent growth and breast cancer cell survival, further indicating its cancer-
promoting role (411). The results presented herein provide for the first time hints that 
DEP-1 could be implicated in the transformation process of cancer cells due to the 
activation of Src, similarly to what was shown for other PTPs. Whether these PTPs 
have a positive or negative role is dependent on the cellular context and on molecular 
events that take place during cancer progression such as mutations, increased 
oxidation and expression levels. Thus, a body of evidence suggest that a number of 
PTPs have the potential to promote cell transformation and subsequently cancer 
progression. Although results are in part controversial, the different experimental 
design of the studies and the probable tumor-promoting role of PTPs during different 
steps of cancer evolution (initiation versus progression) have to be taken into 
consideration. Further work has to be done to clarify the role of PTPs in a cancer 
stage-dependent manner. 
In conclusion, we report for the first time that DEP-1 can promote a pro-
invasive phenotype in breast cancer cells, and that its expression could be associated 
with an unfavourable outcome for patients. This identifies DEP-1 as a novel and 
essential player during breast cancer progression and a predictor for the risk to 
develop metastases.  
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CHAPTER V 
Discussion 
The aim of our work was to characterize the role of DEP-1 in the regulation of 
VEGF-dependent angiogenic processes. Previous work in our laboratory showed that 
DEP-1 dephosphorylates VEGFR2 at Y1054/1059, leading to global attenuation of 
VEGFR2 phosphorylation in confluent endothelial cells. Under these conditions 
major signalling pathways including ERK1/2 are inhibited while the Src-Gab1-AKT 
pathway is activated (160). Previously published studies demonstrated that DEP-1 
mediates cell contact inhibition through the dephosphorylation of VEGFR2 in the 
VE-cadherin complex at adherens junctions (149). Our work added an additional 
aspect to the existing model, as we showed that DEP-1-mediated activation of the 
Src-Gab1-AKT pathway in adherens junctions induces cell survival. Under these 
conditions, DEP-1 activates Src via the dephosphorylation of the inhibitory Y529. 
However, the molecular mechanism implicated in DEP-1-mediated Src activation 
remained poorly defined. A number of previous studies demonstrated that DEP-1 
could be phosphorylated on tyrosine in different cell types following growth factor 
stimulation or treatment with pervanadate (212, 337). However, phosphorylation sites 
and their effect on DEP-1 activity and DEP-1-mediated cell function remained 
unknown. Thus, the aim of our work was to better characterize DEP-1 
phosphorylation sites and their impact on DEP-1 activity and function. Based on the 
positive role of DEP-1 in Src activation and the crucial role of Src in many cellular 
functions, we also wanted to define the influence of DEP-1 on biological function. 
Our recent work demonstrates that DEP-1 is transiently phosphorylated on the 
tyrosine residues Y1311 and Y1320 in its C-terminal tail in response to VEGF. These 
residues are required to bind the SH2 domain of Src, leading to Src activation through 
the dephosphorylation of its inhibitory Y529. In addition to the promotion of cell 
survival, our work demonstrated that DEP-1-dependent Src activation also induces 
angiogenic cell responses including vascular permeability, capillary tube formation 
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and endothelial cell invasion. The involvement of phosphorylated Y1311 and Y1320 
in Src activation allowed us to propose that DEP-1 can activate Src via the “phospho-
displacement” mechanism similar to what was proposed for PTPα. Src binds via its 
SH2 domain to the phosphorylated Y1311 and Y1320 of DEP-1, inducing 
conformational changes of Src. The phosphorylated inhibitory Y529 of Src is 
released from the intramolecular binding to its SH2 domain and is 
dephoshophorylated by DEP-1, leading to Src activation 
Moreover, we identified a threonine residue (T1318) in proximity to Y1320 in 
DEP-1 that is constitutively phosphorylated and displays a consensus sequence for 
the serine/threonine kinase CK2. Indeed, DEP-1 T1318 is phosphorylated by CK2 as 
demonstrated in experiments using the specific CK2 inhibitor (TBCA) or when CK2 
was overexpressed in cells. Upon VEGF stimulation, DEP-1 T1318 phosphorylation 
decreases concomitantly with increased phosphorylation on Y1311 and Y1320. Thus, 
it can be speculated that the negative charge provided by the phosphorylated 
threonine residue 1318 promotes the VEGF-dependent phosphorylation of Y1311 and 
Y1320 in endothelial cells and increases the affinity of Y1320 to bind Src. This 
hypothesis was supported by a sequence analysis of phospho-mimicking mutations of 
T1318 (T1318E or T1318D) using Scansite (http://scansite.mit.edu/), a software 
predicting protein interaction (478). These results thus suggest that the 
phosphorylation of DEP-1 T1318 exerts a regulatory control over DEP-1 tyrosine 
phosphorylation. This hypothesis is further supported by the observation that a DEP-1 
T1318A mutant showed reduced the tyrosine phosphorylation and impaired ability to 
bind and activate Src in response to VEGF stimulation. Hence, these results showed 
for the first time that DEP-1 tyrosine phosphorylation and substrate specificity is 
regulated by the phosphorylation on a proximal threonine residue.  
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Figure 16: DEP-1 threonine phosphorylation promotes VEGF-induced DEP-1 
tyrosine phosphorylation and Src activation. 
At basal levels DEP-1 is constitutively phosphorylated on T1318 via CK2. The 
negative charge of DEP-1 T1318 phosphorylation increases the VEGF-dependent 
phosphorylation of tyrosine 1311 and 1320 in endothelial cells. DEP-1 tyrosine 
phosphorylation is required for Src activation and angiogenic responses in 
endothelial cells. 
 
5.1 Mechanisms to regulate DEP-1 activity and function 
 
The results presented in this work showed that DEP-1 is phosphorylated on its C-
terminal tail in endothelial cells. DEP-1 phosphorylation represents a regulatory 
mechanism to control its substrate specificity towards Src. It can be supposed that 
supplementary control mechanisms such as oxidation, modulation of its expression 
levels and ligands exist in cells and modulate the regulation of DEP-1 activity and 
consequently the dephosphorylation of DEP-1 substrates. 
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5.1.1 Implication of DEP-1 in the recruitment of signalling molecules  
 
The phosphorylation of DEP-1 Y1311 and Y1320 is induced following VEGF 
stimulation. DEP-1 tyrosine phosphorylation is required for Src activation, but 
interestingly, the sequences downstream of Y1311 (YQNT) and Y1320 (YENL) also 
correspond to the consensus sequence of Grb2 binding (YXNX). Grb2 is a docking 
protein involved in the recruitment of many proteins such as Gab1 to RTKs at the cell 
membrane (124, 147, 524, 525). We showed previously that the scaffold protein 
Gab1 is located at adherens junctions in endothelial cells and is involved in the 
induction of cell survival and cell motility (124, 160). Moreover, it was suggested 
that DEP-1 is required for Gab1 recruitment to the VE-cadherin complex. Thus, it 
might be possible that DEP-1 Y1311 and Y1320 contribute to Grb2-mediated Gab1 
recruitment into adherens junctions, inducing Gab1-dependent signalling such as 
endothelial cell survival. 
Further potential phosphorylation sites as well as a PDZ class II binding 
domain (GYIA) are present in DEP-1, which could have roles in the regulation of 
DEP-1 activity, DEP-1-mediated signalling and endothelial cell functions. For 
instance, the DEP-1 PDZ domain could be an additional binding site for Src via 
syntenin. Syntenin is a scaffolding protein containing tandem PDZ domains and was 
reported to bind DEP-1 (526, 527). Interestingly, syntenin was shown to bind Src in a 
human melanoma model. The interaction of syntenin and Src correlates with higher 
Src/FAK complex formation, the promotion of cell motility and invasion as well as 
metastasis formation in vivo (528). Thus, in addition to phosphorylated DEP-1 
tyrosines, syntenin could also contribute to the binding of Src to DEP-1, promoting 
Src activation and biological cell functions. 
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5.1.2 Different DEP-1 expression levels define distinct endothelial cell 
functions 
 
Notably, DEP-1 is a highly active phosphatase in vitro (175, 318). Our work has 
revealed that DEP-1 is similar to a number of other Src-activating PTPs in that it has 
a higher specificity towards the Src inhibitory Y529 than the activatory Y418. 
Nonetheless, DEP-1 can also dephosphorylate the Src activating tyrosine residue 418 
in vitro (318). Consistent with these observations, we demonstrated that DEP-1 
specificity towards Y418 and Y529 of Src in HEK293T cells as well as in endothelial 
cells depends on the DEP-1 expression level. High DEP-1 expression levels in cells 
decrease DEP-1 specificity, as we observed the dephosphorylation of Y529 and Y418 
of Src. Under these conditions, Src activity is decreased in cells. In contrast, moderate 
DEP-1 expression is optimal for appropriate Src activation and induction of 
endothelial cell functions. In agreement with our results, CD45 can also 
dephosphorylate Src Y418 and Y529, leading either to increased or attenuated Src 
activity in T cells (237, 529). It was suggested that the negative role of CD45 on Src 
activation could be explained by high levels of CD45 expression or abnormal 
expression of different CD45 isoforms (462, 530). Based on these data and our 
results, it can be speculated that a large quantity of DEP-1 in cells decreases Src 
activation and endothelial cell function including the remodelling of cell-cell 
junctions and capillary formation, while moderate DEP-1 expression levels stimulate 
Src activity and its downstream pathways. This hypothesis is consistent with a report 
that analyzed the in situ expression of DEP-1 by immunohistochemistry in a wide 
range of tissues and cells. This report shows that DEP-1 is moderately expressed in 
endothelial cells (531). Moreover, in vivo data showed that DEP-1 expression is 
downregulated in migrating and proliferating cells during repair of injured vessels, 
supporting our hypothesis that decreased DEP-1 expression promotes endothelial cell 
functions (262). 
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Several lines of evidence gathered in previous studies suggest that DEP-1 
expression can increase concomitantly with VE-cadherin expression (149, 191).  It is 
tempting to speculate that VE-cadherins and DEP-1 can have distinct functions in 
cells depending on their expression levels, which are in part dictated by endothelial 
cell confluence. Based on these observations, it can be hypothesized that DEP-1 
expression in phalanx cells is upregulated concomitantly with VE-cadherin. These 
cells form non-growing vessels and are tightly aligned and regularly shaped. They are 
characterized by stable cell-cell junctions achieved by the high expression of VE-
cadherin, which tightens the endothelial cell barrier (159). Since high DEP-1 
expression attenuates Src activation in endothelial cells, it is tempting to speculate 
that Src activity is attenuated in quiescent phalanx cells, but that the remaining 
activity is sufficient to mediate endothelial cell survival via the Src-PI3K-AKT 
pathway. In contrast to phalanx cells, DEP-1 expression is lower in stalk and tip cells, 
allowing subsequent Src activation and promotion of permeability, migration and 
invasion in these cells. Stalk and tip cells mediate the formation of the vascular sprout 
(10). These cells form the body of the sprout and are responsible for its elongation. 
Cell-cell junctions are less tight in these cells, probably due to decreased VE-cadherin 
clustering (532).  Thus, we suggest that moderate DEP-1 expression results in optimal 
Src activation in sprout-forming stalk and tip cells, promoting optimal Src activation 
and the induction of endothelial cell functions including the loosening of cell-cell 
junctions, migration and invasion (figure 16). Our hypothesis seems to be supported 
by preliminary in vivo results in DEP-1-/- mice. Vascular permeability is induced 
upon VEGF treatment in DEP-1 WT mice, but impaired in DEP-1-/- mice. 
(unpublished observation, Fournier and Royal).  
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Figure 17: VE-cadherin and DEP-1 expression correlates with activation levels 
of Src in different endothelial subtypes during angiogenic sprouting. 
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Quiescent phalanx cells express high levels of VE-cadherins, leading to higher 
clustering and stable formation of cell-cell junctions. Concomitant DEP-1 
expression, which is known to colocalize with VE-cadherin, is increased. This 
attenuates the level of Src activity due to the partial dephosphorylation of both 
tyrosines (Y418 and Y529). In sprout-forming stalk and tip cells, the expression 
level of VE-cadherin and DEP-1 is decreased, resulting in reduced cell-cell adhesion 
in adherens junctions. Moderate DEP-1 expression levels activate Src to induce 
endothelial cell functions leading to sprout elongation and the formation of a new 
vessel. Adapted from (532). 
 
5.1.3 Potential interaction of DEP-1 with the junctional VE-PTP 
 
In addition to DEP-1, other PTPs such as VE-PTP can localize to and regulate the 
VE-cadherin complex in adherens junctions. Intriguingly, the functional loss of VE-
PTP and the knock-in of a DEP-1 mutant with a non-functional intracellular domain 
during embryonic development result in lethality before embryonic day 10 because of 
defects in vessel remodelling and abnormal angiogenesis (233, 265). These results 
provided strong hints that both PTPs have pivotal roles in angiogenesis. Further 
similarities in structure and function of DEP-1 and VE-PTP can be noticed. For 
instance, both PTPs can dephosphorylate VEGFR2 to regulate VEGF-dependent 
signalling and consequently the remodelling of adherens junctions (149, 252, 260, 
471). In contrast to DEP-1, VE-PTP associates with VE-cadherin at basal levels and 
its dissociation from this complex is essential to induce endothelial cell functions in 
vitro and in vivo (256, 260). Whereas VE-PTP depletion increases VEGF-induced 
permeability in cells, DEP-1 depletion decreases it, suggesting that both PTPs are 
implicated in the regulation of the same processes at adherens junction, but 
interestingly in an opposite manner (260, 471). Moreover, both PTPs can interact 
with and dephosphorylate junctional proteins such as plakoglobin (260, 274). VE-
PTP promotes VE-cadherin-mediated adhesion via plakoglobin, suggesting that VE-
PTP is essential to strengthen the junctional barrier (260, 533). It can be speculated 
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that VE-PTP maintains junctional integrity preferentially in quiescent endothelial 
cells, resulting in an enhanced endothelial cell barrier. Concomitantly, DEP-1 
mediates cell contact inhibition and survival in these cells (149). Thus, DEP-1 and 
VE-PTP may work together to maintain the quiescent phenotype of phalanx cells in 
non-growing vessels. Upon activation of endothelial cells, VE-PTP dissociates from 
the VE-cadherin complex, favouring the loss of the endothelial barrier and 
subsequent induction of permeability. Moreover, we demonstrated that DEP-1 also 
promotes vascular permeability via Src activation in VEGF-stimulated endothelial 
cells. Based on our work, moderate expression of DEP-1 activates Src, and we 
suggest that this could be the case in stalk and tip cells in growing vessels. Hence, in 
these cells DEP-1 has a role in promoting permeability and cell motility. It stands to 
reason that VE-PTP and DEP-1 may cross talk and may regulate each other because 
they both exert different effects on the endothelial barrier function at adherens 
junctions. This could be an interesting question to pursue in future studies. For 
instance, knockdown of VE-PTP could shed light on its role in DEP-1 
phosphorylation and activity at adherens junctions. Similarly, phosphorylation and 
activity of VE-PTP could be elucidated in DEP-1-depleted endothelial cells. 
 
5.1.4 ROS-mediated regulation of DEP-1 and DEP-1-dependent 
signalling 
 
Reactive oxygen species (ROS) are implicated in the regulation of various signalling 
pathways downstream of growth factor receptors. Moreover, the thiol in the side 
chain of cysteines is very sensitive to oxidation, therefore PTPs with their reactive 
cysteine are pivotal candidates for transmission of ROS signalling (534). In 
agreement with this, it was reported that RPTPs are prone to oxidation, leading to 
catalytic inhibition (170). This time-limited reversible inhibition of RPTPs is believed 
to enhance RTK signalling and to promote cell signal transmission. Considering these 
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data and the observation that DEP-1 is highly active and a substrate of itself, 
oxidation of the DEP-1 catalytic cysteine would allow phosphorylation of DEP-1 
tyrosine Y1311 and Y1320 in its C-terminal tail, in turn promoting Src binding and 
subsequent Src activation in response to VEGF. Cells are commonly treated with 
NAC (N-acetyl-cysteine), a scavenger that can directly interact with ROS, to 
inactivate ROS-dependent signalling and provide cytoprotection against intracellular 
ROS damage (535). Consistent with our hypothesis, ROS inactivation by NAC 
treatment increases PTP activity and subsequently reduces PDGFR signalling as 
shown in vascular smooth muscle cells (536). This is further supported by our 
observation that NAC treatment decreased DEP-1 phosphorylation on its C-terminal 
Y1311 and Y1320 in endothelial cells. These results suggest that DEP-1 or possibly 
other PTPs such as VE-PTP are more active and dephosphorylate the DEP-1 Y1311 
and Y1320 (Spring and Royal, unpublished observations). These preliminary data 
support our hypothesis that ROS-induced inactivation of DEP-1 increases its 
phosphorylation of tyrosine 1311 and 1320 in the C-terminal tail. A recent report that 
ROS-dependent signalling occurs in VEGF-stimulated endothelial cells inducing cell 
migration and proliferation through the formation of Cys-OH in cysteine-containing 
proteins  provides additional evidence in support of our hypothesis (484, 485). It is of 
note that CK2 can also be a subject of oxidation. It was demonstrated that ROS 
application leads to CK2 inactivation in a mouse model of cardiac hypertrophy (483). 
Thus, it can be speculated that ROS-mediated CK2 inhibition upon VEGF treatment 
would result in reduced DEP-1 T1318 phosphorylation. Since ROS decrease also PTP 
activity, the initially reduced PTP activity would allow concomitantly the 
accumulation of DEP-1 tyrosine phosphorylation in endothelial cells and 
consequently Src activation. Therefore, the observation that DEP-1 T1318 
phosphorylation is reduced after VEGF stimulation could be indicative of the 
inhibition of CK2 due to ROS production. Based on these data, the regulation of 
DEP-1 by ROS in response to VEGF is very likely. 
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Oxidation is also known to occur in cancer (537). Accordingly, it can be 
speculated that DEP-1 can also be regulated by oxidation in cancer. Recently, a study 
showed that oxidation is implicated in the transformation process in cells expressing 
the AML-related FLT3-ITD variant. The same study showed that oxidative 
attenuation of DEP-1 activity by extensive ROS production contributes to cell 
transformation in FLT3-ITD variant expressing AML cells (223). At the same time, 
another group demonstrated that Src activity mediates the transformation process in 
FLT3-ITD induced AML (538). Since we showed that DEP-1 has a pivotal role in 
Src activation in endothelial and breast cancer cells, it can be presumed that DEP-1 
also activates Src in FLT3-ITD induced AML, promoting cell transformation. These 
results showed that ROS are implicated in the regulation of DEP-1 in cancer cells, 
providing further support to our hypothesis that ROS modulate DEP-1 
phosphorylation and activity. 
DEP-1 can form homodimers following H2O2 treatment via the formation of 
disulphide bonds (184). It can be hypothesized that ROS-dependent formation of 
DEP-1 higher order complexes could contribute to the rapid and transient attenuation 
of DEP-1 activity in endothelial cells following VEGF treatment. Therefore, these 
complexes could be part of a mechanism regulating DEP-1 activity, allowing the 
phosphorylation of its C-terminal tail and Src activation early after VEGF 
stimulation. Following oxidation, cysteines in the catalytic domain of DEP-1 could 
form disulphide bonds leading to dimerization similar to what was shown for PTPα 
(539). H2O2 treatment of PTPα induced rapid and transient formation of disulphide 
bonds between the catalytic cysteines of each monomer, leading to reversible PTPα 
inactivation (540). Thus, this may suggest that under oxidative conditions DEP-1 can 
also form rapid and transient inactive homodimers via oxidized cysteines in its 
catalytic domain. This hypothesis seems to be in contrast with reports showing that 
dimerization induced by ligands or by a bivalent antibody results in the formation of 
an active DEP-1 dimer (191, 198, 199). However, these results were obtained under 
non-oxidative conditions. It is unlikely that DEP-1 dimerizes via the formation of 
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disulphide bonds of cysteines in its catalytic domain under non-oxidative conditions. 
Thus, this may indicate that DEP-1 dimerization due to ligand-induced clustering 
maintains its catalytic activity under these conditions. This hypothesis may explain 
the formation of active dimers after treatment with a bivalent antibody (191). Further 
studies are needed to elucidate the implication of DEP-1 homodimer formation in the 
cellular response to growth factor stimulation and the implication of an oxidative 
environment in this process. For instance, a modified cysteinyl-labeling assay was 
described for detection of reversibly oxidized PTPs in vivo, and this could be used to 
analyse DEP-1 oxidation and dimerization in response to VEGF (541). Further, 
specific antibodies against terminally oxidized catalytic cysteines could be used to 
monitor DEP-1 oxidation in cells as it was already done for other PTPs (542). Mass 
spectrometry-based analysis could differentiate between oxidized and reduced 
cysteines of DEP-1 since this method was already used to monitor differences in 
relative oxidation of different PTPs in tumour cells (543, 544). To determine if DEP-
1 forms dimers under oxidative conditions, differentially tagged DEP-1 constructs 
(i.e. HA- and Flag-tag) could be immunoprecipitated from lysates of untreated and 
H2O2 treated cells. Immunoprecipitates could be analyzed by SDS-PAGE for the 
formation of higher complexes. This strategy was already used to elucidate the 
dimerization of other PTPs including PTPα and PTPμ (176, 545).    
 
5.1.5 Regulatory potential of the DEP-1 extracellular domain on DEP-1 
activity and function – Implication of DEP-1 ligands 
 
DEP-1 activity and function could also be regulated through specific ligands that bind 
to its extracellular domain. DEP-1 ligands have remained unknown for a long time. 
The identification of a component of the extracellular matrix provided initial 
evidence for a DEP-1 ligand, and recently two specific DEP-1 ligands were identified 
(546). Syndecan 2 was the first specific DEP-1 ligand to be identified and is 
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implicated in the regulation of angiogenic processes such as capillary formation (198, 
547). Inhibition of syndecan 2 leads to decreased formation of capillaries on Matrigel, 
similar to what we observed for DEP-1. Moreover, cell spreading and adhesion are 
impaired in these cells, suggesting a promoting role on angiogenic processes. 
Interestingly, syndecan 2 was reported to promote cell migration and invasion in 
different cancer cell types, suggesting a tumour-promoting role (548-550). Thus, it 
can be speculated that syndecan 2 mediates its pro-angiogenic and tumour-promoting 
roles in part via DEP-1. 
The identification of TSP-1 as a DEP-1 ligand offered new insights into the 
biology of physiological and tumour-associated angiogenesis. TSP-1 is the first 
endogenous angiogenic inhibitor discovered (55, 56, 199). It is a matricellular protein 
and well-known anti-angiogenic regulator on endothelial cells growth, sprouting and 
motility in vitro and in vivo (55, 56, 551-554). For instance, TSP-1 can inhibit 
endothelial cell proliferation and neovascularisation under different conditions in 
vivo (56, 555). Intriguingly, some studies provided evidence that TSP-1 can also have 
pro-angiogenic roles under specific conditions (556). For instance, it was associated 
with the increased phosphorylation of junctional proteins including p120 catenin and 
plakoglobin, subsequently resulting in the induction of permeability (557, 558). 
Furthermore, TSP-1 can reorganize the cytoskeleton and can induce cell motility in 
VSMCs and cell spreading in endothelial cells (559-561). Altogether, these studies 
demonstrate that TSP-1 can promote angiogenesis in specific conditions, despite its 
mainly negative regulatory roles on angiogenesis. In concordance with these studies, 
TSP-1 was also reported to have controversial roles in the regulation of 
neovascularization in cancer (562-566). DEP-1 also has crucial roles at adherens 
junctions, promoting the phosphorylation of junctional proteins and the induction of 
permeability similar to what was proposed for TSP-1 (471). Thus, intriguingly, 
obvious parallels between the double-edged functions of DEP-1 and its ligand TSP-1 
occur in angiogenesis. These different and sometimes opposing functions may be 
dependent on the cellular context and the stimulatory factors involved. 
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Several studies also provide evidence that TSP-1 possesses anti-tumorigenic 
properties. For instance, a study revealed that a fragment of TSP-1 is encoded by a 
tumour suppressor gene. However, the overall involvement of TSP-1 in cancer 
remains complex and controversial since activatory roles for TSP-1 in tumorigenesis 
were reported in addition to inhibitory functions (567, 568). Its function as a tumour 
suppressor inhibiting tumour cell growth is well documented in primary tumours 
(569-571). Some studies also showed that despite tumour growth inhibition in 
mammary tumours, TSP-1 promotes metastasis formation to the lung in vivo (572). 
Interestingly, TSP-1 expression was reported to be low in benign breast lesions but 
high in breast cancer cells, suggesting that TSP-1 maybe have positive roles cancer 
promotion (573-575). Additionally, TSP-1 was shown to increase the general 
capacity of breast cancer cells to invade a matrix in vitro (572, 576). Consistent with 
these observations, TSP-1 expression was associated with a higher invasiveness in 
advanced prostate cancer and in pancreatic carcinoma (577, 578). In agreement with 
this, TSP-1 levels are associated with areas characterized by high intratumoral vessel 
density, suggesting a promoting role on angiogenesis and in breast cancer (579). 
Thus, functionally distinct roles of TSP-1 occur in cancer. TSP-1 expression by the 
tumour surrounding stroma cells inhibits tumour growth during early stages of 
cancer. Moreover, TSP-1 could either promote or inhibit tumour neovascularization 
depending on specific conditions and on the levels of available TSP-1. Byrne and 
colleagues demonstrated a direct correlation between TSP-1 plasma levels and the 
breast cancer stages, with highest levels of TSP-1 in metastatic breast cancer (579). 
During tumour progression, the tumour becomes hypoxic and pro-angiogenic factors 
such as VEGF are induced, which overrides the inhibitory effect of TSP-1 and results 
in the angiogenic switch. The overwhelming VEGF secretion counterbalances the 
negative role of TSP-1 on angiogenesis and results in new vessel formation in the 
tumour. Concomitantly, high TSP-1 expression increases invasiveness in tumour 
cells, promoting metastasis formation due to induction of matrix degrading enzymes 
such as plasmin and the altered regulation of cell adhesion (576, 580-583). 
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Similarly to the dual role of TSP-1 depending on the cell context in cancer, 
DEP-1 also displays distinct roles in cancer. Various studies demonstrated a tumour 
suppressive role for DEP-1 in different cancers. For instance, Keane and colleagues 
proposed that DEP-1 expression mediates growth inhibition in MCF-7 cells (392). 
Moreover, the same inhibitory effect of DEP-1 on tumour cell proliferation was 
shown in the context of colon, thyroid and pancreatic cancer (394, 395, 402, 584). In 
contrast to these data, our work rather suggests a positive role for DEP-1 in terms of 
promotion of migration and invasion in a particular subtype of breast cancer cells. 
The parallels between distinct TSP-1 and DEP-1 functions in cancer are intriguing. It 
can be speculated that the functional differences of both proteins could be correlated. 
They may be caused by an altered dose-dependent binding capacity of DEP-1 and 
TSP-1 due to different expression levels of the proteins or specific mutations in the 
extracellular domain of DEP-1 in cancer. Furthermore, the availability of TSP-1 as a 
ligand for DEP-1 can be altered in different stages of cancer since TSP-1 is expressed 
by tumour surrounding stromal cells in the early stages, whereas tumour cells are the 
main source of TSP-1 in later stages. Further work will be necessary to clarify this 
point. 
 
5.1.6 Regulatory potential of the DEP-1 extracellular domain on DEP-1 
activity and function – N-glycosylation 
 
N-linked glycosylation is a fundamental post-translational modification and a number 
of potential N-linked glycosylation sites are predicted in the extracellular and 
transmembrane domain of DEP-1. Moreover, some sites are identified by 
glycoproteomic analysis or mass spectrometry in the human plasma or in the liver, 
and digestion of DEP-1 immunoprecipitates with N-glycosidase revealed that DEP-1 
is highly modified by N-glycosylation (263, 585, 586). N-glycosylation regulates 
protein localization at the cell surface and is implicated in a multitude of cellular 
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processes including cell-cell or cell-matrix interactions as well as receptor-ligand 
interactions (587). Since N-glycans were reported to be implicated in the regulation 
of endothelial cell proliferation and capillary tube formation, it can be speculated that 
N-glycosylation may represent a regulatory mechanism for DEP-1 function. 
Interestingly, such a posttranslational modification was demonstrated for two other 
RPTP and was suggested to alter PTP functions. For instance, two distinctly 
glycosylated isoforms of PTPα with different molecular weights were identified and 
it was presumed that they can be distinguished by their ligand specificity (292). 
Posttranslational modification by N-glycosylation was also described for PTPε. 
Intriguingly, the transmembrane form of PTPε occurs differentially N-glycosylated 
depending on the tissue where PTPε is expressed. Thus, this may indicate that N-
glycosylation influences PTPε function in a tissue-specific manner (588). Similar 
roles of N-glycosylation-mediated modifications could be assumed for DEP-1, 
influencing its capacity to bind its ligand and subsequently its cellular functions. 
 
5.2 The implication of DEP-1 in cancer progression 
 
In this work we identified a novel role of DEP-1 in breast cancer. In contrast to its 
known tumour-suppressing function in cancer due to cell contact inhibition and the 
promotion of cell differentiation, we demonstrated its oncogenic potential in basal-
like breast cancer cells based on its ability to activate Src. DEP-1 expression is higher 
in basal-like breast cancer cells, which are known to be highly invasive and more 
aggressive than luminal breast cancer cell lines. Interestingly, tyrosine 1311 and 1320 
of DEP-1, which we previously identified as important residues for Src activation in 
endothelial cells, are also important for Src activation in breast cancer cell lines. We 
showed that Src-dependent activation of pro-invasive signalling is impaired in DEP-
1-depleted basal-like breast cancer cell lines, consistent with reduced recruitment of 
Src and Cortactin to the leading edge of these cells. Consequently, cell migration and 
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invasion are reduced, suggesting that DEP-1 has a pivotal role in cytoskeleton 
organization and cell motility in highly invasive breast cancer cells. These results are 
reminiscent of data obtained in macrophages, where DEP-1 was reported to mediate 
cytoskeletal rearrangements. LPS and CSF-1 treatment induce the formation of 
membrane ruffles, and DEP-1 is redistributed to these structures (508, 589, 590). 
Moreover, DEP-1 promotes macrophage spreading, migration and chemotaxis, but 
does not alter cell proliferation and cell survival. These results indicate that DEP-1 
activates important cell functions associated with cytoskeletal rearrangement in 
macrophages (508, 591). 
The clinical significance of DEP-1 expression in breast cancer was addressed 
by analyzing DEP-1 expression levels in a tissue microarray (TMA) derived from 
human breast tumours. Consistent with our results showing the involvement of DEP-
1 in the promotion of an invasive response, DEP-1 expression is negatively correlated 
with the overall survival of breast cancer patients. Moreover, DEP-1 expression is 
positively correlated with an increased probability of a previous breast tumour in the 
same or the opposed breast. These results suggest DEP-1 expression correlates with a 
poorer clinical outcome in breast cancer patients. Altogether, we provide initial 
evidence for the oncogenic potential of DEP-1 in breast cancer. 
Several PTPs display oncogenic capabilities. In some cases the oncogenic potential of 
PTPs is linked to their ability to activate Src as it was proposed for PTPα and PTPε 
(162, 303, 406). Recently, a study revealed a positive role for PTPε in EGFR-induced 
cell survival and anchorage-independent growth in breast cancer, providing evidence 
for the oncogenic potential of PTPε in breast cancer (411). Breast cancer is classified 
into different subtypes depending on distinct molecular signatures (361-363). 
According to this molecular taxonomy, some breast cancer subtypes including basal-
like and Her2 are associated with an unfavourable prognosis for patients (362). 
Cancer cells pass through adaptive and selective mechanisms during tumour 
progression that are accompanied by the appearance of epithelial-to-mesenchymal-
transition (EMT) in human solid tumours such as breast cancer. EMT is believed to 
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be a transient mechanism defining cellular plasticity and is generally associated with 
higher aggressiveness in breast cancer. The neoplastic progression during cancer 
development induces the loss of cell polarity and epithelial cell characteristics 
including the downregulation of E-cadherin and cytokeratins and the gain of 
mesenchymal markers such as Vimentin and N-cadherin (592, 593). The loss of E-
cadherin in carcinomas induces the disruption of cell-cell junctions and promotes 
EMT. Phosphorylation of proteins associated with E-cadherin such as β-catenin 
further promotes the loss of cell-cell contacts (594-596). Since DEP-1 is implicated in 
the regulation of cell-cell junctions, it can be hypothesized DEP-1 could promote 
EMT. The molecular changes during EMT are accompanied by a more invasive 
behaviour. Indeed, EMT can play essential roles in cancer cell invasion, when 
transformed cells start to disassemble from the cell complex and invade tissue 
surrounding the primary tumour to spread to distant sites. Thus, it is not surprising 
that EMT is found at the invasive front of cancer cells and is implicated in the 
formation of metastases (592, 597). A body of literature provides evidence that EMT 
occurs especially in basal-like breast cancer, which displays high aggressiveness and 
metastatic spreading (363, 598, 599). It is known that Src and FAK are important 
mediators of EMT (339, 354, 600). Interestingly, we observed that DEP-1 can 
regulate Src and FAK activity in basal-like breast cancer cell lines, further suggesting 
that DEP-1 could be implicated in the mediation of EMT in this breast cancer 
subtype. Moreover, DEP-1 could have a pivotal role during the disassembly of 
potentially invasive cells from the cell complex. It is known that activated FAK and 
Src induce cytoskeleton rearrangements resulting in polarized cells and directed 
migration (121, 122, 355). Polarized cells form leading edges that are mediated by 
various proteins including the Src substrate Cortactin. Cortactin is essential to 
maintain and stabilize lamellipodia and the actin assembly at the leading edge (499, 
500). Based on our results that DEP-1-depleted basal-like breast cancer cells fail to 
recruit Cortactin and Src to the leading edge, it can be suggested that DEP-1 is a 
positive regulator of cytoskeletal arrangement mediating, their appropriate 
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localization in migrating cells. Considering these data and our observation that DEP-1 
expression is enhanced in basal-like cell lines, it can be hypothesized that DEP-1 
could be implicated in the process of EMT, leading to higher cell motility in some 
breast cancer cells. Thus, it is tempting to speculate that DEP-1 could promote the 
formation of metastases in basal-like breast cancer. 
Interestingly, various studies linked the EMT-like phenotype to tumour 
propagating cells (TPCs) (601-603). Of note, TPCs were identified in a number of 
cancer types including that of the breast. They are highly invasive and resistant to 
chemotherapy, and by definition they can induce de novo tumour growth (604, 605). 
However, it was suggested that the EMT and TPC cell programs can overlap in some 
cells, since invading TPC had to undergo EMT to adopt these invasive features (606). 
Recent studies suggest that TPCs arise from a fully differentiated cancer cells through 
mechanisms such as EMT that counteract cell differentiation (607-609). Since DEP-1 
regulates breast cancer cell invasion and could be implicated in EMT, it could be 
hypothesized that DEP-1 can also influence TPCs through the promotion of EMT, 
which is essential to allow cells to invade and migrate. Additionally, the data 
obtained in the tissue microarray also suggest that DEP-1 expression could be 
associated with TPCs, as we observed a correlation of DEP-1 expression and the 
occurrence of a previous breast tumour in patients before the current breast cancer 
(Pearson correlation p=0,05). In agreement with this, SHP-2 was recently proposed to 
be a key factor in TPC regulation due to its activating effect on tumour initiating cells 
and subsequently on tumour maintenance and progression (610). The role of DEP-1 
in EMT and the formation of metastases would be an exciting object of future work. 
For instance, the impact of DEP-1 depletion on the EMT-like phenotype could be 
analyzed by the evaluation of epithelial and mesenchymal cell surface markers. 
Moreover, the expression of TPC markers could be analyzed in DEP-depleted cells 
(611). In vivo experiments could provide insights into the tumour-seeding capacity of 
DEP-1-depleted breast cancer cells to highlight the potential implication of DEP-1 in 
the regulation of TPC.                                     .                       
  
CHAPTER VI 
Conclusion 
Angiogenesis is a hallmark of cancer allowing the tumour to grow and to invade 
surrounding tissue. The identification of VEGF as a key regulator of angiogenesis 
encouraged development of the first anti-angiogenic therapeutic approach targeting 
VEGF and its receptor. However, although most anti-angiogenic treatments were 
partially successful in preclinical studies, they only provide moderate benefits for 
cancer patients. Tumour evasion due to resistance to anti-angiogenic treatment 
through the upregulation of other redundant angiogenic factors such as FGF is a 
current problem of these therapies. Additionally, as shown for other anti-cancer 
treatments, it was reported in a mouse model that anti-angiogenic treatment could 
induce local tumour invasion followed by accelerated formation of metastases. To 
improve anti-angiogenic therapies, we need a wider and deeper understanding of the 
molecular mechanisms underlying the angiogenic process, especially in pathologies 
such as cancer. Future approaches of anti-angiogenic treatments could target 
components downstream of several angiogenic factors in addition to the VEGFR2 
pathway to attenuate tumour resistance and evasion. Metastasis formation involves 
the entrance of tumour cells into the blood circulation to escape from unfavourable 
conditions due to oxygen and nutrient deprivation at the site of the primary tumour. 
The understanding of the implicated molecular mechanisms leading to the 
disassembly of tumour cells from the cell complex may be the cutting edge for 
successful anti-cancer treatments in the future.  
The fundamental aim of this doctoral thesis was to define the role of the 
protein tyrosine phosphatase DEP-1 in angiogenic processes in endothelial cells and 
in the pro-invasive phenotype of breast cancer cells. To accomplish this aim, the 
objectives of our first two studies were to define the molecular mechanism of DEP-1-
mediated Src activation and its implication in the mediation of endothelial cell 
functions. In particular, we were interested in characterizing the role of DEP-1 
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phosphorylation in the regulation of DEP-1 activity and DEP-1-mediated endothelial 
cell functions. Our results revealed DEP-1 phosphorylation as a major component 
regulating DEP-1 activity and in particular DEP-1 substrate specificity towards Src. 
Moreover, our results demonstrate a supplementary level of Src regulation in 
response to VEGF through the temporal VEGF-dependent control of DEP-1 tyrosine 
phosphorylation and subsequent Src activation. These studies also revealed DEP-1 as 
an important positive regulator of the VEGF-induced angiogenic program in 
endothelial cells and may pave the way for a specific anti-angiogenic therapy 
targeting DEP-1 or its phosphorylated residues. Our work is among few studies that 
used DEP-1 depletion by siRNA to highlight this positive role of DEP-1 on 
endothelial cell functions. To date, the majority of reports studied DEP-1 in the 
context of its overexpression and focused on its negative role in angiogenesis and 
cancer. 
In concordance with our data obtained in endothelial cells and using DEP-1 
depletion as experimental approach, our third study unravelled a novel unexpected 
role for DEP-1 in breast cancer. In contrast to its initially recognized role as a tumour 
suppressor, our work demonstrated that DEP-1 promotes the invasive phenotype of 
human basal-like breast cancer cell lines. Immunohistochemical studies argue for a 
direct association between DEP-1 expression and the clinical outcome of breast 
cancer patients, showing that DEP-1 expression tends to reduce the overall survival 
of breast cancer patients. Thus, these results highlight an oncogenic role for DEP-1 in 
basal-like breast cancer cell lines. To our knowledge, this is the first study that 
provides evidence that DEP-1 can act as tumour promoter under certain conditions. 
Thus, the work we performed in endothelial and breast tumour cells contributed to the 
discovery of an unsuspected positive role for DEP-1 in the promotion of the Src 
pathway in these cell systems, and consequently on biological responses that are 
intimately linked to the activation status of Src in both cellular systems. It is 
noteworthy that a similar positive role for DEP-1 through the activation of SFK in 
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immune cells is also being discovered, identifying DEP-1 as a critical regulator of 
this family of enzymes and of important biological functions. 
In conclusion, this thesis investigated important questions leading to the better 
understanding of the angiogenic process in physiological and pathological conditions. 
We further the understanding of the role of DEP-1 in endothelial cells and these new 
insights may contribute to answer current challenges in anti-angiogenic therapies in 
cancer. Moreover, our results in breast cancer broadened the horizon of DEP-1 
function in cancer due to its unexpected tumour-promoting role. Finally, the 
quantification of DEP-1 expression might also offer a new marker to predict the risk 
of developing metastases in breast cancer patients and may improve the treatment of 
breast cancer. 
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